[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 134
1. Richardson-Burns SM, Hendricks JL, Foster B, Povlich LK, Kim DH, Martin DC: Polymerization of the conducting polymer poly(3,4-ethylenedioxythiophene) (PEDOT) around living neural cells. Biomaterials; 2007 Mar;28(8):1539-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymerization of the conducting polymer poly(3,4-ethylenedioxythiophene) (PEDOT) around living neural cells.
  • In this paper, we describe interactions between neural cells and the conducting polymer poly(3,4-ethylenedioxythiophene) (PEDOT) toward development of electrically conductive biomaterials intended for direct, functional contact with electrically active tissues such as the nervous system, heart, and skeletal muscle.
  • We introduce a process for polymerizing PEDOT around living cells and describe a neural cell-templated conducting polymer coating for microelectrodes and a hybrid conducting polymer-live neural cell electrode.
  • We found that neural cells could be exposed to working concentrations (0.01 m) of the EDOT monomer for as long as 72 h while maintaining 80% cell viability.
  • PEDOT could be electrochemically deposited around neurons cultured on electrodes using 0.5-1 microA/mm(2) galvanostatic current.
  • PEDOT polymerized on the electrode and surrounded the cells, covering cell processes.
  • The polymerization was impeded in regions where cells were well adhered to the substrate.
  • The cells could be removed from the PEDOT matrix to generate a neural cell-templated biomimetic conductive substrate with cell-shaped features that were cell attracting.
  • Live cells embedded within the conductive polymer matrix remained viable for at least 120 h following polymerization.
  • Dying cells primarily underwent apoptotic cell death.
  • PEDOT, PEDOT+live neurons, and neuron-templated PEDOT coatings on electrodes significantly enhanced the electrical properties as compared to the bare electrode as indicated by decreased electrical impedance of 1-1.5 orders of magnitude at 0.01-1 kHz and significantly increased charge transfer capacity.
  • PEDOT coatings showed a decrease of the phase angle of the impedance from roughly 80 degrees for the bare electrode to 5-35 degrees at frequencies >0.1 kHz.
  • Equivalent circuit modeling indicated that PEDOT-coated electrodes were best described by R(C(RT)) circuit.
  • We found that an RC parallel circuit must be added to the model for PEDOT+live neuron and neuron-templated PEDOT coatings.
  • [MeSH-major] Bicyclo Compounds, Heterocyclic / chemical synthesis. Biocompatible Materials / chemical synthesis. Neurons. Polymers / chemical synthesis
  • [MeSH-minor] Animals. Cell Line, Tumor. Mice

  • ResearchGate. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biomaterials. 2001 Jun;22(11):1289-300 [11336301.001]
  • [Cites] Acta Biomater. 2005 Jan;1(1):125-36 [16701786.001]
  • [Cites] Biotechniques. 2002 Aug;33(2):348, 350, 352 passim [12188187.001]
  • [Cites] Biomaterials. 2003 Feb;24(5):777-87 [12485796.001]
  • [Cites] Chemphyschem. 2002 Mar 12;3(3):276-84 [12503174.001]
  • [Cites] N Engl J Med. 2003 Apr 3;348(14):1365-75 [12672865.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:677-95 [14570586.001]
  • [Cites] J Biomed Mater Res A. 2004 Mar 1;68(3):411-22 [14762920.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Apr 1;196(1):29-36 [15050405.001]
  • [Cites] Eur J Neurosci. 2004 Apr;19(8):2231-8 [15090049.001]
  • [Cites] Nat Neurosci. 2004 May;7(5):452-5 [15114357.001]
  • [Cites] Cell Motil Cytoskeleton. 2004 Jul;58(3):143-59 [15146534.001]
  • [Cites] Stroke. 2004 Nov;35(11 Suppl 1):2702-5 [15486335.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):8948-53 [9256415.001]
  • [Cites] J Biomed Mater Res A. 2004 Dec 15;71(4):577-85 [15514937.001]
  • [Cites] Biomaterials. 2005 Jun;26(16):2983-90 [15603793.001]
  • [Cites] Biomaterials. 2005 Jun;26(17):3511-9 [15621241.001]
  • [Cites] J Control Release. 2005 Sep 2;106(3):309-18 [15978692.001]
  • [Cites] J Neurosci Methods. 2005 Oct 15;148(1):1-18 [16198003.001]
  • [Cites] Cancer Metastasis Rev. 2005 Sep;24(3):425-39 [16258730.001]
  • [Cites] IEEE Eng Med Biol Mag. 2005 Nov-Dec;24(6):30-3 [16382802.001]
  • [Cites] Appl Biochem Biotechnol. 2006 Feb;128(2):117-30 [16484721.001]
  • [Cites] J Neural Eng. 2006 Mar;3(1):59-70 [16510943.001]
  • [Cites] J Biomed Mater Res. 2001 Aug;56(2):261-72 [11340598.001]
  • (PMID = 17169420.001).
  • [ISSN] 0142-9612
  • [Journal-full-title] Biomaterials
  • [ISO-abbreviation] Biomaterials
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / F32 NS054618-01; United States / NINDS NIH HHS / NS / N01-NS-1-2338; United States / NIDDK NIH HHS / DK / T90-DK070071-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bicyclo Compounds, Heterocyclic; 0 / Biocompatible Materials; 0 / Polymers; 0 / poly(3,4-ethylene dioxythiophene)
  • [Other-IDs] NLM/ NIHMS16763; NLM/ PMC1941689
  •  go-up   go-down


2. Yang H, Gumucio DL, Teitelbaum DH: Intestinal specific overexpression of interleukin-7 attenuates the alternation of intestinal intraepithelial lymphocytes after total parenteral nutrition administration. Ann Surg; 2008 Nov;248(5):849-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal specific overexpression of interleukin-7 attenuates the alternation of intestinal intraepithelial lymphocytes after total parenteral nutrition administration.
  • OBJECTIVE: Total parenteral nutrition (TPN), with the complete removal of enteral nutrition, results in marked changes in intestinal intraepithelial lymphocyte (IEL) function and phenotype.
  • Previous work shows that TPN results in a loss of intestinal epithelial cell-derived interleukin-7 (IL-7), and this loss may play an important role in development of such TPN-associated IEL changes.
  • METHODS: To further understand this relation, we generated a transgenic mouse (IL-7), which overexpresses IL-7 specifically in intestinal epithelial cells.
  • We hypothesized that this localized overexpression would attenuate many of the observed TPN-associated IEL changes.
  • RESULTS: Our study showed that TPN administration led to significant changes in IEL phenotype, including a marked decline in the CD8alphabeta+, CD4+, and alphabeta-TCR+ populations.
  • IEL basal proliferation decreased 1.7-fold compared with wild-type TPN mice.
  • TPN administration in wild-type mice resulted in several changes in IEL-derived cytokine expression.
  • IL-7 mice given TPN, however, maintained IEL proliferation, and sustained normal IEL numbers and phenotype.
  • CONCLUSIONS: We conclude that specific intestinal IL-7 overexpression significantly attenuated many IEL changes in phenotype and function after TPN administration.
  • These findings suggest a mechanism by which TPN results in observed IEL changes.
  • [MeSH-major] Interleukin-7 / metabolism. Intestinal Mucosa / metabolism. Intestine, Small / metabolism. Lymphocytes / cytology. Parenteral Nutrition, Total
  • [MeSH-minor] Animals. Antigens, CD44 / metabolism. Blotting, Western. Epithelial Cells / cytology. Epithelial Cells / immunology. Flow Cytometry. Mice. Mice, Transgenic. Models, Animal

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1995 Jan;95(1):55-65 [7814646.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G84-91 [17215438.001]
  • [Cites] J Clin Invest. 1995 Jun;95(6):2945-53 [7769137.001]
  • [Cites] Inflamm Bowel Dis. 1999 Nov;5(4):262-70 [10579119.001]
  • [Cites] J Exp Med. 2000 May 1;191(9):1569-80 [10790431.001]
  • [Cites] Microbes Infect. 1999 Mar;1(3):235-40 [10801235.001]
  • [Cites] Semin Immunol. 2000 Oct;12(5):465-74 [11085179.001]
  • [Cites] Immunity. 2000 Nov;13(5):691-702 [11114381.001]
  • [Cites] J Immunol. 2001 Mar 1;166(5):3019-27 [11207251.001]
  • [Cites] Shock. 2001 Apr;15(4):318-22 [11303733.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8732-7 [11447288.001]
  • [Cites] Nat Immunol. 2001 Nov;2(11):997-1003 [11685222.001]
  • [Cites] Dig Dis Sci. 2002 May;47(5):1147-57 [12018915.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):226-34 [12170028.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33275-83 [12065599.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 2002 Nov-Dec;26(6):333-40; discussion 340-1 [12405644.001]
  • [Cites] Am J Surg. 2003 Jan;185(1):16-21 [12531438.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Apr;284(4):G629-37 [12529260.001]
  • [Cites] Crit Care Med. 2003 Apr;31(4):1118-25 [12682482.001]
  • [Cites] J Surg Res. 2003 Mar;110(1):276-86 [12697412.001]
  • [Cites] J Immunol. 2003 Aug 1;171(3):1556-63 [12874249.001]
  • [Cites] Curr Drug Targets Inflamm Allergy. 2003 Jun;2(2):119-23 [14561163.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1797-806 [14662907.001]
  • [Cites] J Immunol. 2004 Apr 1;172(7):4151-8 [15034027.001]
  • [Cites] J Exp Med. 1987 Nov 1;166(5):1471-83 [2960770.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Mar;86(5):1578-82 [2466294.001]
  • [Cites] J Trauma. 1989 Jul;29(7):916-22; discussion 922-3 [2501509.001]
  • [Cites] Eur J Immunol. 1989 Aug;19(8):1513-6 [2570703.001]
  • [Cites] Ann Surg. 1992 May;215(5):503-11; discussion 511-3 [1616387.001]
  • [Cites] Ann Surg. 1992 Aug;216(2):172-83 [1386982.001]
  • [Cites] J Immunol. 1993 Feb 15;150(4):1296-306 [8094406.001]
  • [Cites] Eur J Immunol. 1993 Aug;23(8):1818-25 [8344343.001]
  • [Cites] J Immunol. 1994 Dec 15;153(12):5730-9 [7989770.001]
  • [Cites] Eur J Immunol. 1995 May;25(5):1385-90 [7774642.001]
  • [Cites] J Trauma. 1995 Jul;39(1):44-51; discussion 51-2 [7636909.001]
  • [Cites] Nutrition. 1995 Jul-Aug;11(4):339-44 [8580573.001]
  • [Cites] J Immunol. 1996 Feb 15;156(4):1333-8 [8568231.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7172-7 [8692964.001]
  • [Cites] J Exp Med. 1998 Feb 2;187(3):389-402 [9449719.001]
  • [Cites] J Immunol. 1998 Jul 15;161(2):707-13 [9670946.001]
  • [Cites] Clin Immunol Immunopathol. 1998 Sep;88(3):287-96 [9743616.001]
  • [Cites] J Surg Res. 1998 Oct;79(2):91-6 [9758721.001]
  • [Cites] Hepatology. 1999 Aug;30(2):430-6 [10421651.001]
  • [Cites] Cytokine. 2005 Sep 21;31(6):419-28 [16102972.001]
  • [Cites] Shock. 2005 Dec;24(6):541-6 [16317385.001]
  • [Cites] Gastroenterology. 2006 Feb;130(2 Suppl 1):S117-21 [16473058.001]
  • [Cites] Ann Surg. 2006 Sep;244(3):392-9 [16926565.001]
  • [Cites] J Exp Med. 1995 Apr 1;181(4):1399-409 [7699326.001]
  • (PMID = 18948814.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / 2R01-AI044076-09; United States / NIAID NIH HHS / AI / R01 AI044076; United States / NIAID NIH HHS / AI / R01 AI044076-08; United States / NIAID NIH HHS / AI / R01 AI044076-09; United States / NIAID NIH HHS / AI / R01 AI044076-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Interleukin-7
  • [Other-IDs] NLM/ NIHMS63923; NLM/ PMC2597497
  •  go-up   go-down


3. Gao F, Sui D, Garavito RM, Worden RM, Wang DH: Salt intake augments hypotensive effects of transient receptor potential vanilloid 4: functional significance and implication. Hypertension; 2009 Feb;53(2):228-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salt intake augments hypotensive effects of transient receptor potential vanilloid 4: functional significance and implication.
  • To test the hypothesis that activation of the transient receptor potential vanilloid 4 (TRPV4) channel conveys a hypotensive effect that is enhanced during salt load, male Wistar rats fed a normal-sodium (0.5%) or high-sodium (HS; 4%) diet for 3 weeks were given 4 alpha-phorbol 12,13-didecanoate (4 alpha-PDD), a specific TRPV4 activator, in the presence or absence of capsazepine, a selective TRPV1 blocker, ruthenium red, a TRPV4 blocker, or TRPV4 small hairpin RNA that selectively knockdowns TRPV4.
  • 4 alpha-PDD (1, 2.5, or 5 mg/kg IV) dose-dependently decreased mean arterial pressure (P<0.05).
  • HS enhanced 4 alpha-PDD-induced depressor effects as well as 4 alpha-PDD-mediated release of calcitonin gene-related peptide and substance P (P<0.001).
  • Ruthenium red markedly blunted (P<0.001), whereas capsazepine slightly attenuated (P<0.05) 4 alpha-PDD-induced depressor effects in HS and normal-sodium diet rats.
  • Ruthenium red alone increased baseline mean arterial pressure in both HS and normal-sodium diet rats with a greater magnitude in the former (P<0.05).
  • Western blot analysis showed that HS increased TRPV4 expression in dorsal root ganglia and mesenteric arteries (P<0.05) but not the renal cortex and medulla.
  • Gene-silencing approach revealed that TRPV4 small hairpin RNA downregulated TRPV4 expression leading to blunted 4 alpha-PDD-induced hypotension (P<0.05).
  • Thus, TRPV4 activation decreases blood pressure in rats given a normal-sodium diet.
  • HS enhances TRPV4 expression in sensory nerves/mesenteric arteries and TRPV4-mediated depressor effects and calcitonin gene-related peptide/substance P release such that HS causes a greater increase in blood pressure when TRPV4 is blocked.
  • Our data indicate that TRPV4 activation may constitute a compensatory mechanism in preventing salt-induced increases in blood pressure.
  • [MeSH-major] Blood Pressure / drug effects. Hypertension / prevention & control. Hypotension / physiopathology. Sodium Chloride, Dietary / pharmacology. TRPV Cation Channels / physiology
  • [MeSH-minor] Animals. Calcitonin Gene-Related Peptide / metabolism. Capsaicin / analogs & derivatives. Capsaicin / pharmacology. Disease Models, Animal. Dose-Response Relationship, Drug. Ganglia, Spinal / metabolism. Kidney / metabolism. Male. Mesenteric Arteries / metabolism. Phorbol Esters / pharmacology. Rats. Rats, Wistar. Ruthenium Red / pharmacology. Salt-Tolerance / physiology. Substance P / metabolism

  • MedlinePlus Health Information. consumer health - Dietary Sodium.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Low Blood Pressure.
  • HSDB. structure - CAPSAICIN.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. See the articles recommended by F1000Prime's Faculty of more than 5,000 expert scientists and clinical researchers. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Control Release. 2000 Mar 1;65(1-2):133-48 [10699277.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47044-51 [12354759.001]
  • [Cites] Life Sci. 2000 Mar 24;66(18):1695-704 [10809166.001]
  • [Cites] Cell. 2000 Oct 27;103(3):525-35 [11081638.001]
  • [Cites] Circ Res. 2001 Nov 23;89(11):983-90 [11717154.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13569-77 [11827975.001]
  • [Cites] J Neurosci. 2002 Aug 1;22(15):6408-14 [12151520.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33704-10 [12093812.001]
  • [Cites] Nature. 1988 Sep 8;335(6186):164-7 [2901042.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1993 Dec;348(6):638-42 [7510855.001]
  • [Cites] Circ Res. 1996 Mar;78(3):415-23 [8593700.001]
  • [Cites] Respir Physiol. 1996 Jan;103(1):11-7 [8822219.001]
  • [Cites] J Neurosci. 2005 Feb 2;25(5):1304-10 [15689568.001]
  • [Cites] Nat Biotechnol. 2005 Feb;23(2):227-31 [15619616.001]
  • [Cites] Hypertension. 2005 Oct;46(4):986-91 [16144988.001]
  • [Cites] Hypertension. 2003 Mar;41(3 Pt 2):757-62 [12623992.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):26541-9 [12724311.001]
  • [Cites] J Hypertens. 2003 Aug;21(8):1525-30 [12872047.001]
  • [Cites] Nature. 2003 Jul 24;424(6947):434-8 [12879072.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12480-5 [14523239.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13698-703 [14581612.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100 Suppl 2:14531-6 [14581619.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):396-401 [14691263.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Jul;287(1):F17-24 [15026302.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Aug;287(2):L272-8 [15075247.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Aug;287(2):L269-71 [15246981.001]
  • [Cites] Circ Res. 2005 Oct 28;97(9):908-15 [16179585.001]
  • [Cites] Circ Res. 2005 Dec 9;97(12):1270-9 [16269659.001]
  • [Cites] Hypertension. 2006 Mar;47(3):609-14 [16365187.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Jun;290(6):L1267-76 [16399784.001]
  • [Cites] Pharmacol Biochem Behav. 2006 Apr;83(4):508-16 [16647109.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Jul;26(7):1495-502 [16675722.001]
  • [Cites] Circ Res. 2006 Jul 21;99(2):119-31 [16857972.001]
  • [Cites] Handb Exp Pharmacol. 2007;(179):189-205 [17217058.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Mar;292(3):H1390-7 [17071727.001]
  • [Cites] J Pharmacol Exp Ther. 2007 May;321(2):763-9 [17308041.001]
  • [Cites] Am J Kidney Dis. 2007 Oct;50(4):655-72 [17900467.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2039-53 [17693546.001]
  • [CommentIn] Hypertension. 2009 Feb;53(2):118-9 [19075088.001]
  • (PMID = 19075100.001).
  • [ISSN] 1524-4563
  • [Journal-full-title] Hypertension
  • [ISO-abbreviation] Hypertension
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK67620; United States / NHLBI NIH HHS / HL / HL-57853; United States / NHLBI NIH HHS / HL / HL-73287; United States / NIDDK NIH HHS / DK / R01 DK067620; United States / NIDDK NIH HHS / DK / R01 DK067620-03; United States / NIDDK NIH HHS / DK / R01 DK067620-04; United States / NHLBI NIH HHS / HL / R01 HL057853; United States / NHLBI NIH HHS / HL / R01 HL057853-06; United States / NHLBI NIH HHS / HL / R01 HL057853-07; United States / NHLBI NIH HHS / HL / R01 HL073287; United States / NHLBI NIH HHS / HL / R01 HL073287-04; United States / NHLBI NIH HHS / HL / R01 HL073287-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phorbol Esters; 0 / Sodium Chloride, Dietary; 0 / TRPV Cation Channels; 0 / Trpv1 protein, rat; 0 / Trpv4 protein, rat; 11103-72-3 / Ruthenium Red; 24928-17-4 / phorbol-12,13-didecanoate; 33507-63-0 / Substance P; 83652-28-2 / Calcitonin Gene-Related Peptide; LFW48MY844 / capsazepine; S07O44R1ZM / Capsaicin
  • [Other-IDs] NLM/ NIHMS96829; NLM/ PMC2729143
  •  go-up   go-down


Advertisement
4. Pfleger BF, Kim Y, Nusca TD, Maltseva N, Lee JY, Rath CM, Scaglione JB, Janes BK, Anderson EC, Bergman NH, Hanna PC, Joachimiak A, Sherman DH: Structural and functional analysis of AsbF: origin of the stealth 3,4-dihydroxybenzoic acid subunit for petrobactin biosynthesis. Proc Natl Acad Sci U S A; 2008 Nov 4;105(44):17133-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural and functional analysis of AsbF: origin of the stealth 3,4-dihydroxybenzoic acid subunit for petrobactin biosynthesis.
  • Petrobactin, a virulence-associated siderophore produced by Bacillus anthracis, chelates ferric iron through the rare 3,4-isomer of dihydroxybenzoic acid (3,4-DHBA).
  • Most catechol siderophores, including bacillibactin and enterobactin, use 2,3-DHBA as a biosynthetic subunit.
  • Significantly, siderocalin, a factor involved in human innate immunity, sequesters ferric siderophores bearing the more typical 2,3-DHBA moiety, thereby impeding uptake of iron by the pathogenic bacterial cell.
  • In contrast, the unusual 3,4-DHBA component of petrobactin renders the siderocalin system incapable of obstructing bacterial iron uptake.
  • Although recent genetic and biochemical studies have revealed selected early steps in petrobactin biosynthesis, the origin of 3,4-DHBA as well as the function of the protein encoded by the final gene in the B. anthracis siderophore biosynthetic (asb) operon, asbF (BA1986), has remained unclear.
  • In this study we demonstrate that 3,4-DHBA is produced through conversion of the common bacterial metabolite 3-dehydroshikimate (3-DHS) by AsbF-a 3-DHS dehydratase.
  • Elucidation of the cocrystal structure of AsbF with 3,4-DHBA, in conjunction with a series of biochemical studies, supports a mechanism in which an enolate intermediate is formed through the action of this 3-DHS dehydratase metalloenzyme.
  • Structural and functional parallels are evident between AsbF and other enzymes within the xylose isomerase TIM-barrel family.
  • Overall, these data indicate that microbial species shown to possess homologs of AsbF may, like B. anthracis, also rely on production of the unique 3,4-DHBA metabolite to achieve full viability in the environment or virulence within the host.
  • [MeSH-major] Bacterial Proteins / chemistry. Benzamides / metabolism. Hydro-Lyases / chemistry. Hydroxybenzoates / metabolism
  • [MeSH-minor] Animals. Bacillus anthracis / genetics. Bacillus anthracis / metabolism. Crystallography, X-Ray. Hydrogen-Ion Concentration. Mice. Models, Molecular. Operon. Protein Conformation. Shikimic Acid / analogs & derivatives. Shikimic Acid / chemistry. Shikimic Acid / metabolism. Structure-Activity Relationship

  • HSDB. structure - SHIKIMIC ACID.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • DNASU Plasmid Repository. clones/clone libraries - Plasmid Clone (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Protein Expr Purif. 2002 Jun;25(1):8-15 [12071693.001]
  • [Cites] Biometals. 2008 Oct;21(5):581-9 [18459058.001]
  • [Cites] Biotechnol Prog. 2002 Nov-Dec;18(6):1141-8 [12467444.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2003 Jan;59(Pt 1):38-44 [12499537.001]
  • [Cites] FEMS Microbiol Rev. 2003 Jun;27(2-3):215-37 [12829269.001]
  • [Cites] Methods Enzymol. 2003;374:229-44 [14696376.001]
  • [Cites] Mol Microbiol. 2004 Jan;51(2):407-17 [14756782.001]
  • [Cites] J Org Chem. 2004 May 14;69(10):3530-7 [15132566.001]
  • [Cites] J Struct Funct Genomics. 2004;5(1-2):111-8 [15263850.001]
  • [Cites] Curr Microbiol. 2004 Aug;49(2):89-94 [15297912.001]
  • [Cites] J Biol Chem. 1966 May 25;241(10):2453-60 [4380381.001]
  • [Cites] J Biol Chem. 1978 Jul 10;253(13):4593-8 [149131.001]
  • [Cites] Nucleic Acids Res. 1990 Oct 25;18(20):6069-74 [2235490.001]
  • [Cites] J Biol Chem. 1992 Nov 5;267(31):22237-42 [1429576.001]
  • [Cites] J Mol Biol. 1993 Jan 5;229(1):105-24 [7678431.001]
  • [Cites] Annu Rev Microbiol. 1995;49:557-79 [8561472.001]
  • [Cites] Biochem J. 1996 Apr 1;315 ( Pt 1):195-205 [8670107.001]
  • [Cites] Protein Eng. 1995 Sep;8(9):925-33 [8746730.001]
  • [Cites] J Biol Chem. 1998 Apr 17;273(16):9602-7 [9545291.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 1999 Jun;55(Pt 6):1168-73 [10329779.001]
  • [Cites] Nat Struct Biol. 1999 Jun;6(6):521-5 [10360352.001]
  • [Cites] J Nat Prod. 2004 Nov;67(11):1897-9 [15568785.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32 [15572765.001]
  • [Cites] Biometals. 2005 Dec;18(6):577-85 [16388397.001]
  • [Cites] J Bacteriol. 2006 Feb;188(4):1301-9 [16452412.001]
  • [Cites] Nat Chem Biol. 2006 Mar;2(3):132-8 [16485005.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2006 Aug;62(Pt 8):859-66 [16855301.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 15;348(1):320-5 [16875672.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18499-503 [17132740.001]
  • [Cites] J Bacteriol. 2007 Mar;189(5):1698-710 [17189355.001]
  • [Cites] Biochemistry. 2007 Apr 3;46(13):4147-57 [17346033.001]
  • [Cites] J Mol Biol. 2007 Sep 21;372(3):774-97 [17681537.001]
  • [Cites] J Am Chem Soc. 2007 Oct 10;129(40):12263-71 [17850151.001]
  • [Cites] J Am Chem Soc. 2008 Feb 20;130(7):2124-5 [18220393.001]
  • [Cites] J Org Chem. 2008 Aug 1;73(15):5759-65 [18582113.001]
  • [Cites] J Inorg Biochem. 2008 Sep;102(9):1765-76 [18614239.001]
  • [Cites] Proteins. 2002 Aug 1;48(2):423-6 [12112707.001]
  • (PMID = 18955706.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] PDB/ 3DX5
  • [Grant] United States / PHS HHS / / HHSN266200400059C; United States / NIAID NIH HHS / AI / N01-AI-40059; United States / NIAID NIH HHS / AI / U54 AI057153; United States / NIGMS NIH HHS / GM / U54 GM074942; United States / NIGMS NIH HHS / GM / U54 GM074942-04S2; United States / NIAID NIH HHS / AI / U54AI57153
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Benzamides; 0 / Hydroxybenzoates; 0 / petrobactin; 27655-56-7 / 3-dehydroshikimate; 29MS2WI2NU / Shikimic Acid; 99-50-3 / protocatechuic acid; EC 4.2.1.- / Hydro-Lyases; EC 4.2.1.10 / 3-dehydroquinate dehydratase
  • [Other-IDs] NLM/ PMC2579390
  •  go-up   go-down


5. Huang W, Rubinstein J, Prieto AR, Thang LV, Wang DH: Transient receptor potential vanilloid gene deletion exacerbates inflammation and atypical cardiac remodeling after myocardial infarction. Hypertension; 2009 Feb;53(2):243-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transient receptor potential vanilloid (TRPV1) channels expressed in sensory afferent fibers innervating the heart may be activated by protons or endovanilloids released during myocardial ischemia (MI), leading to angina.
  • The infarct size was greater in TRPV1(-/-) than in WT mice (P<0.001) 3 days after MI, and the mortality rate was higher in TRPV1(-/-) than in WT mice (P<0.05) 7 days after MI.
  • The levels of plasma cardiac troponin I; cytokines, including tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6; chemokines, including monocyte chemoattractant protein-1 and macrophage inflammatory protein-2; and infiltration of inflammatory cells, including neutrophils, macrophages, and myofibroblasts; as well as collagen contents, were greater in TRPV1(-/-) than in WT mice (P<0.05) in the infarct area on days 3 and 7 after MI.
  • These data show that TRPV1 gene deletion results in excessive inflammation, disproportional left ventricular remodeling, and deteriorated cardiac function after MI, indicating that TRPV1 may prevent infarct expansion and cardiac injury by inhibiting inflammation and abnormal tissue remodeling.

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. See the articles recommended by F1000Prime's Faculty of more than 5,000 expert scientists and clinical researchers. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2002 Dec 19-26;420(6917):846-52 [12490957.001]
  • [Cites] Circulation. 2002 Oct 22;106(17):2167-9 [12390941.001]
  • [Cites] Circulation. 2003 May 27;107(20):2577-82 [12732606.001]
  • [Cites] J Physiol. 2003 Sep 1;551(Pt 2):515-23 [12829722.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2433-40 [14633615.001]
  • [Cites] Circulation. 2003 Dec 23;108(25):3075-8 [14676146.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):665-77 [14742270.001]
  • [Cites] Circ Res. 2004 Jun 25;94(12):1543-53 [15217919.001]
  • [Cites] Circulation. 2004 Sep 28;110(13):1826-31 [15364816.001]
  • [Cites] Am J Cardiol. 1973 Dec;32(7):889-94 [4271258.001]
  • [Cites] Am Heart J. 1987 Jun;113(6):1333-44 [3591601.001]
  • [Cites] Circulation. 1990 Apr;81(4):1161-72 [2138525.001]
  • [Cites] Cell. 1996 Oct 4;87(1):13-20 [8858144.001]
  • [Cites] J Immunol. 1996 Nov 15;157(10):4412-20 [8906816.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):816-24 [9349813.001]
  • [Cites] Circulation. 1997 Nov 18;96(10):3294-9 [9396419.001]
  • [Cites] J Immunol. 1998 Jan 15;160(2):993-1000 [9551939.001]
  • [Cites] J Am Geriatr Soc. 1998 Sep;46(9):1157-62 [9736113.001]
  • [Cites] Pharmacol Rev. 1999 Jun;51(2):159-212 [10353985.001]
  • [Cites] Circulation. 2004 Nov 16;110(20):3221-8 [15533863.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4536-41 [15764707.001]
  • [Cites] Circulation. 2005 Jun 7;111(22):2935-42 [15927970.001]
  • [Cites] Circulation. 2005 Dec 6;112(23):3617-23 [16314376.001]
  • [Cites] Circulation. 2005 Dec 6;112(23):3541-3 [16330693.001]
  • [Cites] Neurobiol Aging. 2006 Jun;27(6):895-903 [15979214.001]
  • [Cites] Brain Res. 2006 Apr 26;1085(1):87-94 [16564032.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1097-9 [17174888.001]
  • [Cites] Am J Pathol. 2007 Mar;170(3):818-29 [17322368.001]
  • [Cites] Circulation. 2007 Apr 10;115(14):1885-94 [17389268.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1173-81 [17237150.001]
  • [Cites] Cell Calcium. 2007 Jul;42(1):17-25 [17184838.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1791-8 [17586621.001]
  • [Cites] FASEB J. 2007 Nov;21(13):3747-55 [17601984.001]
  • [Cites] Mol Cell Neurosci. 2007 Nov;36(3):381-91 [17851089.001]
  • [Cites] Arthritis Rheum. 2008 Jan;58(1):292-301 [18163477.001]
  • [Cites] Cardiovasc Res. 2000 Jan 14;45(2):330-8 [10728353.001]
  • [Cites] Science. 2000 Apr 14;288(5464):306-13 [10764638.001]
  • [Cites] Circ Res. 2000 Sep 29;87(7):543-50 [11009558.001]
  • [Cites] Hypertension. 2001 Mar;37(3):974-80 [11244026.001]
  • [Cites] Cardiovasc Res. 2002 Jan;53(1):31-47 [11744011.001]
  • [Cites] J Am Coll Cardiol. 2002 Jul 3;40(1):56-61 [12103256.001]
  • [Cites] Cell Calcium. 2003 May-Jun;33(5-6):533-40 [12765698.001]
  • (PMID = 19114647.001).
  • [ISSN] 1524-4563
  • [Journal-full-title] Hypertension
  • [ISO-abbreviation] Hypertension
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK67620; United States / NHLBI NIH HHS / HL / HL-57853; United States / NHLBI NIH HHS / HL / HL-73287; United States / NIDDK NIH HHS / DK / R01 DK067620; United States / NIDDK NIH HHS / DK / R01 DK067620-03; United States / NIDDK NIH HHS / DK / R01 DK067620-04; United States / NHLBI NIH HHS / HL / R01 HL057853; United States / NHLBI NIH HHS / HL / R01 HL057853-06; United States / NHLBI NIH HHS / HL / R01 HL057853-07; United States / NHLBI NIH HHS / HL / R01 HL073287; United States / NHLBI NIH HHS / HL / R01 HL073287-04; United States / NHLBI NIH HHS / HL / R01 HL073287-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1beta; 0 / Interleukin-6; 0 / TRPV Cation Channels; 0 / TRPV1 protein, mouse; 0 / Troponin I; 0 / Tumor Necrosis Factor-alpha; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ NIHMS96833; NLM/ PMC2669745
  •  go-up   go-down


6. de Waard MC, van der Velden J, Bito V, Ozdemir S, Biesmans L, Boontje NM, Dekkers DH, Schoonderwoerd K, Schuurbiers HC, de Crom R, Stienen GJ, Sipido KR, Lamers JM, Duncker DJ: Early exercise training normalizes myofilament function and attenuates left ventricular pump dysfunction in mice with a large myocardial infarction. Circ Res; 2007 Apr 13;100(7):1079-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The extent and mechanism of the cardiac benefit of early exercise training following myocardial infarction (MI) is incompletely understood, but may involve blunting of abnormalities in Ca(2+)-handling and myofilament function.
  • Consequently, we investigated the effects of 8-weeks of voluntary exercise, started early after a large MI, on left ventricular (LV) remodeling and dysfunction in the mouse.
  • Exercise had no effect on survival, MI size or LV dimensions, but improved LV fractional shortening from 8+/-1 to 12+/-1%, and LVdP/dt(P30) from 5295+/-207 to 5794+/-207 mm Hg/s (both P<0.05), and reduced pulmonary congestion.
  • These global effects of exercise were associated with normalization of the MI-induced increase in myofilament Ca(2+)-sensitivity (DeltapCa(50)=0.037).
  • Exercise prevented the MI-induced decreased maximum force generating capacity of skinned cardiomyocytes (F(max) increased from 14.3+/-0.7 to 18.3+/-0.8 kN/m(2) P<0.05), which was associated with enhanced shortening of unloaded intact cardiomyocytes (from 4.1+/-0.3 to 7.0+/-0.6%; P<0.05).
  • In conclusion, early exercise in mice after a large MI has no effect on LV remodeling, but attenuates global LV dysfunction.

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Circ Res. 2007 Apr 13;100(7):937-9 [17431194.001]
  • (PMID = 17347478.001).
  • [ISSN] 1524-4571
  • [Journal-full-title] Circulation research
  • [ISO-abbreviation] Circ. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins; E0399OZS9N / Cyclic AMP
  •  go-up   go-down


7. Mukherjee R, Mingoia JT, Bruce JA, Austin JS, Stroud RE, Escobar GP, McClister DM Jr, Allen CM, Alfonso-Jaume MA, Fini ME, Lovett DH, Spinale FG: Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol; 2006 Nov;291(5):H2216-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myocardial remodeling after myocardial infarction (MI) is associated with increased levels of the matrix metalloproteinases (MMPs).
  • Levels of two MMP species, MMP-2 and MMP-9, are increased after MI, and transgenic deletion of these MMPs attenuates post-MI left ventricular (LV) remodeling.
  • This study characterized the spatiotemporal patterns of gene promoter induction for MMP-2 and MMP-9 after MI.
  • MI was induced in transgenic mice in which the MMP-2 or MMP-9 promoter sequence was fused to the beta-galactosidase reporter, and reporter level was assayed up to 28 days after MI.
  • After MI, LV diameter increased by 70% (P < 0.05), consistent with LV remodeling. beta-Galactosidase staining in MMP-2 reporter mice was increased by 1 day after MI and increased further to 64 +/- 6% of LV epicardial area by 7 days after MI (P < 0.05).
  • MMP-2 promoter activation occurred in fibroblasts and myofibroblasts in the MI region.
  • In MMP-9 reporter mice, promoter induction was detected after 3 days and peaked at 7 days after MI (53 +/- 6%, P < 0.05) and was colocalized with inflammatory cells at the peri-infarct region.
  • Although MMP-2 promoter activation was similarly distributed in the MI and border regions, activation of the MMP-9 promoter was highest at the border between the MI and remote regions.
  • These unique findings visually demonstrated that activation of the MMP-2 and MMP-9 gene promoters occurs in a distinct spatial relation with reference to the MI region and changes in a characteristic time-dependent manner after MI.

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766634.001).
  • [ISSN] 0363-6135
  • [Journal-full-title] American journal of physiology. Heart and circulatory physiology
  • [ISO-abbreviation] Am. J. Physiol. Heart Circ. Physiol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK-29776; United States / NEI NIH HHS / EY / EY-12651; United States / NEI NIH HHS / EY / EY-14801; United States / NHLBI NIH HHS / HL / HL-45024; United States / NHLBI NIH HHS / HL / HL-66029; United States / NHLBI NIH HHS / HL / HL-97012; United States / NHLBI NIH HHS / HL / P01-HL-48788; United States / NHLBI NIH HHS / HL / P01-HL-68738
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.1.23 / beta-Galactosidase; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


8. Kaski JC, Consuegra-Sanchez L, Fernandez-Berges DJ, Cruz-Fernandez JM, Garcia-Moll X, Marrugat J, Mostaza J, Toro-Cebada R, González-Juanatey JR, Guzmán-Martínez G, SIESTA Investigators: Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome. Atherosclerosis; 2008 Nov;201(1):176-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to assess whether plasma neopterin levels predict adverse clinical outcomes in Mediterranean patients with non-ST elevation (NSTE) ACS, i.e. unstable angina (UA) and NSTE myocardial infarction (MI).

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336825.001).
  • [ISSN] 1879-1484
  • [Journal-full-title] Atherosclerosis
  • [ISO-abbreviation] Atherosclerosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biological Markers; 670-65-5 / Neopterin; 9007-41-4 / C-Reactive Protein
  • [Investigator] Fernández MC; López García-Aranda V; Cabrera R; García de la Borbolla M; Toro R; Sancho Jaldón M; Fernández-Bergés D; Zaro MJ; Alzugaray R; Veiga M; Cordoba A; González-Juanatey JR; Grigorian L; Bassante P; Martín Jadraque L; Guzmán Martínez G; Martín Luengo C; Sánchez PL; Moriñigo JL; Castro Beiras A; Mosquera I; Montes Orbe PM; Eguía Astobiza I; García-Moll X; Martí MM; Barriales Alvarez V; Lee Hwang DH; Carrasco Sánchez FJ; Tobaruela A; Santos JM; Delgado S; Santos C; Villaroel MT; Capdevila A; Limiñana C; Castillo Domínguez JC; Sotillo Martí J; Dallí E; Martinez ML; Moreno MT; Castillo Lueña E; López-Bescós L; Jiménez J; Vallés Belsúe F; López Granados A; Diago Torrent JL; Marcos Gómez G; Sogorb Garrí F; Payá Mora E; Valls A; Muñoz Aguilera R; Serrano Sanz JA; Pascual Hernández D; García Robles JA; Pérez de Juan Romero M; Mostaza J; Lahoz C
  •  go-up   go-down


9. Li YN, Zou DH, Gu M, Mi YC, Wang JX, Qiu LG: [The role of BCR/ABL isoforms in the presentations and outcome of Philadelphia-positive acute lymphoblastic leukemia in adult patients]. Zhonghua Nei Ke Za Zhi; 2009 Jun;48(6):481-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of BCR/ABL isoforms in the presentations and outcome of Philadelphia-positive acute lymphoblastic leukemia in adult patients].
  • OBJECTIVE: To investigate the difference of clinical characteristics and outcomes between different isoforms of BCR/ABL in adults with Philadelphia-positive acute lymphoblastic leukemia (ALL).
  • METHODS: The data of 106 adults with Ph+ ALL diagnosed in our hospital from January 1, 1996 to December 31, 2007 were reviewed.
  • The difference of clinical characteristics between different subgroups of BCR/ABL was compared and their relation with outcomes was studied.
  • RESULTS: The median age of the 106 patients was 34 years and the median white blood cell count at baseline was 28.5 x 10(9)/L.
  • Comparative analysis demonstrated that patients in p210 group had an older age, higher blood platelet count (BPC) and more frequent occurrence of splenomegaly.
  • Referring to the outcomes, the complete remission (CR) rate of the two groups were 92.2% and 93.9%, respectively.
  • The median overall survival (OS) and relapse free survival (RFS) in p190 group were 13 months and 10 months, the 1, 3-year estimated OS were (54.7 +/- 6.7)% and (5.5 +/- 5.2)%, and the 1, 3-year estimated RFS were (40.2 +/- 6.8)% and (7.8 +/- 6.7)%, while in p210 group, the median OS and RFS were 15 months and 10 months, respectively, the 1, 3-year estimated OS were (65.8 +/- 8.9)% and (14.5 +/- 7.4)%, and the 1, 3-year estimated RFS were (48.3 +/- 9.4)% and (12.9 +/- 7.7)%.
  • All of the above data had no statistic significance between the two groups.
  • CONCLUSION: Majority of the adults with Ph+ ALL is p190 positive and patients with p210 have older age, higher BPC and more frequent occurrence of splenomegaly, while there is no significant difference between p190 group and p210 group in CR rate, RFS and OS.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Philadelphia Chromosome. Prognosis. Protein Isoforms / genetics. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954044.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / abl-bcr fusion protein, human; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


10. Yan AT, Yan RT, Tan M, Senaratne M, Fitchett DH, Langer A, Goodman SG, INTERACT Investigators: Long-term prognostic value and therapeutic implications of continuous ST-segment monitoring in acute coronary syndrome. Am Heart J; 2007 Apr;153(4):500-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After a median follow-up of 30 months, patients with ST-segment shifts had a higher risk of death (17.7% vs 5.8%, log-rank P < .001) and death or myocardial infarction (MI) (24.6% vs 11.1%, log-rank P < .001).
  • In multivariable analysis adjusting for GRACE risk score, the presence of ST-segment shifts remained an independent predictor of death (adjusted hazard ratio = 2.37, 95% CI 1.38-4.09, P = .002) and death/MI (adjusted hazard ratio = 1.93, 95% CI 1.25-3.00, P = .003).
  • Inhospital revascularization was independently associated with a lower risk of death/MI among patients with ST-segment shifts but not among those without (P for interaction = .02).

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • ResearchGate. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17383285.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Morden P, Drongowski RA, Geiger JD, Hirschl RB, Teitelbaum DH: Comparison of Karydakis versus midline excision for treatment of pilonidal sinus disease. Pediatr Surg Int; 2005 Oct;21(10):793-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of Karydakis versus midline excision for treatment of pilonidal sinus disease.
  • Pilonidal sinus disease is associated with a high rate of recurrence and complications.
  • The Karydakis (KAR) method, whereby an asymmetric subcutaneous flap obliterates the anal crease, has been shown to be effective in adults.
  • The goal of this study is to assess the efficacy of the KAR procedure in the operative treatment of children with pilonidal sinus disease compared to those treated via a midline excision (ME).
  • Sixty-eight cases of pediatric pilonidal sinus excision were reviewed over the past 10 years.
  • Data abstracted included surgical approach, complication rate and recurrence rate.
  • Student's t-test or the Chi square test was used for statistical analysis, with P < 0.05 being considered significant.
  • An ME was performed in 44 patients; the KAR method was used in 24 patients.
  • Mean age at diagnosis was 14.4 +/- 4.2 years for the ME group compared to 15.7 +/- 4.3 years for the KAR patients (P = 0.18).
  • Mean operative time was significantly longer with the KAR method (58.7 +/- 25.6 min) compared to 46.3 +/- 18.6 for the primary ME (P = 0.04).
  • Despite the increased operative dissection, there was no difference (P = 0.42) in early post-operative complication rates between groups (25% in the KAR group compared to 34.8% in the ME group).
  • Initial drainage of an abscess had no significant effect upon the recurrence/complication rate in either group.
  • Recurrence rate alone was lower in patients operated on via the KAR approach 0% versus 11.0% using the ME (P = 0.153).
  • Recurrence and complication rates were lower for those patients with a pilonidal sinus treated by the KAR method compared to the ME, but the results did not reach significance.
  • In conclusion, this study does show a potential benefit for children treated with the KAR method for pilonidal sinus.
  • This study mimics the data obtained in adult patients and suggests that a larger study is likely to achieve significance.
  • [MeSH-major] Pilonidal Sinus / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Postoperative Complications. Recurrence. Reoperation. Surgical Flaps

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172873.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Roberts FO, Gunawardana DH, Pathmaraj K, Wallace A, U PL, Mi T, Berlangieri SU, O'Keefe GJ, Rowe CC, Scott AM: Radiation dose to PET technologists and strategies to lower occupational exposure. J Nucl Med Technol; 2005 Mar;33(1):44-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose to PET technologists and strategies to lower occupational exposure.
  • OBJECTIVE: The use of PET in Australia has grown rapidly.
  • We conducted a prospective study of the radiation exposure of technologists working in PET and evaluated the occupational radiation dose after implementation of strategies to lower exposure.
  • METHODS: Radiation doses measured by thermoluminescent dosimeters over a 2-y period were reviewed both for technologists working in PET and for technologists working in general nuclear medicine in a busy academic nuclear medicine department.
  • The separate components of the procedures for dose administration and patient monitoring were assessed to identify the areas contributing the most to the dose received.
  • The impact on dose of implementing portable 511-keV syringe shields (primary shields) and larger trolley-mounted shields (secondary shields) was also compared with initial results using no shield.
  • RESULTS: We found that the radiation exposure of PET technologists was higher than that of technologists performing general nuclear medicine studies, with doses averaging 771 +/- 147 and 524 +/- 123 microSv per quarter, respectively (P = 0.01).
  • The estimated dose per PET procedure was 4.1 microSv (11 nSv/MBq).
  • Injection of 18F-FDG contributed the most to radiation exposure.
  • The 511-keV syringe shield reduced the average dose per injection from 2.5 to 1.4 microSv (P < 0.001).
  • For the longer period of dose transportation and injection, the additional use of the secondary shield resulted in a significantly lower dose of radiation than did use of the primary shield alone or no shield (1.9 vs. 3.6 microSv [P = 0.01] and 3.4 microSv [P = 0.03], respectively).
  • CONCLUSION: The radiation doses currently received by technologists working in PET are within accepted occupational health guidelines, but improved shielding can further reduce the dose.
  • [MeSH-major] Nuclear Medicine Department, Hospital / statistics & numerical data. Occupational Exposure / prevention & control. Occupational Exposure / statistics & numerical data. Positron-Emission Tomography / statistics & numerical data. Radiation Monitoring / methods. Radiation Protection / methods. Risk Assessment / methods
  • [MeSH-minor] Australia / epidemiology. Humans. Radiation Dosage. Radiation Injuries / prevention & control. Risk Factors. Thermoluminescent Dosimetry / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15731021.001).
  • [ISSN] 0091-4916
  • [Journal-full-title] Journal of nuclear medicine technology
  • [ISO-abbreviation] J Nucl Med Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Xagoraraki I, Kuo DH, Wong K, Wong M, Rose JB: Occurrence of human adenoviruses at two recreational beaches of the great lakes. Appl Environ Microbiol; 2007 Dec;73(24):7874-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of human adenoviruses at two recreational beaches of the great lakes.
  • Human adenoviruses (HAdVs) have been related to several waterborne diseases such as acute gastroenteritis, conjunctivitis, and respiratory illness, and it has been shown that an important human exposure pathway is through recreational waters.
  • However, HAdV occurrence at recreational freshwater beaches has not been previously investigated.
  • In this study, a total of 58 water samples were collected from two recreational beaches on Lake Michigan (i.e., Silver Beach and Washington Park Beach) during the summer of 2004.
  • Occurrences of HAdVs in these lake samples were determined using two hexon-based real-time PCR assays (one for monitoring all 51 serotypes of HAdVs and another for specifically detecting F species HAdVs, i.e., serotypes 40 and 41) and compared to an integrated cell culture (ICC) PCR method.
  • The real-time PCR results showed that 8 of 30 Silver Beach samples and 6 of 28 Washington Park Beach samples contained HAdVs, and F species HAdVs were detected in three of these positive samples.
  • The concentrations of HAdVs ranged from (1.7 +/- 0.7) x 10(1) to (3.4 +/- 0.8) x 10(2) and from (7 +/- 2) x 10(0) to (3.8 +/- 0.3) x 10(3) virus particles/liter for Silver Beach and Washington Park Beach, respectively.
  • F species HAdVs were detected at levels ranging from (4.8 +/- 0.8) x 10(1) to (4.6 +/- 1.5) x 10(2) virus particles/liter.
  • Approximately 60% of the ICC-PCR analyses agreed with the real-time PCR results.
  • This study revealed the occurrence of HAdVs at Lake Michigan recreational beaches.
  • Given the potential health risks, further assessment regarding sources, virus transport, and survival is needed to improve the safety of the region.
  • [MeSH-major] Adenoviridae / classification. Adenoviridae / isolation & purification. Fresh Water / virology
  • [MeSH-minor] Capsid Proteins / genetics. DNA, Viral / genetics. Great Lakes Region. Humans. Polymerase Chain Reaction / methods. Virus Cultivation / methods

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 2001 Feb;39(2):498-505 [11158096.001]
  • [Cites] J Clin Microbiol. 2006 Sep;44(9):3189-95 [16954246.001]
  • [Cites] Water Sci Technol. 2001;43(12):1-8 [11464736.001]
  • [Cites] J Appl Microbiol. 2002;93(5):745-50 [12392518.001]
  • [Cites] Appl Environ Microbiol. 2002 Dec;68(12):5990-8 [12450820.001]
  • [Cites] J Med Virol. 2003 Jun;70(2):228-39 [12696109.001]
  • [Cites] Water Res. 2003 Sep;37(15):3704-8 [12867338.001]
  • [Cites] J Virol Methods. 2004 Jun 1;118(1):49-59 [15158068.001]
  • [Cites] Appl Environ Microbiol. 2004 Jun;70(6):3632-6 [15184167.001]
  • [Cites] J Appl Microbiol. 2004;97(1):17-28 [15186438.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3232-9 [15243087.001]
  • [Cites] Water Sci Technol. 2004;50(1):39-43 [15318484.001]
  • [Cites] J Clin Microbiol. 2004 Sep;42(9):3963-9 [15364976.001]
  • [Cites] Appl Environ Microbiol. 1984 Mar;47(3):591-2 [6324679.001]
  • [Cites] J Infect. 1986 Jul;13(1):73-89 [3734469.001]
  • [Cites] South Med J. 1987 Jun;80(6):712-5 [3035727.001]
  • [Cites] J Clin Microbiol. 1990 Aug;28(8):1780-4 [2168438.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] J Clin Microbiol. 1990 Dec;28(12):2659-67 [2279998.001]
  • [Cites] J Med Virol. 1992 Jun;37(2):149-57 [1629713.001]
  • [Cites] J Virol. 1994 Jan;68(1):379-89 [8254750.001]
  • [Cites] Appl Environ Microbiol. 1994 Aug;60(8):2963-70 [8085832.001]
  • [Cites] Appl Environ Microbiol. 1997 Oct;63(10):3741-51 [9327537.001]
  • [Cites] Scand J Infect Dis. 1997;29(4):415-8 [9360259.001]
  • [Cites] Appl Environ Microbiol. 2000 Jun;66(6):2520-5 [10831432.001]
  • [Cites] J Clin Microbiol. 2000 Nov;38(11):4114-20 [11060077.001]
  • [Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]
  • [Cites] J Infect. 1998 Jan;36(1):101-3 [9515677.001]
  • [Cites] Nucleic Acids Res. 1998 Jul 1;26(13):3309-10 [9628935.001]
  • [Cites] Mol Cell Probes. 1998 Jun;12(3):175-80 [9664580.001]
  • [Cites] Appl Environ Microbiol. 1998 Sep;64(9):3376-82 [9726885.001]
  • [Cites] J Clin Microbiol. 1998 Nov;36(11):3323-6 [9774586.001]
  • [Cites] Appl Environ Microbiol. 2004 Nov;70(11):6695-705 [15528536.001]
  • [Cites] Water Res. 2005 Jan-Feb;39(2-3):297-304 [15644238.001]
  • [Cites] J Virol Methods. 2005 May;125(2):111-8 [15794979.001]
  • [Cites] Appl Environ Microbiol. 2005 Apr;71(4):2070-8 [15812040.001]
  • [Cites] Arch Virol. 2005 May;150(5):929-47 [15645371.001]
  • [Cites] J Appl Microbiol. 2005;98(5):1020-9 [15836470.001]
  • [Cites] Appl Environ Microbiol. 2005 May;71(5):2250-5 [15870308.001]
  • [Cites] Appl Environ Microbiol. 2005 Jun;71(6):3131-6 [15933012.001]
  • [Cites] J Virol Methods. 2005 Aug;127(2):148-53 [15967237.001]
  • [Cites] Can J Microbiol. 2005 May;51(5):393-8 [16088334.001]
  • [Cites] J Appl Microbiol. 2005;99(5):1256-64 [16238757.001]
  • [Cites] Appl Environ Microbiol. 2005 Nov;71(11):7426-33 [16269784.001]
  • [Cites] J Microbiol. 2006 Apr;44(2):162-70 [16728952.001]
  • [Cites] Arch Virol. 2006 Aug;151(8):1587-602 [16502282.001]
  • [Cites] J Virol Methods. 2001 Apr;92(2):113-20 [11226558.001]
  • (PMID = 17933924.001).
  • [ISSN] 1098-5336
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Capsid Proteins; 0 / DNA, Viral; 0 / hexon capsid protein, Adenovirus
  • [Other-IDs] NLM/ PMC2168141
  •  go-up   go-down


14. Barr JR, Pierce CL, Smith JR, Capacio BR, Woolfitt AR, Solano MI, Wooten JV, Lemire SW, Thomas JD, Ash DH, Ashley DL: Analysis of urinary metabolites of sulfur mustard in two individuals after accidental exposure. J Anal Toxicol; 2008 Jan-Feb;32(1):10-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of urinary metabolites of sulfur mustard in two individuals after accidental exposure.
  • In July 2004, two individuals developed blisters after the destruction of a WWI-era munition.
  • To determine the causative agent, urine samples were collected from both the highly blistered patient (patient 1; 6.5% of total body surface area) and patient 2, who had only one small blister.
  • Their urine was analyzed for metabolites of known vesicants including sulfur mustard (HD), Lewisite (L1), and nitrogen mustards.
  • The urine samples only tested positive for metabolites of HD.
  • Additional metabolites were measured to confirm the exposure of sulfur mustard agent HD, including thiodiglycol (TDG), TDG-sulfoxide, and the bis-mercapturate of mustard sulfone.
  • On day 2 after the exposure, patient 1 had a beta-lyase metabolite level of 41 ng/mL, and patient 2 had a level of 2.6 ng/mL.
  • Detectable levels of the beta-lyase metabolite were observed in patient 1 for 11 days and in patient 2 for 7 days.
  • Levels of TDG and both TDG and its sulfoxide measured together in the urine of patient 1 were found to be 24 ng/mL and 50 ng/mL, respectively, on day 2.
  • The bis-mercapturate of mustard sulfone was detected in patient 1 (3.1 ng/mL) on day 2 but was not detected in samples taken on subsequent days.
  • [MeSH-major] Environmental Monitoring / methods. Mustard Gas / analysis
  • [MeSH-minor] Biological Markers / urine. Chromatography, Liquid. Environmental Exposure / analysis. Gas Chromatography-Mass Spectrometry. Humans. Lyases / metabolism. Sulfhydryl Compounds / urine. Sulfoxides / urine. Tandem Mass Spectrometry

  • HSDB. structure - THIODIGLYCOL.
  • HSDB. structure - BIS(2-CHLOROETHYL)SULFIDE.
  • ResearchGate. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269787.001).
  • [ISSN] 0146-4760
  • [Journal-full-title] Journal of analytical toxicology
  • [ISO-abbreviation] J Anal Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biological Markers; 0 / Sulfhydryl Compounds; 0 / Sulfoxides; 2580-77-0 / 2,2'-sulfinylbisethanol; 9BW5T43J04 / 2,2'-thiodiethanol; EC 4.- / Lyases; T8KEC9FH9P / Mustard Gas
  •  go-up   go-down


15. Slottow TL, Steinberg DH, Roy P, Javaid A, Buch AN, Okabe T, Xue Z, Smith K, Torguson R, Pichard AD, Satler LF, Suddath WO, Kent KM, Waksman R: Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction. Cardiovasc Revasc Med; 2008 Jan-Mar;9(1):24-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At 1 year, all-cause mortality was 13.3% in the BMS group and 9.2% in the DES group [P=not significant (ns)], recurrent MI was 5.3% in the BMS group vs. 4.4% in the DES group (P=ns), and TVR was 7% in the BMS group vs. 8.7% in the DES group (P=ns).

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • HSDB. structure - TAXOL.
  • HSDB. structure - SIROLIMUS.
  • ResearchGate. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206634.001).
  • [ISSN] 1878-0938
  • [Journal-full-title] Cardiovascular revascularization medicine : including molecular interventions
  • [ISO-abbreviation] Cardiovasc Revasc Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cardiovascular Agents; 0 / Metals; 0 / Platelet Aggregation Inhibitors; 33069-62-4 / Paclitaxel; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


16. Klaver D, Hung AC, Gasperini R, Foa L, Aguilar MI, Small DH: Effect of heparin on APP metabolism and Abeta production in cortical neurons. Neurodegener Dis; 2010;7(1-3):187-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of heparin on APP metabolism and Abeta production in cortical neurons.
  • BACKGROUND: The beta-site APP cleaving enzyme 1 (BACE1) is a major target for drug design in Alzheimer's disease.
  • BACE1 binds strongly to heparin and other glycosaminoglycans, and there is evidence that the enzyme may interact with proteoglycans in vivo.
  • Several studies suggest that heparin or heparan sulfate analogues may have value as therapeutic agents for the treatment of AD.
  • OBJECTIVE: To determine whether heparin can inhibit Abeta production in cortical neurons by inhibiting BACE1.
  • METHODS: Cortical neurons from APP (SW) Tg2576 mice were incubated with heparin and the amount of APP processing and Abeta production were measured by enzyme-linked immunosorbent assay and Western blotting.
  • RESULTS: Treatment of cortical neurons with heparin inhibited Abeta secretion.
  • However, this effect was not mediated via inhibition of BACE1.
  • CONCLUSIONS: Heparin or other glycosaminoglycans may have value for the treatment of Alzheimer's disease.
  • However, the data do not support the view that a heparin-induced decrease in Abeta secretion is due to inhibition of BACE1.
  • [MeSH-major] Amyloid beta-Peptides / metabolism. Amyloid beta-Protein Precursor / metabolism. Cerebral Cortex / cytology. Fibrinolytic Agents / pharmacology. Heparin / pharmacology. Neurons / drug effects
  • [MeSH-minor] Amyloid Precursor Protein Secretases / metabolism. Animals. Animals, Newborn. Aspartic Acid Endopeptidases / metabolism. Cells, Cultured. Dose-Response Relationship, Drug. Gene Expression Regulation / drug effects. Humans. Mice. Mice, Transgenic

  • Genetics Home Reference. consumer health - APP Gene.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • HSDB. structure - HEPARIN.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20224283.001).
  • [ISSN] 1660-2862
  • [Journal-full-title] Neuro-degenerative diseases
  • [ISO-abbreviation] Neurodegener Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Amyloid beta-Peptides; 0 / Amyloid beta-Protein Precursor; 0 / Fibrinolytic Agents; 9005-49-6 / Heparin; EC 3.4.- / Amyloid Precursor Protein Secretases; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.46 / Bace1 protein, mouse
  •  go-up   go-down


17. Kang SJ, Lee EY, Song JK, Do KH, Seo JB, Lim TH, Song JM, Kang DH, Kim YH, Lee CW, Hong MK, Park SW, Park SJ: Assessment of papillary muscle function in patients with inferior wall myocardial infarction using Doppler tissue imaging. J Am Soc Echocardiogr; 2005 Aug;18(8):815-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: We sought to assess the relationship between infarct status and systolic contractile function of papillary muscle (PM) for patients with inferior wall myocardial infarction (MI).
  • METHODS: Peak systolic velocity (V) of posteromedial PM, systolic strain (epsilon) of posteromedial PM (epsilonPM), V of adjacent inferior wall, and of adjacent inferior wall (epsilonW) were calculated from color Doppler tissue imaging images obtained at apical views in 25 patients with inferior MI and in 13 healthy control subjects.
  • All 25 patients with MI underwent magnetic resonance imaging to assess the infarct status of PM.
  • RESULTS: Compared with the control subjects, patients with MI had significantly lower V of adjacent inferior wall (5.0 +/- 0.8 vs 4.4 +/- 1.1 cm/s, P = .049) and V of posteromedial PM (4.9 +/- 0.8 vs 4.0 +/- 1.2 cm/s, P = .005), and less systolic deformation, as demonstrated by epsilonW (-17 +/- 3 vs -6 +/- 5%, P < .001) and epsilonPM (-24 +/- 5 vs -11 +/- 6%, P < .001).
  • There was a weak positive correlation between epsilonW and epsilonPM (r = 0.393, P = .052) for patients with MI.
  • CONCLUSIONS: In patients with inferior wall MI, infarct status of the PM is variable and determines its systolic contractile function, which can be quantified by epsilon measurement using Doppler tissue imaging.

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084333.001).
  • [ISSN] 1097-6795
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Lemesle G, Bonello L, De Labriolle A, Steinberg DH, Roy P, Slottow TL, Torguson R, Kaneshige K, Xue Z, Suddath WO, Satler LF, Kent KM, Lindsay J, Pichard AD, Waksman R: Impact of bivalirudin use on outcomes in nonagenarians undergoing percutaneous coronary intervention. J Interv Cardiol; 2009 Feb;22(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In-hospital and 6-month rates of major adverse cardiovascular events (MACE) including death, myocardial infarction (MI), and target lesion revascularization were indexed.
  • The clinical presentation was an acute MI in 59% of the cases.
  • Clinical presentations as MI or cardiogenic shock were associated with high rates of in-hospital death: 19.3% and 30%, respectively.
  • Predictors of 6-month outcomes were clinical presentations as MI or cardiogenic shock, renal failure, and total stent length.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • HSDB. structure - HEPARIN.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19281522.001).
  • [ISSN] 1540-8183
  • [Journal-full-title] Journal of interventional cardiology
  • [ISO-abbreviation] J Interv Cardiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Hirudins; 0 / Peptide Fragments; 0 / Recombinant Proteins; 128270-60-0 / bivalirudin; 9005-49-6 / Heparin
  •  go-up   go-down


19. Kostianev SS, Hodgev VA, Iluchev DH: Multidimensional system for assessment of COPD patients. Comparison with BODE index. Folia Med (Plovdiv); 2008 Oct-Dec;50(4):29-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The letters of the abbreviation stand for the following: D--dyspnea, O--obstruction, RE--rate of exacerbation, MI--movement (exercise) intolerance, B--Body Mass Index, OX--blood oxygen disturbances.

  • MedlinePlus Health Information. consumer health - COPD.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19209528.001).
  • [ISSN] 0204-8043
  • [Journal-full-title] Folia medica
  • [ISO-abbreviation] Folia Med (Plovdiv)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


20. Wang GR, Zhao YZ, Qian LS, Zou DH, Li R, Mi YC, Wang XX, Qiu LG: [Analysis of long-term treatment outcome and related factors in 95 chronic myeloid leukemia patients treated with imatinib]. Zhonghua Xue Ye Xue Za Zhi; 2008 Jan;29(1):18-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of long-term treatment outcome and related factors in 95 chronic myeloid leukemia patients treated with imatinib].
  • OBJECTIVE: To investigate the efficacy of imatinib in the treatment of chronic myeloid leukemia (CML) and analyse the treatment outcome and related factors.
  • METHODS: Ninety five CML patients were treated with imatinib in our hospital from May 2002 to May 2006.
  • The outcomes and related factors were analysed. RESULTS:.
  • (1) One year after therapy, there were 95.5% of chronic phase (CP) patients achieved complete hematologic response (CHR).
  • Fifty-two patients with complete cytogenetic dates were divided into primary-therapy group (n = 19) and secondary-therapy group (n = 33).
  • The major cytogenetic responses (MCyR) at 6-, 12-, 18-, 24- and 30-months after therapy for the former group were 84.2%, 84.2%, 89.5%, 89.5% and 94.7%, and for the latter group were 36.4%, 39.4%, 39.4%, 39.4% and 39.4%, respectively (P < 0.01).
  • The expected survival at 12-, 24-, 36- and 50-month after imatinib treatment for CP group was (98.1 +/-1.9)%, (87.8 +/- 7.1)%, (81.9 +/- 8.7)% and (81.9 +/- 8.7)%, respectively. (2) Twelve month after therapy, there are 70% of accelerated phase (AP) patients achieve CHR and 10% get MCyR.
  • The expected survival at 12-, 24- and 36-month after imatinib treatment for AP group was (63.0 +/- 17.7)%, (15.8 +/- 14.3)% and (15.8 +/- 14.3)%, respectively. (3) Six month after therapy, 57.9% of blast crisis (BC) patients achieve CHR, with the expected survival at 12- and 24-month of (40.6 +/- 12.3)% and 0, respectively. (4) COX analysis CP group indicated that imatinib therapy administered for previously untreated was an independent favorable prognostic factor.
  • Conclusion (1) Imatinib as a primary treatment for CP CML can significantly improve the survival time as compared with that AP or BC patients or with that used in previously treated patients. (2) Imatinib could induce hematologic, even cytogenetic response to a certain extent, in CP or BC patients and prolong the survival time.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Benzamides. Female. Humans. Male. Middle Aged. Treatment Outcome. Young Adult


21. Spencer AU, Sun X, El-Sawaf M, Haxhija EQ, Brei D, Luntz J, Yang H, Teitelbaum DH: Enterogenesis in a clinically feasible model of mechanical small-bowel lengthening. Surgery; 2006 Aug;140(2):212-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enterogenesis in a clinically feasible model of mechanical small-bowel lengthening.
  • BACKGROUND: Recent work indicates that mechanical force induces small-bowel growth, although methods reported do not have direct clinical application.
  • We report a clinically feasible technique of enterogenesis and describe intestinal function in this model.
  • METHODS: Using a pig model (n = 11), we stretched isolated small intestinal segments mechanically for 7 days in vivo with an intraluminal device.
  • Control segments were not stretched.
  • Morphology, histology, and epithelial proliferation were assessed.
  • Absorption and epithelial barrier function were examined in an Ussing chamber.
  • RESULTS: Stretch segments were significantly longer than Control segments and had nearly 2-fold greater surface area (P < .001).
  • Mucosal thickness was much greater in Stretch than Control segments (772 +/- 134 vs. 647 +/- 75 microm, P = .02).
  • Although villus height was reduced in Stretch and Control segments (353 +/- 76 vs. 324 +/- 76 microm, P = .6) versus native jejunum (522 +/- 87, P < .0005), crypt depth was increased dramatically in Stretch (450 +/- 95 microm) versus Control segments (341 +/- 64, P = .005).
  • This observation was accompanied by a 2-fold increase in cellular proliferation (26.3 +/- 3.8 vs 12.1 +/- 6.6 % bromodeoxyuridine+, P < .05).
  • Barrier function was intact ([3H]-mannitol permeation, 0.16 +/- 0.08%, vs native jejunum, 0.17 +/- 0.08%, P = .81).
  • Glucose-mediated sodium transport was similar in Stretch versus native jejunum segments (60.0 +/- 23.5 vs 82.3 +/- 47.3 microA/cm2, P = .31), as was carbachol-induced chloride transport (82.4 +/- 72.2 vs 57.2 +/- 33.4 microA/cm2, P = .54) and alanine absorption (16.46 +/- 12.94 vs 23.53 +/- 21.31 microA/cm2, P = .53).
  • CONCLUSIONS: Mechanical stretching induces small intestinal growth, while maintaining function.
  • Epithelial architecture does change, such that a decrease in villus height is offset by a marked increase in crypt depth and a 2-fold increase in epithelial proliferation.
  • Epithelial barrier and absorptive functions remain intact.
  • The device described may have direct clinical applicability.
  • [MeSH-major] Jejunum / growth & development. Stress, Mechanical. Tissue Expansion Devices
  • [MeSH-minor] Animals. Equipment Design. Feasibility Studies. Female. Intestinal Absorption / physiology. Models, Animal. Swine. Tensile Strength

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2004 Apr 1;172(7):4151-8 [15034027.001]
  • [Cites] Annu Rev Biomed Eng. 2004;6:275-302 [15255771.001]
  • [Cites] Clin Orthop Relat Res. 1990 Jan;(250):8-26 [2403497.001]
  • [Cites] Pediatr Clin North Am. 1993 Dec;40(6):1335-50 [8255628.001]
  • [Cites] Curr Opin Pediatr. 1995 Oct;7(5):560-8 [8541957.001]
  • [Cites] J Pediatr Surg. 1996 Mar;31(3):415-9 [8708915.001]
  • [Cites] J Am Coll Surg. 1996 Nov;183(5):441-9 [8912612.001]
  • [Cites] Digestion. 1997;58(3):240-8 [9243119.001]
  • [Cites] J R Soc Med. 1997 Aug;90(8):429-32 [9306995.001]
  • [Cites] Endocrinology. 1997 Nov;138(11):4837-43 [9348213.001]
  • [Cites] J Surg Res. 1998 Jun;77(1):17-22 [9698526.001]
  • [Cites] Am J Physiol. 1998 Sep;275(3 Pt 1):G534-41 [9724266.001]
  • [Cites] Plast Reconstr Surg (1946). 1957 Feb;19(2):124-30 [13419574.001]
  • [Cites] J Pediatr Surg. 2004 Dec;39(12):1823-7 [15616941.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Mar 18;328(3):751-5 [15694410.001]
  • [Cites] Gut. 2005 Aug;54(8):1085-90 [15840689.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11594-9 [16049098.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):403-9; discussion 409-12 [16135926.001]
  • [Cites] Ann Surg. 2005 Nov;242(5):655-61 [16244538.001]
  • [Cites] Eur J Pediatr Surg. 1999 Aug;9(4):256-9 [10532271.001]
  • [Cites] Gastroenterology. 1999 Nov;117(5):1043-50 [10535866.001]
  • [Cites] Biochem Biophys Res Commun. 2000 May 27;272(1):298-302 [10872843.001]
  • [Cites] Mol Biol Cell. 2000 Jul;11(7):2485-96 [10888683.001]
  • [Cites] Gut. 2000 Aug;47(2):164 [10896902.001]
  • [Cites] J Pediatr Surg. 2001 Jan;36(1):178-83 [11150461.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 2001 Jan-Feb;25(1):18-22 [11190985.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):806-15 [11231933.001]
  • [Cites] Curr Gastroenterol Rep. 2002 Jun;4(3):229-37 [12010624.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):226-34 [12170028.001]
  • [Cites] Plast Reconstr Surg. 2003 Jan;111(1):211-22; discussion 223-4 [12496582.001]
  • [Cites] J Pediatr Surg. 2003 Mar;38(3):425-9 [12632361.001]
  • [Cites] Crit Care Med. 2003 Apr;31(4):1118-25 [12682482.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 2003 May-Jun;27(3):198-206; discussion 206-7 [12757114.001]
  • (PMID = 16904972.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI044076
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS15554; NLM/ PMC1764912
  •  go-up   go-down


22. Gruber SA, West MS, Sillix DH, El-Amm JM, Garnick J, Morawski K, Haririan A: Preliminary results with early corticosteroid withdrawal in African American renal allograft recipients. Surgery; 2005 Oct;138(4):772-8; discussion 778-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary results with early corticosteroid withdrawal in African American renal allograft recipients.
  • BACKGROUND: There is a paucity of data regarding the use of steroid-avoidance immunosuppression (SAI) in African American (AA) renal allograft recipients, traditionally considered a high-risk subgroup of patients with higher reported rates of acute rejection and graft loss.
  • METHODS: We compared the outcomes of 27 AA renal allograft recipients receiving SAI (SA group; mean follow-up period, 12 +/- 3 mo) with those of 20 patients receiving a steroid taper (ST group; 24 +/- 11 mo).
  • In both groups, thymoglobulin was used for induction, and mycophenolate mofetil and tacrolimus were used for maintenance.
  • Four doses of methylprednisolone were given on days 0 to 3.
  • In the SA group no further steroids were given, whereas in the ST group a prednisone taper was continued thereafter.
  • RESULTS: ST patients were more likely to have current panel reactive antibody titers greater than 10%, undergo retransplantation, and receive more doses of thymoglobulin.
  • There were no significant differences between the SA and ST groups with regard to patient survival (96% vs 95%), graft survival (96% vs 90%), acute rejection (11% vs 14%), cytomegalovirus infection (7% vs 10%), posttransplant diabetes mellitus (11% vs 24%), or mean serum creatinine concentration at 6 months (1.6 vs 1.5 mg/dL), respectively, with a trend toward less percent weight gain in SA patients at 6 months (5% vs 11%, P = .06).
  • CONCLUSIONS: SAI can produce excellent short-term results in AA kidney transplant patients when compared with a conventional ST protocol.
  • Our results will need to be verified in larger numbers of patients with longer follow-up evaluation.
  • [MeSH-major] Adrenal Cortex Hormones / administration & dosage. African Americans. Kidney Transplantation
  • [MeSH-minor] Acute Disease. Adult. Biopsy. Case-Control Studies. Drug Administration Schedule. Graft Rejection / epidemiology. Graft Survival. Humans. Immunosuppressive Agents / therapeutic use. Incidence. Kidney / pathology. Leukopenia / epidemiology. Methylprednisolone / administration & dosage. Methylprednisolone / therapeutic use. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Treatment Outcome


23. Siri JG, Wilson ML, Murray S, Rosen DH, Vulule JM, Slutsker L, Lindblade KA: Significance of travel to rural areas as a risk factor for malarial anemia in an urban setting. Am J Trop Med Hyg; 2010 Mar;82(3):391-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of travel to rural areas as a risk factor for malarial anemia in an urban setting.
  • The epidemiology of malaria in urban environments is poorly characterized, yet increasingly problematic.
  • We conducted an unmatched case-control study of risk factors for malarial anemia with high parasitemia in urban Kisumu, Kenya, from June 2002 through February 2003.
  • Cases (n = 80) were hospital patients with a hemoglobin level < or = 8 g/dL and a Plasmodium parasite density > or = 10,000/microL.
  • Controls (n = 826) were healthy respondents to a concurrent citywide knowledge, attitude, and practice survey.
  • Children who reported spending at least one night per month in a rural area were especially at risk (35% of cases; odds ratio = 9.3, 95% confidence interval [CI] = 4.4-19.7, P < 0.0001), and use of mosquito coils, bed net ownership, and house construction were non-significant, potentially indicating that malaria exposure during rural travel comprises an important element of risk.
  • Control of severe malaria in an urban setting may be complicated by Plasmodium infections acquired elsewhere.
  • Epidemiologic studies of urban malaria in low transmission settings should take travel history into account.
  • [MeSH-major] Malaria / epidemiology. Rural Population. Travel. Urban Population
  • [MeSH-minor] Case-Control Studies. Child. Child, Preschool. Humans. Infant. Kenya. Logistic Models. Odds Ratio. Risk Factors

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Malaria.
  • MedlinePlus Health Information. consumer health - Rural Health Concerns.
  • MedlinePlus Health Information. consumer health - Traveler's Health.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Parassitologia. 1999 Sep;41(1-3):241-6 [10697862.001]
  • [Cites] Trop Med Int Health. 1999 Dec;4(12):836-45 [10632992.001]
  • [Cites] Demography. 2001 Feb;38(1):115-32 [11227840.001]
  • [Cites] Am J Trop Med Hyg. 2001 Jan-Feb;64(1-2 Suppl):57-67 [11425178.001]
  • [Cites] Am J Trop Med Hyg. 2001 Dec;65(6):822-7 [11791980.001]
  • [Cites] Trop Med Int Health. 2002 Mar;7(3):220-30 [11903984.001]
  • [Cites] Trop Med Int Health. 2002 Oct;7(10):823-30 [12358616.001]
  • [Cites] QJM. 2003 May;96(5):355-62 [12702784.001]
  • [Cites] Am J Trop Med Hyg. 2003 Apr;68(4 Suppl):68-77 [12749488.001]
  • [Cites] Pharmacol Ther. 2003 Aug;99(2):221-60 [12888113.001]
  • [Cites] Acta Trop. 2004 Apr;90(2):131-40 [15177139.001]
  • [Cites] Lancet. 1990 Feb 24;335(8687):472 [1968190.001]
  • [Cites] J Med Entomol. 1990 Jul;27(4):570-7 [2388233.001]
  • [Cites] Am J Trop Med Hyg. 1992 Aug;47(2):181-9 [1354414.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1992 May-Jun;86(3):237-9 [1412642.001]
  • [Cites] Ann Trop Med Parasitol. 1993 Aug;87(4):379-91 [8250629.001]
  • [Cites] Am J Trop Med Hyg. 1994 Feb;50(2):131-6 [8116802.001]
  • [Cites] Lancet. 1994 Oct 29;344(8931):1175-81 [7934537.001]
  • [Cites] Lancet. 1995 Feb 25;345(8948):479-83 [7861874.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1995 Mar-Apr;89(2):151-4 [7778138.001]
  • [Cites] Trop Med Int Health. 1996 Apr;1(2):139-46 [8665377.001]
  • [Cites] J Clin Epidemiol. 1996 Dec;49(12):1373-9 [8970487.001]
  • [Cites] Rev Panam Salud Publica. 1997 Apr;1(4):287-94 [9303813.001]
  • [Cites] Lancet. 1997 Jun 7;349(9066):1650-4 [9186382.001]
  • [Cites] Am J Trop Med Hyg. 1997 Nov;57(5):550-9 [9392594.001]
  • [Cites] Ann Trop Med Parasitol. 1997 Oct;91(7):763-9 [9625932.001]
  • [Cites] Am J Trop Med Hyg. 1998 Oct;59(4):539-42 [9790426.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1998 Jul-Aug;92(4):381-5 [9850385.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1998 Sep-Oct;92(5):478-81 [9861356.001]
  • [Cites] Am J Trop Med Hyg. 1999 May;60(5):781-5 [10344652.001]
  • [Cites] Stat Methods Med Res. 1999 Mar;8(1):3-15 [10347857.001]
  • [Cites] Soc Sci Med. 1999 Sep;49(5):601-9 [10452416.001]
  • [Cites] Trends Parasitol. 2004 Dec;20(12):597-603 [15522670.001]
  • [Cites] Malar J. 2005;4:10 [15703076.001]
  • [Cites] Nature. 2005 Mar 10;434(7030):214-7 [15759000.001]
  • [Cites] JAMA. 2005 Mar 23;293(12):1461-70 [15784869.001]
  • [Cites] Am J Trop Med Hyg. 2005 Sep;73(3):622-5 [16172493.001]
  • [Cites] Am J Trop Med Hyg. 2006 Mar;74(3):376-85 [16525094.001]
  • [Cites] Trop Med Int Health. 2006 May;11(5):578-88 [16640609.001]
  • [Cites] Malar J. 2006;5:105 [17094806.001]
  • [Cites] Malar J. 2008;7:34 [18298857.001]
  • [Cites] Malar J. 2008;7:39 [18312632.001]
  • [Cites] Acta Trop. 2000 Mar 25;75(2):163-71 [10708656.001]
  • (PMID = 20207862.001).
  • [ISSN] 1476-1645
  • [Journal-full-title] The American journal of tropical medicine and hygiene
  • [ISO-abbreviation] Am. J. Trop. Med. Hyg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2829898
  •  go-up   go-down


24. Lee SP, Kim SY, Park KW, Shin DH, Kang HJ, Koo BK, Suh JW, Cho YS, Yeon TJ, Chae IH, Choi DJ, Kim HS: Long-term clinical outcome of chronic total occlusive lesions treated with drug-eluting stents: comparison of sirolimus-eluting and paclitaxel-eluting stents. Circ J; 2010 Apr;74(4):693-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During mean follow-up of 2 years, the SES group had a significantly lower cumulative target vessel failure (TVF) rate than the PES group (14.9% vs 28.4%, P=0.01), as a consequence of lower target vessel revascularization (9.7% vs 23.9%, P=0.01) and also a partially lower rate of myocardial infarction (MI: 3.1% vs 7.6%, P=0.04).
  • Predictors for TVF were use of PES (hazard ratio (HR) 3.81, P<0.01), previous history of MI (HR 4.06, P<0.01), diabetes (HR 2.07, P=0.04) and chronic kidney disease (CKD; HR 3.56, P=0.05).

  • HSDB. structure - TAXOL.
  • HSDB. structure - SIROLIMUS.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20197629.001).
  • [ISSN] 1347-4820
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 33069-62-4 / Paclitaxel; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


25. Wang H, Wang DH, Galligan JJ: P2Y2 receptors mediate ATP-induced resensitization of TRPV1 expressed by kidney projecting sensory neurons. Am J Physiol Regul Integr Comp Physiol; 2010 Jun;298(6):R1634-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P2Y2 receptors mediate ATP-induced resensitization of TRPV1 expressed by kidney projecting sensory neurons.
  • The transient receptor potential vanilloid type 1 (TRPV1) channel is a ligand-gated cation channel expressed by sensory nerves.
  • P2Y receptors are G protein-coupled receptors that are also expressed by TRPV1-positive sensory neurons.
  • Therefore, we studied interactions between P2Y receptors and TRPV1 function on kidney projecting sensory neurons.
  • Application of Fast Blue (FB) to nerves surrounding the renal artery retrogradely labeled neurons in dorsal root ganglia of rats.
  • Whole cell recording was performed on FB-labeled neurons maintained in primary culture.
  • Capsaicin was used to activate TRPV1.
  • Four types of kidney projecting neurons were identified based on capsaicin responses:.
  • 1) desensitizing (35%), 2) nondesensitizing (29%), 3) silent (3%), and 4) insensitive (30%).
  • Silent neurons responded to capsaicin only after ATP (100 microM) pretreatment.
  • ATP reversed desensitization in desensitizing neurons.
  • Insensitive neurons never responded to capsaicin.
  • UTP, a P2Y purinoceptor 2 (P2Y(2))/P2Y(4) receptor agonist, reversed capsaicin-induced TRPV1 desensitization.
  • 2-methyl-thio-ATP (2-Me-S-ATP), a P2Y(1) receptor agonist, did not change desensitization.
  • MRS 2179 and pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid (PPADS), drugs that block P2Y(1) receptors, did not block ATP-induced resensitization of TRPV1.
  • Suramin, a P2Y(2) receptor antagonist, blocked resensitization caused by UTP.
  • Immunocytochemical studies showed that FB-labeled neurons coexpressed P2Y(2) receptors and TRPV1.
  • We conclude that P2Y(2) receptor activation can maintain TRPV1 function perhaps during sustained episodes of activity of kidney projecting sensory neurons.
  • [MeSH-major] Neurons / metabolism. Receptors, Purinergic P2 / metabolism. TRPV Cation Channels / metabolism
  • [MeSH-minor] Animals. Capsaicin / pharmacology. Drug Interactions. Ganglia, Spinal / cytology. Ion Channels / metabolism. Kidney / metabolism. Male. Mercaptoethanol / pharmacology. Neurons, Afferent / drug effects. Neurons, Afferent / metabolism. Neurons, Afferent / physiology. Patch-Clamp Techniques. Rats. Rats, Wistar. Receptors, Purinergic P2Y2. Sensory Receptor Cells. Suramin / pharmacology. Uridine Triphosphate / pharmacology

  • HSDB. structure - CAPSAICIN.
  • HSDB. structure - 2-MERCAPTOETHANOL.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pflugers Arch. 1996 Apr;431(6):828-37 [8927498.001]
  • [Cites] Handb Exp Pharmacol. 2009;(194):333-92 [19655112.001]
  • [Cites] Br J Pharmacol. 1996 Dec;119(7):1301-3 [8968535.001]
  • [Cites] J Neurosci. 1997 May 15;17(10):3525-37 [9133377.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):816-24 [9349813.001]
  • [Cites] Hypertension. 1999 Jan;33(1 Pt 2):493-8 [9931154.001]
  • [Cites] J Neurosci. 1999 Mar 1;19(5):1844-54 [10024368.001]
  • [Cites] Pharmacol Rev. 1999 Jun;51(2):159-212 [10353985.001]
  • [Cites] Neuron. 1999 Jul;23(3):617-24 [10433272.001]
  • [Cites] Am J Physiol. 1999 Nov;277(5 Pt 2):R1513-21 [10564226.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):310-23 [11111826.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6951-6 [11371611.001]
  • [Cites] Neurosci Res. 2001 Dec;41(4):355-63 [11755222.001]
  • [Cites] Neuron. 2002 Aug 15;35(4):721-31 [12194871.001]
  • [Cites] Folia Histochem Cytobiol. 2002;40(4):367-72 [12502188.001]
  • [Cites] J Neurosci. 2003 Jul 9;23(14):6058-62 [12853424.001]
  • [Cites] Cell Mol Life Sci. 2003 Oct;60(10):2228-40 [14618269.001]
  • [Cites] Cell Calcium. 2004 May;35(5):471-8 [15003856.001]
  • [Cites] Cephalalgia. 2004 Sep;24(9):717-27 [15315527.001]
  • [Cites] Pflugers Arch. 1981 Aug;391(2):85-100 [6270629.001]
  • [Cites] Brain Res. 1983 Jan 17;259(1):119-22 [6824924.001]
  • [Cites] Neurosci Lett. 1985 Jun 12;57(2):125-30 [2412189.001]
  • [Cites] Neurosci Lett. 1985 Sep 30;60(2):183-8 [2414700.001]
  • [Cites] Am J Physiol. 1986 Feb;250(2 Pt 2):F189-96 [3753828.001]
  • [Cites] J Auton Nerv Syst. 1986 Aug;16(4):279-88 [2427560.001]
  • [Cites] Pharmacol Rev. 1986 Sep;38(3):179-226 [3534898.001]
  • [Cites] Neuroscience. 1989;32(3):557-69 [2689906.001]
  • [Cites] Pharmacol Toxicol. 1995 Apr;76(4):228-39 [7617551.001]
  • [Cites] Nature. 1995 Oct 5;377(6548):432-5 [7566120.001]
  • [Cites] Neuropeptides. 2004 Dec;38(6):377-84 [15567473.001]
  • [Cites] Acta Pharmacol Sin. 2005 Mar;26(3):286-94 [15715923.001]
  • [Cites] Sci STKE. 2005 Feb 22;2005(272):re3 [15728426.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):13424-32 [15691846.001]
  • [Cites] J Neurosci. 2005 May 11;25(19):4835-43 [15888659.001]
  • [Cites] Sci STKE. 2005 Aug 2;2005(295):re8 [16077087.001]
  • [Cites] Hypertension. 2005 Oct;46(4):992-7 [16087784.001]
  • [Cites] Hypertension. 2006 Mar;47(3):609-14 [16365187.001]
  • [Cites] Circ Res. 2006 Jul 21;99(2):119-31 [16857972.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2007 Mar;375(1):29-38 [17295025.001]
  • [Cites] Pharmacol Res. 2008 Mar;57(3):239-46 [18329285.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Jun;325(3):751-7 [18364471.001]
  • [Cites] J Cardiovasc Pharmacol. 2008 May;51(5):513-20 [18460982.001]
  • [Cites] Exp Physiol. 2008 Aug;93(8):945-53 [18403445.001]
  • [Cites] Mol Neurobiol. 2008 Apr-Jun;37(2-3):153-63 [18528787.001]
  • [Cites] Exp Physiol. 2009 Jan;94(1):31-7 [18931047.001]
  • [Cites] Curr Vasc Pharmacol. 2009 Jan;7(1):15-25 [19149636.001]
  • [Cites] Nephrol Dial Transplant. 1995 Oct;10 Suppl 9:9-16 [8643211.001]
  • (PMID = 20335377.001).
  • [ISSN] 1522-1490
  • [Journal-full-title] American journal of physiology. Regulatory, integrative and comparative physiology
  • [ISO-abbreviation] Am. J. Physiol. Regul. Integr. Comp. Physiol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL70687; United States / NHLBI NIH HHS / HL / R01HL073287
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ion Channels; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2Y2; 0 / TRPV Cation Channels; 0 / vanilloid receptor subtype 1; 60-24-2 / Mercaptoethanol; 6032D45BEM / Suramin; S07O44R1ZM / Capsaicin; UT0S826Z60 / Uridine Triphosphate
  • [Other-IDs] NLM/ PMC2886708
  •  go-up   go-down


26. Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H, Avorn J, Stürmer T: Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum; 2008 Aug 15;59(8):1097-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We calculated the relative risk (RR) for CVD events (myocardial infarction [MI], stroke, congestive heart failure, and cardiovascular death) among users of coxibs or nonselective NSAIDs in the prior 6 months compared with nonusers.
  • Several patient characteristics were found to increase the risk of CVD events among users of some agents in both the primary and secondary cohorts, including age >/=80 years, hypertension, prior MI, prior CVD, rheumatoid arthritis, chronic renal disease, and chronic obstructive pulmonary disease.

  • MedlinePlus Health Information. consumer health - Arthritis.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2005 Jul;52(7):1968-78 [15986365.001]
  • [Cites] Med Care. 2005 May;43(5):480-5 [15838413.001]
  • [Cites] Eur J Epidemiol. 2005;20(7):563-4 [16119427.001]
  • [Cites] Eur J Epidemiol. 2005;20(7):575-9 [16119429.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):4-15 [16395396.001]
  • [Cites] Arthritis Rheum. 2006 May;54(5):1378-89 [16645966.001]
  • [Cites] BMJ. 2006 Jun 3;332(7553):1302-8 [16740558.001]
  • [Cites] N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528 [11087881.001]
  • [Cites] Epidemiology. 1990 Jan;1(1):43-6 [2081237.001]
  • [Cites] Am Heart J. 2004 Jul;148(1):99-104 [15215798.001]
  • [Cites] N Engl J Med. 2001 Dec 20;345(25):1809-17 [11752357.001]
  • [Cites] Epidemiology. 1991 Jul;2(4):244-51 [1912039.001]
  • [Cites] J Clin Epidemiol. 1993 Oct;46(10):1075-9; discussion 1081-90 [8410092.001]
  • [Cites] Epidemiology. 1996 May;7(3):286-90 [8728443.001]
  • [Cites] Am J Epidemiol. 1998 May 1;147(9):813-4; discussion 815 [9583710.001]
  • [Cites] Epidemiology. 2005 Jan;16(1):17-24 [15613941.001]
  • [Cites] Med Care. 2005 Feb;43(2):182-8 [15655432.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1081-91 [15713945.001]
  • [Cites] Circulation. 2005 Aug 16;112(7):941-5 [16103251.001]
  • (PMID = 18668605.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR 48264; United States / NIAMS NIH HHS / AR / AR 48616; United States / NIDA NIH HHS / DA / DA 15507; United States / NIAMS NIH HHS / AR / K23 AR048616; United States / NIAMS NIH HHS / AR / K23 AR048616-05; United States / NIAMS NIH HHS / AR / K24 AR055989; United States / NIDA NIH HHS / DA / R01 DA015507; United States / NIDA NIH HHS / DA / R01 DA015507-03; United States / NIAMS NIH HHS / AR / R55 AR048264; United States / NIAMS NIH HHS / AR / R55 AR048264-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antirheumatic Agents; 0 / Cyclooxygenase 2 Inhibitors
  • [Other-IDs] NLM/ NIHMS205082; NLM/ PMC2884183
  •  go-up   go-down


27. Grüschow S, Chang LC, Mao Y, Sherman DH: Hydroxyquinone O-methylation in mitomycin biosynthesis. J Am Chem Soc; 2007 May 23;129(20):6470-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydroxyquinone O-methylation in mitomycin biosynthesis.
  • Mitomycins are bioreductively activated DNA-alkylating agents.
  • One member of this family, mitomycin C, is in clinical use as part of combination therapy for certain solid tumors.
  • The cytotoxicity displayed by mitomycins is dependent on their electrochemical potential which, in turn, is governed in part by the substituents of the quinone moiety.
  • In this paper we describe studies on the biogenesis of the quinone methoxy group present in mitomycins A and B.
  • An engineered Streptomyces lavendulae strain in which the mmcR methyltransferase gene had been deleted failed to produce the three mitomycins (A, B, and C) that are typically isolated from the wild type organism.
  • Analysis of the culture extracts from the mmcR-deletion mutant strain revealed that two new metabolites, 7-demethylmitomycin A and 7-demethylmitomycin B, had accumulated instead.
  • Production of mitomycins A and C or mitomycin B was selectively restored upon supplementing the culture medium of a S. lavendulae strain unable to produce the key precursor 3-amino-5-hydroxybenzoate with either 7-demethylmitomycin A or 7-demethylmitomycin B, respectively.
  • MmcR methyltransferase obtained by cloning and overexpression of the corresponding mmcR gene was shown to catalyze the 7-O-methylation of both C9beta- and C9alpha-configured 7-hydroxymitomycins in vitro.
  • This study provides direct evidence for the catalytic role of MmcR in formation of the 7-OMe group that is characteristic of mitomycins A and B and demonstrates the prerequisite of 7-O-methylation for the production of the clinical agent mitomycin C.
  • [MeSH-major] Mitomycins / biosynthesis. Mitomycins / chemistry
  • [MeSH-minor] Catalysis. Methylation. Methyltransferases / genetics. Methyltransferases / metabolism. Molecular Structure. Mutation / genetics. Streptomyces / genetics. Streptomyces / metabolism

  • HSDB. structure - MITOMYCIN A.
  • HSDB. structure - MITOMYCIN B.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17461583.001).
  • [ISSN] 0002-7863
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 81172
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mitomycins; 4055-39-4 / mitomycin A; EC 2.1.1.- / Methyltransferases
  •  go-up   go-down


28. Nishizawa T, Aldrich CC, Sherman DH: Molecular analysis of the rebeccamycin L-amino acid oxidase from Lechevalieria aerocolonigenes ATCC 39243. J Bacteriol; 2005 Mar;187(6):2084-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analysis of the rebeccamycin L-amino acid oxidase from Lechevalieria aerocolonigenes ATCC 39243.
  • Rebeccamycin, a member of the tryptophan-derived indolocarbazole family, is produced by Lechevalieria aerocolonigenes ATCC 39243.
  • The biosynthetic pathway that specifies biosynthesis of this important metabolite is comprised of 11 genes spanning 18 kb of DNA.
  • A presumed early enzyme involved in elaboration of the rebeccamycin aglycone is encoded by rebO, located at the left-hand region of the reb gene cluster.
  • The deduced protein product, RebO (51.9 kDa), is an L-amino acid oxidase (L-AAO) that has 27% identity to an L-AAO from Scomber japonicus (animal, mackerel) and is a member of the family of FAD-dependent oxidase enzymes.
  • In order to study the biochemical properties of this key enzyme, the rebO gene was overexpressed and purified from Escherichia coli.
  • Biochemical characterization showed that RebO is dimeric, with a molecular mass of approximately 101 kDa.
  • Further analysis revealed that the enzyme contains a noncovalently bound FAD cofactor and is reoxidized at the expense of molecular oxygen by producing one molecule of hydrogen peroxide.
  • Based on kinetic studies, RebO shows significant preference for 7-chloro-L-tryptophan, suggesting its likely role as the natural early pathway substrate.
  • Furthermore, the native RebO enzyme has evident, albeit limited, flexibility as shown by bioconversion studies with unnatural substrates.
  • This work provides the first analysis of a structural enzyme involved in construction of this important class of indolocarbazole natural products.
  • [MeSH-major] Actinomycetales / enzymology. Actinomycetales / genetics. Amino Acid Oxidoreductases / genetics. Amino Acid Oxidoreductases / metabolism. Carbazoles / metabolism. Indoles / metabolism
  • [MeSH-minor] Amino Acid Sequence. Gene Expression Regulation, Bacterial. Gene Expression Regulation, Enzymologic. L-Amino Acid Oxidase. Molecular Biology. Phylogeny. Substrate Specificity. Tryptophan / metabolism

  • HSDB. structure - (L)-TRYPTOPHAN.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 1975 Oct 21;14(21):4634-8 [1101952.001]
  • [Cites] Arch Microbiol. 1975;102(2):151-3 [1115559.001]
  • [Cites] J Nat Prod. 1988 Sep-Oct;51(5):893-9 [3204381.001]
  • [Cites] J Nat Prod. 1988 Sep-Oct;51(5):937-40 [3204382.001]
  • [Cites] J Biol Chem. 1990 Oct 5;265(28):17246-51 [2145270.001]
  • [Cites] J Ind Microbiol. 1990 Dec;6(4):291-4 [1366997.001]
  • [Cites] Biochemistry. 1992 Dec 8;31(48):12069-75 [1333791.001]
  • [Cites] J Biol Chem. 1994 Jul 8;269(27):18177-84 [8027079.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7546-51 [8755511.001]
  • [Cites] Appl Environ Microbiol. 1997 Jun;63(6):2147-54 [9172332.001]
  • [Cites] J Bacteriol. 1998 Apr;180(7):1939-43 [9537395.001]
  • [Cites] Biochemistry. 1999 Apr 27;38(17):5588-95 [10220347.001]
  • [Cites] J Med Chem. 1999 May 20;42(10):1816-22 [10346933.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):461-6 [15625109.001]
  • [Cites] Proteins. 2000 Jan 1;38(1):95-114 [10651042.001]
  • [Cites] Appl Environ Microbiol. 2000 Mar;66(3):884-9 [10698746.001]
  • [Cites] Biosci Biotechnol Biochem. 2000 Jul;64(7):1486-93 [10945268.001]
  • [Cites] EMBO J. 2000 Aug 15;19(16):4204-15 [10944103.001]
  • [Cites] Biochemistry. 2001 Feb 6;40(5):1441-50 [11170472.001]
  • [Cites] Eur J Biochem. 2001 Mar;268(6):1679-86 [11248687.001]
  • [Cites] J Antibiot (Tokyo). 2001 Jan;54(1):1-9 [11269705.001]
  • [Cites] Int J Syst Evol Microbiol. 2001 May;51(Pt 3):1045-50 [11411672.001]
  • [Cites] Microbiology. 2001 Oct;147(Pt 10):2817-29 [11577160.001]
  • [Cites] Chem Biol. 2002 Apr;9(4):519-31 [11983340.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):19080-6 [11907037.001]
  • [Cites] FEBS Lett. 2002 Nov 20;531(3):509-12 [12435602.001]
  • [Cites] Chembiochem. 2003 Jan 3;4(1):114-7 [12512086.001]
  • [Cites] J Mol Biol. 2003 Jan 31;325(5):857-72 [12527296.001]
  • [Cites] J Antibiot (Tokyo). 2002 Dec;55(12):1063-71 [12617516.001]
  • [Cites] Biosci Biotechnol Biochem. 2003 Jan;67(1):127-38 [12619684.001]
  • [Cites] Protein Expr Purif. 2003 Apr;28(2):303-9 [12699695.001]
  • [Cites] Bioorg Med Chem. 2003 Nov 17;11(23):4871-9 [14604648.001]
  • [Cites] J Biol Chem. 1967 Mar 25;242(6):1259-64 [6067195.001]
  • [Cites] Biochimie. 1972;54(7):837-42 [4631948.001]
  • [Cites] J Antibiot (Tokyo). 1987 May;40(5):668-78 [3112080.001]
  • (PMID = 15743957.001).
  • [ISSN] 0021-9193
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI48521
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbazoles; 0 / Indoles; 8DUH1N11BX / Tryptophan; 93908-02-2 / rebeccamycin; EC 1.4.- / Amino Acid Oxidoreductases; EC 1.4.3.2 / L-Amino Acid Oxidase
  • [Other-IDs] NLM/ PMC1064027
  •  go-up   go-down


29. Esper DH, Coplin WM, Carhuapoma JR: Energy expenditure in patients with nontraumatic intracranial hemorrhage. JPEN J Parenter Enteral Nutr; 2006 Mar-Apr;30(2):71-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Energy expenditure in patients with nontraumatic intracranial hemorrhage.
  • BACKGROUND: Patients with intracerebral (ICH), intraventricular (IVH) and subarachnoid hemorrhage (SAH) have increased morbidity and mortality compared with other forms of stroke.
  • We postulate that the systemic inflammatory state triggered by these forms of nontraumatic intracranial hemorrhage (IH) translates into higher nutrition requirements than traditionally assumed.
  • In order to test this hypothesis, we performed a retrospective study comparing the resting energy expenditure (REE) of 14 mechanically ventilated IH patients with the REE of 6 severe traumatic brain injury (sTBI) patients (a disease known to induce an increased metabolic state).
  • METHODS: Using nonparametric analysis, we compared 2 contemporary cohorts of patients-IH and sTBI-who required mechanical ventilation and who underwent indirect calorimetry (IC) within 7 days after the ictus.
  • RESULTS: Fourteen patients with nontraumatic IH (IVH, 2; SAH, 9; SAH/ICH, 1; ICH/SAH/IVH, 2) who underwent IC within 7 days from injury were identified; median age: 59 (28-84) years, median admission Glasgow Coma Scale (GCS): 6 (4-9), and median APACHE II: 19.5 (15-28).
  • A control cohort of 6 patients with sTBI was identified; median age: 57.5 (18-80) years, admission GCS: 6.5 (4-8), and APACHE II: 16 (11-31).
  • Sedation was used in 11/14 patients with IH and in 5/6 severe TBI patients.
  • No patient was pharmacologically paralyzed.
  • Median REE was 1810 (1124-2806) and 2238 (1860-2780) kcal/d for the IH and for the sTBI patient cohorts, respectively.
  • Using Wilcoxon signed ranks test, the 2 patient groups were found comparable in regard to baseline clinical variables and disease severity (APACHE II).
  • We did not identify a statistically significant difference in the REE between these 2 cohorts of patients (p = .25).
  • CONCLUSIONS: Patients with severe TBI and patients with IH have similar increments in metabolic rate during the initial phase (1 week from onset) of their disease.
  • This information needs to be confirmed in a larger cohort of patients.
  • If reproduced, our results suggest that nontraumatic IH patients are at high risk of inadequate nutrition if their metabolic rate is estimated after conventional nutrition practice.
  • [MeSH-major] Energy Metabolism / physiology. Intracranial Hemorrhages / metabolism
  • [MeSH-minor] APACHE. Adolescent. Adult. Aged. Aged, 80 and over. Brain Injuries / metabolism. Calorimetry, Indirect. Cerebral Hemorrhage / metabolism. Energy Intake. Humans. Middle Aged. Nutritional Requirements. Respiration, Artificial. Rest. Retrospective Studies. Subarachnoid Hemorrhage / metabolism

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517949.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Wang Y, Babánková D, Huang J, Swain GM, Wang DH: Deletion of transient receptor potential vanilloid type 1 receptors exaggerates renal damage in deoxycorticosterone acetate-salt hypertension. Hypertension; 2008 Aug;52(2):264-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion of transient receptor potential vanilloid type 1 receptors exaggerates renal damage in deoxycorticosterone acetate-salt hypertension.
  • To determine whether the transient receptor potential vanilloid type 1 (TRPV1) channel provides protection against hypertension-induced renal damage, hypertension was induced by uninephrectomy and by giving deoxycorticosterone acetate (DOCA)-salt in wild-type (WT) and TRPV1-null mutant (TRPV1-/-) mice.
  • Mean arterial pressure, as determined by radiotelemetry, increased significantly and reached the peak 7 days after DOCA-salt treatment in both WT and TRPV1-/- mice.
  • There was no difference in mean arterial pressure between the 2 strains at the baseline or at the peak that lasted for 4 treatment weeks.
  • DOCA-salt treatment in both WT and TRPV1-/- mice led to increased urinary excretion of albumin and 8-isoprostane, glomerulosclerosis, renal cortical tubulointerstitial injury, tubulointerstitial fibrosis, increased number of tubular proliferating cell nuclear antigen-positive cells, and renal monocyte/macrophage infiltration, all of which were much more severe in DOCA-salt-treated TRPV1-/- compared with DOCA-salt-treated WT mice.
  • Renal TRPV1 protein expression, but not the renal anandamide content, was elevated in DOCA-salt-treated WT compared with vehicle-treated WT mice.
  • Renal anandamide levels were markedly elevated in DOCA-salt-treated TRPV1-/- but not in vehicle-treated TRPV1-/- mice.
  • Thus, our data show that ablation of the TRPV1 gene exacerbates renal damage induced by DOCA-salt hypertension, indicating that TRPV1 may constitute a protective mechanism against end-organ damage induced by hypertension.
  • [MeSH-major] Hypertension / complications. Hypertension / physiopathology. Nephrosclerosis / etiology. Nephrosclerosis / pathology. TRPV Cation Channels / metabolism
  • [MeSH-minor] Albuminuria / diagnosis. Albuminuria / etiology. Analysis of Variance. Animals. Blotting, Western. Desoxycorticosterone. Disease Models, Animal. Glomerular Filtration Rate. Immunohistochemistry. Isoprostanes / urine. Mice. Mice, Mutant Strains. Probability. Random Allocation. Urinalysis

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • Faculty of 1000. See the articles recommended by F1000Prime's Faculty of more than 5,000 expert scientists and clinical researchers. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Apr 14;288(5464):306-13 [10764638.001]
  • [Cites] J Biol Chem. 1957 May;226(1):497-509 [13428781.001]
  • [Cites] Hypertension. 2001 Mar;37(3):974-80 [11244026.001]
  • [Cites] Am J Kidney Dis. 2001 Jul;38(1):153-64 [11431195.001]
  • [Cites] Nature. 2001 Sep 13;413(6852):203-10 [11557989.001]
  • [Cites] Circ Res. 2001 Nov 23;89(11):983-90 [11717154.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1679-93 [12414515.001]
  • [Cites] J Am Soc Nephrol. 2002 Dec;13(12):3005-15 [12444221.001]
  • [Cites] Arch Biochem Biophys. 1961 May;93:440-7 [13786180.001]
  • [Cites] Curr Pharm Des. 2004;10(29):3621-37 [15579059.001]
  • [Cites] Kidney Int Suppl. 2005 Apr;(94):S14-8 [15752232.001]
  • [Cites] Hypertension. 2005 May;45(5):934-9 [15837840.001]
  • [Cites] Hypertension. 2005 Oct;46(4):986-91 [16144988.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Nov;289(5):H2005-11 [15994858.001]
  • [Cites] Hypertension. 2006 Mar;47(3):609-14 [16365187.001]
  • [Cites] Hypertension. 2006 Jun;47(6):1084-93 [16636193.001]
  • [Cites] Hypertension. 2006 Oct;48(4):658-63 [16966581.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1173-81 [17237150.001]
  • [Cites] FASEB J. 2007 Nov;21(13):3747-55 [17601984.001]
  • [Cites] J Am Soc Nephrol. 2000 Aug;11(8):1387-97 [10906152.001]
  • [Cites] Hypertension. 2003 Nov;42(5):968-73 [14568995.001]
  • [Cites] J Am Soc Nephrol. 2004 Mar;15(3):524-37 [14978154.001]
  • [Cites] N Engl J Med. 1982 May 27;306(21):1276-9 [7040967.001]
  • [Cites] Am J Physiol. 1986 Aug;251(2 Pt 2):R289-94 [3740311.001]
  • [Cites] Kidney Int. 1987 Nov;32(5):691-9 [3323599.001]
  • [Cites] Kidney Int. 1988 Jun;33(6):1113-8 [3261370.001]
  • [Cites] J Pathol. 1991 Oct;165(2):173-8 [1683905.001]
  • [Cites] J Clin Invest. 1992 Sep;90(3):1116-21 [1325992.001]
  • [Cites] Am J Physiol. 1992 Sep;263(3 Pt 2):F554-61 [1415585.001]
  • [Cites] Br J Pharmacol. 1992 Nov;107(3):691-6 [1361870.001]
  • [Cites] Am J Physiol. 1994 May;266(5 Pt 2):F731-7 [8203556.001]
  • [Cites] Hypertension. 1994 Nov;24(5):564-70 [7960014.001]
  • [Cites] J Pharmacol Exp Ther. 1995 Jul;274(1):64-71 [7616449.001]
  • [Cites] Endocr Rev. 1996 Oct;17(5):533-85 [8897024.001]
  • [Cites] Lancet. 1997 Dec 13;350(9093):1734-7 [9413464.001]
  • [Cites] Hypertension. 1998 Jan;31(1 Pt 2):397-402 [9453335.001]
  • [Cites] J Am Soc Nephrol. 1999 Feb;10(2):387-91 [10215340.001]
  • [Cites] Nature. 1999 Jul 29;400(6743):452-7 [10440374.001]
  • [CommentIn] Hypertension. 2008 Aug;52(2):213-4 [18606896.001]
  • (PMID = 18606907.001).
  • [ISSN] 1524-4563
  • [Journal-full-title] Hypertension
  • [ISO-abbreviation] Hypertension
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK67620; United States / NHLBI NIH HHS / HL / HL-57853; United States / NHLBI NIH HHS / HL / HL-73287; United States / NIDDK NIH HHS / DK / R01 DK067620; United States / NIDDK NIH HHS / DK / R01 DK067620-03; United States / NIDDK NIH HHS / DK / R01 DK067620-04; United States / NHLBI NIH HHS / HL / R01 HL057853; United States / NHLBI NIH HHS / HL / R01 HL057853-06; United States / NHLBI NIH HHS / HL / R01 HL057853-07; United States / NHLBI NIH HHS / HL / R01 HL073287; United States / NHLBI NIH HHS / HL / R01 HL073287-04; United States / NHLBI NIH HHS / HL / R01 HL073287-05
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoprostanes; 0 / TRPV Cation Channels; 0 / TRPV1 protein, human; 0 / vanilloid receptor subtype 1; 40GP35YQ49 / Desoxycorticosterone
  • [Other-IDs] NLM/ NIHMS96825; NLM/ PMC2669743
  •  go-up   go-down


31. Rosselló RA, Wang Z, Kizana E, Krebsbach PH, Kohn DH: Connexin 43 as a signaling platform for increasing the volume and spatial distribution of regenerated tissue. Proc Natl Acad Sci U S A; 2009 Aug 11;106(32):13219-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Connexin 43 as a signaling platform for increasing the volume and spatial distribution of regenerated tissue.
  • Gap junction intercellular communication (GJIC) is ubiquitous in the majority of vertebrate cells and is required for the proper development of most tissues.
  • The loss of gap junction-mediated cell-to-cell communication leads to compromised development in many tissues and organs.
  • Because cells constantly interact through gap junctions to coordinate tissue functions and homeostasis, we hypothesized that increasing cell-to-cell communication, via genetically engineering cells to overexpress gap junction proteins, could enhance cell differentiation in the interior regions of 3D tissue equivalents, thereby increasing the ability to regenerate larger and more uniform volumes of tissue.
  • To test this hypothesis, we used bone as a model tissue because of the difficulty in achieving spatially uniform bone regeneration in 3D.
  • In bone marrow stromal cells (BMSC), GJIC and osteogenic differentiation were compromised in 3D cultures relative to 2D monolayers and in the core of 3D cultures relative to the surface.
  • Overexpression of connexin 43 (Cx43) via transduction of BMSCs with a lentivirus overcame this problem, enhancing both the magnitude and spatial distribution of GJIC and osteogenic differentiation markers throughout 3D constructs.
  • Transplantation of cells overexpressing Cx43 resulted in an increased volume fraction and spatial uniformity of bone in vivo, relative to nontransduced BMSCs.
  • Increased GJIC also enhanced the effect of a potent osteoinductive agent (BMP-7), suggesting a synergism between the soluble factor and GJIC.
  • These findings present a platform to improve cell-to-cell communication in 3D and to achieve uniformly distributed tissue regeneration in 3D.
  • [MeSH-major] Bone Regeneration. Bone and Bones / pathology. Connexin 43 / metabolism. Signal Transduction
  • [MeSH-minor] Animals. Biological Markers / metabolism. Bone Marrow Cells / cytology. Bone Marrow Cells / metabolism. Cell Communication. Cell Differentiation. Gene Expression Regulation. Green Fluorescent Proteins / metabolism. Mice. Mice, Inbred C57BL. Organ Size. Osteocalcin / genetics. Osteocalcin / metabolism. Osteogenesis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Recombinant Fusion Proteins / metabolism. Regenerative Medicine. Stromal Cells / cytology. Stromal Cells / metabolism. Tissue Engineering. Transduction, Genetic. X-Ray Microtomography

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1993 May 14;260(5110):920-6 [8493529.001]
  • [Cites] Biomaterials. 2009 Apr;30(12):2252-8 [19152974.001]
  • [Cites] Hum Gene Ther. 2000 May 20;11(8):1201-10 [10834621.001]
  • [Cites] J Cell Biochem. 2000 Jun 6;78(3):476-86 [10861845.001]
  • [Cites] Circ Res. 2000 Jun 23;86(12):1193-7 [10864907.001]
  • [Cites] J Biomed Mater Res. 2000 Sep 5;51(3):376-82 [10880079.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):118-21 [11689957.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2806-12 [12019157.001]
  • [Cites] Tissue Eng. 2002 Jul;8(3):441-52 [12167230.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):4082-6 [12446698.001]
  • [Cites] J Biol Chem. 2003 Jul 4;278(27):24377-87 [12700237.001]
  • [Cites] Cell Commun Adhes. 2003 Jan-Feb;10(1):37-50 [12881039.001]
  • [Cites] Physiol Rev. 2003 Oct;83(4):1359-400 [14506308.001]
  • [Cites] Adv Nephrol Necker Hosp. 1987;16:125-36 [3101418.001]
  • [Cites] J Bone Miner Res. 1989 Feb;4(1):3-11 [2718776.001]
  • [Cites] Blood. 1993 Jul 1;82(1):38-45 [8391877.001]
  • [Cites] J Biomed Mater Res. 1997 Jul;36(1):17-28 [9212385.001]
  • [Cites] J Cell Biochem. 1998 Jan 1;68(1):8-21 [9407310.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15735-40 [9861039.001]
  • [Cites] Development. 2005 Oct;132(19):4375-86 [16155213.001]
  • [Cites] Biochim Biophys Acta. 2005 Dec 20;1719(1-2):146-60 [16263076.001]
  • [Cites] J Cell Sci. 2006 Feb 1;119(Pt 3):532-41 [16418219.001]
  • [Cites] Radiol Clin North Am. 2006 May;44(3):451-61 [16644361.001]
  • [Cites] Bone. 2006 Jul;39(1):106-16 [16527557.001]
  • [Cites] J Biomed Mater Res A. 2006 Nov;79(2):263-70 [16817221.001]
  • [Cites] Crit Rev Oral Biol Med. 1999;10(2):165-81 [10759420.001]
  • (PMID = 19628695.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / DE 013380; United States / NIAMS NIH HHS / AR / P30-AR46024; United States / NIDCR NIH HHS / DE / R01 DE 015411; United States / NIDCR NIH HHS / DE / R01 DE013380; United States / NIDCR NIH HHS / DE / R01 DE013380-07; United States / NIDCR NIH HHS / DE / R01 DE015411; United States / NIDCR NIH HHS / DE / R01 DE015411-04; United States / NIDCR NIH HHS / DE / R56 DE013380; United States / NIDCR NIH HHS / DE / R56 DE013380-06A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biological Markers; 0 / Connexin 43; 0 / RNA, Messenger; 0 / Recombinant Fusion Proteins; 104982-03-8 / Osteocalcin; 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ PMC2726403
  •  go-up   go-down


32. Steinberg DH, Pinto Slottow TL, Buch AN, Javaid A, Roy PK, Garg S, Okabe T, Torguson R, Smith KA, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Lindsay J, Waksman R: Impact of in-stent restenosis on death and myocardial infarction. Am J Cardiol; 2007 Oct 1;100(7):1109-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Major adverse cardiac events, including mortality and myocardial infarction (MI), were assessed at clinical presentation, 30 days, and 6 months.
  • Patients with acute presentation (i.e., unstable angina requiring hospitalization or MI) were compared with patients with stable presentation.
  • At presentation, 19.2% of patients were asymptomatic, 27.5% had exertional angina, 46.6% had unstable angina, and 6.7% had MI.
  • Mortality and MI rates were 1.1% and 1.4%, respectively, at 30 days and 3.3% and 4.5%, respectively, at 6 months.
  • Patients with acute coronary syndrome (ACS) and those without ACS had similarly low mortality rates at 30 days (1.2% ACS vs 1.0% non-ACS, p = 0.65) and 6 months (3.4% ACS vs 3.3% non-ACS, p = 0.93) and MI rates at 30 days (1.3% ACS vs 1.4% non-ACS, p = 0.87) and 6 months (4.7% ACS vs 4.3% non-ACS, p = 0.65).

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884372.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Cote ML, Schenk M, Schwartz AG, Vigneau FD, Kinnard M, Greenson JK, Fryzek JP, Ying GS, Garabrant DH: Risk of other cancers in individuals with a family history of pancreas cancer. J Gastrointest Cancer; 2007;38(2-4):119-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of other cancers in individuals with a family history of pancreas cancer.
  • BACKGROUND: Inherited predisposition to pancreas cancer accounts for approximately 10% of cases.
  • Familial aggregation may be influenced by shared environmental factors and shared genes.
  • We evaluate whether a family history of pancreas cancer is a risk factor for ten specified cancers in first-degree relatives: bladder, breast, colon, head and neck, lung, lymphoma, melanoma, ovary, pancreas, and prostate.
  • METHODS: Risk factor data and cancer family history were obtained for 1,816 first-degree relatives of pancreas cancer case probands (n = 247) and 3,157 first-degree relatives of control probands (n = 420).
  • Unconditional logistic regression models using generalized estimating equations were used to estimate odds ratios (ORs), and 95% confidence intervals of having a first-degree relative a specified cancer.
  • RESULTS: A family history of pancreas cancer was associated with a doubled risk of lymphoma (OR = 2.83, 95% CI = 1.02-7.86) and ovarian cancer (OR = 2.25, 95% CI = 0.77-6.60) among relatives after adjustment.
  • Relatives with a family history of early-onset pancreas cancer in a proband had a sevenfold increased risk of lymphoma (OR = 7.31, 95% CI = 1.45 to 36.7).
  • Relatives who ever smoked and had a family history of pancreas cancer had a fivefold increased risk of ovarian cancer (OR = 4.89, 95% CI = 1.16-20.6).
  • CONCLUSION: Family history assessment of cancer risk should include all cancers.
  • Assessment of other known and suspected risk factors in relatives will improve risk evaluation.
  • As screening and surveillance methods are developed, identifying those at highest risk is crucial for a successful screening program.
  • [MeSH-major] Adenocarcinoma / genetics. Genetic Predisposition to Disease. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Adult. Age Factors. Aged. Case-Control Studies. Family Health. Female. Humans. Interviews as Topic. Male. Middle Aged. Risk Factors. Smoking

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 Dec;119(6):1447-53 [11113065.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Feb;127(2):73-9 [11216917.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):738-44 [11297271.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):640-4 [11309441.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3789-93 [12097290.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 18;94(18):1358-65 [12237281.001]
  • [Cites] Am J Med Genet. 2002 Oct 30;115(3):125-9 [12407692.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 5;95(3):214-21 [12569143.001]
  • [Cites] Arch Dermatol. 2003 Aug;139(8):1019-25 [12925390.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):133-9 [14718214.001]
  • [Cites] JAMA. 2004 Sep 22;292(12):1480-9 [15383520.001]
  • [Cites] Clin Genet. 1976 May;9(5):463-9 [1269168.001]
  • [Cites] Am J Epidemiol. 1984 Dec;120(6):825-33 [6334439.001]
  • [Cites] Br J Cancer. 1985 Aug;52(2):271-3 [4027169.001]
  • [Cites] Cancer. 1987 May 1;59(9):1661-4 [3828965.001]
  • [Cites] Am J Epidemiol. 1987 Jul;126(1):112-7 [3591776.001]
  • [Cites] Cancer Genet Cytogenet. 1990 May;46(1):21-7 [2184933.001]
  • [Cites] Epidemiology. 1990 Sep;1(5):408-12 [2078619.001]
  • [Cites] Leuk Res. 1991;15(5):305-14 [2046383.001]
  • [Cites] Int J Pancreatol. 1991 Nov-Dec;10(3-4):183-96 [1787333.001]
  • [Cites] Gut. 1993 Oct;34(10):1394-6 [8244108.001]
  • [Cites] Eur J Cancer Prev. 1994 Jul;3(4):321-7 [7950886.001]
  • [Cites] Arch Intern Med. 1995 May 8;155(9):905-12 [7726698.001]
  • [Cites] Science. 1995 Jun 23;268(5218):1749-53 [7792600.001]
  • [Cites] N Engl J Med. 1995 Oct 12;333(15):970-4 [7666916.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4570-4 [7553631.001]
  • [Cites] Nature. 1995 Dec 21-28;378(6559):789-92 [8524414.001]
  • [Cites] Semin Oncol. 1996 Apr;23(2):251-75 [8623061.001]
  • [Cites] Conn Med. 1996 Oct;60(10):579-82 [8952129.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5360-4 [8968085.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6 [10433620.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1830-7 [10468306.001]
  • [Cites] J Cell Biochem. 2005 Jul 1;95(4):649-56 [15849724.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):388-94 [15912495.001]
  • [Cites] Acta Pharmacol Sin. 2005 Aug;26(8):897-907 [16038621.001]
  • [Cites] J Med Genet. 2005 Sep;42(9):711-9 [16141007.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):197-209 [16549324.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):211-26 [16549325.001]
  • [Cites] Genes Dev. 2006 May 15;20(10):1218-49 [16702400.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):405-8 [17337643.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4 [17337646.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):377-80 [17372233.001]
  • (PMID = 19089664.001).
  • [ISSN] 1941-6628
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-65064; United States / NIEHS NIH HHS / ES / R01 ES007129-03; United States / NIEHS NIH HHS / ES / R01 ES07129; United States / NCI NIH HHS / CA / RC25-CA7716
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS126067; NLM/ PMC2719298
  •  go-up   go-down


34. Roy P, Buch AN, Javaid A, Okabe T, Raya V, Pinto Slottow TL, Steinberg DH, Smith K, Xue Z, Gevorkian N, Satler LF, Kent KM, Suddath WO, Pichard AD, Lindsay J, Waksman R: Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. Am J Cardiol; 2008 Feb 1;101(3):293-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Safety concerns have arisen from recent reports that suggested increased mortality and nonfatal myocardial infarction (MI) with DES usage.
  • The primary endpoint was major adverse cardiac events (cardiac death, nonfatal Q-wave myocardial infarction [MI], and target vessel revascularization) at 12 months.
  • There was no significant difference in freedom from cardiac death or nonfatal Q-wave MI between groups (p=0.27).
  • "Off-label" DES use was not associated with increased rates of cardiac death and nonfatal MI at 12 months.

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18237587.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Kuo DH, Simmons FJ, Blair S, Hart E, Rose JB, Xagoraraki I: Assessment of human adenovirus removal in a full-scale membrane bioreactor treating municipal wastewater. Water Res; 2010 Mar;44(5):1520-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of human adenovirus removal in a full-scale membrane bioreactor treating municipal wastewater.
  • Human adenoviruses (HAdVs) in wastewater samples taken from four different treatment stages of a full-scale municipal wastewater treatment plant (i.e., incoming raw sewage, primary sedimentation effluent, membrane bioreactor (MBR) influent, and MBR effluent) were quantified by real-time PCR assays to further estimate removal efficiency of the HAdvs. Based on hexon gene sequence comparisons, HAdV species A, C, and F were consistently found in the wastewater samples.
  • In general, all three identified HAdV species were detected in most of the wastewater samples using the real-time PCR assays.
  • Overall HAdV concentrations were rather stable over the entire 8-month study period (January-August, 2008) (approximately 10(6)-10(7)viral particles/L of wastewater for the raw sewage and primary effluent; 10(8)-10(9)viral particles/L for the MBR influent; and, 10(3)-10(4)viral particles/L for the MBR effluent).
  • No significant seasonal differences were noticed for the HAdV abundances.
  • Removal efficiencies of the viral particles in the full-scale MBR process were assessed and showed an average HAdV removal of 5.0+/-0.6logs over the study period.
  • The removal efficiencies for F species (average log removal of 6.5+/-1.3logs) were typically higher (p-value <0.05) than those of the other two species (average of 4.1+/-0.9 and 4.6+/-0.5logs for species A and C, respectively).
  • These results demonstrate that the full-scale MBR system efficiently removed most HAdV from the wastewater leaving about 10(3)viral particles/L in the MBR effluent.
  • [MeSH-major] Adenoviruses, Human / isolation & purification. Bioreactors / virology. Cities. Membranes, Artificial. Waste Disposal, Fluid / instrumentation. Water Purification / instrumentation
  • [MeSH-minor] Humans. Phylogeny. Sewage / virology

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009. Published by Elsevier Ltd.
  • (PMID = 19944439.001).
  • [ISSN] 1879-2448
  • [Journal-full-title] Water research
  • [ISO-abbreviation] Water Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membranes, Artificial; 0 / Sewage
  •  go-up   go-down


36. Hashish M, Raghavan S, Somara S, Gilmont RR, Miyasaka E, Bitar KN, Teitelbaum DH: Surgical implantation of a bioengineered internal anal sphincter. J Pediatr Surg; 2010 Jan;45(1):52-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical implantation of a bioengineered internal anal sphincter.
  • PURPOSE: Fecal incontinence is a common disorder that can have devastating social and psychologic consequences.
  • However, there are no long-term ideal solutions for such patients.
  • Although loss of continence is multifactorial, the integrity of the internal anal sphincter (IAS) has particular significance.
  • We previously described the development of 3-dimensional bioengineered constructs using isolated smooth muscle tissue from donor C57BL/6 IAS.
  • We hypothesized that the bioengineered ring constructs would retain cellular viability and promote neovascularization upon implantation into a recipient mouse.
  • METHODS: Internal anal sphincter ring constructs were surgically implanted into the subcutaneous tissue of syngeneic C57BL/6 mice and treated with either fibroblastic growth factor 2 (0.26 microg daily) or saline controls using a microosmotic pump.
  • Internal anal sphincter constructs were harvested after 25 days (range, 23-26 days) and assessed morphologically and for tissue viability.
  • RESULT: Gross morphology showed that there was no rejection.
  • Rings showed muscle attachment to the back of the mouse with no sign of inflammation.
  • Fibroblastic growth factor 2 infusion resulted in a significantly improved histologic score and muscle viability compared with the control group.
  • CONCLUSIONS: Three-dimensional bioengineered IAS rings can be successfully implanted into the subcutaneous tissue of recipient mice.
  • The addition of fibroblastic growth factor 2 led to improved muscle viability, vascularity, and survival.
  • This approach may become a feasible option for patients with fecal incontinence.
  • [MeSH-major] Anal Canal / surgery. Prosthesis Implantation / methods. Tissue Engineering / methods
  • [MeSH-minor] Animals. Biomedical Engineering. Cells, Cultured. Disease Models, Animal. Fecal Incontinence / surgery. Female. Fibroblast Growth Factor 2 / therapeutic use. Humans. Manometry. Mice. Mice, Inbred C57BL. Muscle, Smooth / cytology. Muscle, Smooth / surgery. Myocytes, Smooth Muscle / physiology. Prosthesis Design. Tissue Culture Techniques

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Circulation. 2000 Nov 7;102(19 Suppl 3):III56-61 [11082363.001]
  • [Cites] Arch Oral Biol. 2000 Nov;45(11):1013-6 [11000388.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 May;121(5):932-42 [11326237.001]
  • [Cites] Dis Colon Rectum. 2001 Jan;44(1):131-42; discussion 142-4 [11805574.001]
  • [Cites] Circ Res. 2002 Feb 22;90(3):e40 [11861428.001]
  • [Cites] Gut. 2002 Apr;50(4):480-4 [11889066.001]
  • [Cites] Can J Gastroenterol. 2002 Apr;16(4):249-57 [11981578.001]
  • [Cites] Acta Oncol. 2002;41(1):84-90 [11990524.001]
  • [Cites] J Mol Cell Cardiol. 2002 Jul;34(7):775-87 [12099717.001]
  • [Cites] Basic Res Cardiol. 2002;97 Suppl 1:I146-52 [12479248.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):204-9 [15043291.001]
  • [Cites] Med J Malaysia. 2004 May;59 Suppl B:15-6 [15468796.001]
  • [Cites] Nature. 1982 May 6;297(5861):72-4 [6122163.001]
  • [Cites] Science. 1982 Apr 30;216(4545):531-3 [6176025.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1984;24:199-236 [6375546.001]
  • [Cites] Science. 1987 May 8;236(4802):714-8 [3472348.001]
  • [Cites] J Clin Invest. 1990 Jun;85(6):2004-8 [2347923.001]
  • [Cites] Ann N Y Acad Sci. 1991;638:329-40 [1785810.001]
  • [Cites] Br J Surg. 1993 Aug;80(8):977-80 [8402094.001]
  • [Cites] BMJ. 1994 Apr 2;308(6933):887-91 [8173367.001]
  • [Cites] JAMA. 1995 Aug 16;274(7):559-61 [7629985.001]
  • [Cites] Muscle Nerve. 1998 Nov;21(11):1451-6 [9771669.001]
  • [Cites] Am J Physiol. 1999 Aug;277(2 Pt 2):H433-44 [10444466.001]
  • [Cites] Tissue Eng. 2005 Jan-Feb;11(1-2):257-66 [15738680.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Aug;289(2):G188-96 [15774939.001]
  • [Cites] Artif Organs. 2005 Nov;29(11):866-75 [16266299.001]
  • [Cites] Hum Reprod. 2006 Feb;21(2):436-42 [16253976.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):966-80 [16795075.001]
  • [Cites] Laryngoscope. 2006 Oct;116(10):1829-34 [17016212.001]
  • [Cites] Exp Biol Med (Maywood). 2007 Apr;232(4):481-7 [17392483.001]
  • [Cites] Plast Reconstr Surg. 2008 Apr;121(4):1153-64 [18349632.001]
  • [Cites] Gastroenterology. 2009 Jul;137(1):53-61 [19328796.001]
  • [Cites] J Cell Mol Med. 2009 Sep;13(9B):3380-6 [18624770.001]
  • [Cites] Hum Reprod. 2000 Mar;15(3):572-7 [10686198.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2000 May;36(5):327-35 [10937836.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 Feb;280(2):C288-95 [11208523.001]
  • (PMID = 20105579.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / 2R01DK042876; United States / NCI NIH HHS / CA / 5 P03 CA46592; United States / NIDDK NIH HHS / DK / 5R01DK071614; United States / NIDDK NIH HHS / DK / R01 DK071614; United States / NIDDK NIH HHS / DK / R01 DK071614-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 103107-01-3 / Fibroblast Growth Factor 2
  • [Other-IDs] NLM/ NIHMS255019; NLM/ PMC3018766
  •  go-up   go-down


37. Coker RH, Williams RH, Kortebein PM, Sullivan DH, Evans WJ: Influence of exercise intensity on abdominal fat and adiponectin in elderly adults. Metab Syndr Relat Disord; 2009 Aug;7(4):363-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To examine the influence of moderate-intensity (50% of VO(2peak)) exercise training (MI) versus high-intensity (75% of VO(2peak)) exercise training (HI) on regional fat distribution and plasma adiponectin, we randomized 18 overweight (body mass index [BMI] = 30 +/- 1 kg/m(2)) elderly (71 +/- 1 years) to HI, MI, or a control group (CON).
  • Subjects enrolled in HI or MI completed a 12-week exercise training protocol designed to expend 1000 kcal/week.
  • VO(2peak) improved in HI and MI, whereas there was no change in VO(2peak) in CON.
  • No significant change in body weight, BMI, and % fat occurred in MI, HI, or CON.
  • Although there was a significant reduction in visceral fat with HI (-39 cm(2)), there was no change in the MI or CON groups.
  • There were no changes in thigh muscle attenuation in the MI and CON groups.
  • Also, there was no change in plasma adiponectin in the MI, HI, or CON groups.

  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • MedlinePlus Health Information. consumer health - Exercise for Seniors.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exerc Sport Sci Rev. 1999;27:1-35 [10791012.001]
  • [Cites] Ann Intern Med. 2000 Jul 18;133(2):92-103 [10896648.001]
  • [Cites] Cell Metab. 2006 Jul;4(1):75-87 [16814734.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2310-6 [16551730.001]
  • [Cites] Diabetes Care. 2001 May;24(5):933-41 [11347757.001]
  • [Cites] J Appl Physiol (1985). 2001 Jun;90(6):2033-40 [11356762.001]
  • [Cites] JAMA. 2002 Jan 16;287(3):356-9 [11790215.001]
  • [Cites] Int J Sport Nutr Exerc Metab. 2001 Dec;11 Suppl:S58-63 [11915929.001]
  • [Cites] Diabetes. 2003 Jul;52(7):1779-85 [12829646.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Sep;285(3):E527-33 [12736161.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Sep;27(9):1066-71 [12917712.001]
  • [Cites] Obes Res. 2003 Sep;11(9):1048-54 [12972674.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):421-4 [14585088.001]
  • [Cites] Circulation. 2004 Jan 27;109(3):433-8 [14744958.001]
  • [Cites] Am J Physiol. 1990 Jun;258(6 Pt 1):E937-43 [2193534.001]
  • [Cites] Acta Physiol Scand. 1993 Aug;148(4):379-85 [8213193.001]
  • [Cites] JAMA. 1995 Feb 1;273(5):402-7 [7823386.001]
  • [Cites] Diabetes Care. 1997 Mar;20(3):385-91 [9051392.001]
  • [Cites] Eur J Appl Physiol Occup Physiol. 1998 May;77(6):551-5 [9650742.001]
  • [Cites] Am J Prev Med. 2005 Jan;28(1):9-18 [15626550.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Apr;288(4):E741-7 [15562250.001]
  • [Cites] J Am Geriatr Soc. 2005 Jun;53(6 Suppl):S245-56 [15963180.001]
  • [Cites] Metabolism. 2005 Jul;54(7):866-75 [15988694.001]
  • [Cites] J Appl Physiol (1985). 2006 Jan;100(1):142-9 [16141382.001]
  • [Cites] Diabetes Care. 2006 Mar;29(3):673-8 [16505525.001]
  • [Cites] Med Sci Sports Exerc. 2006 Mar;38(3):433-8 [16540829.001]
  • [Cites] Eur J Endocrinol. 2006 Apr;154(4):577-85 [16556721.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2006 Mar;61(3):299-304 [16567381.001]
  • [Cites] J Appl Physiol (1985). 2006 May;100(5):1584-9 [16373444.001]
  • [Cites] Endocr J. 2006 Apr;53(2):189-95 [16618976.001]
  • (PMID = 19196080.001).
  • [ISSN] 1557-8518
  • [Journal-full-title] Metabolic syndrome and related disorders
  • [ISO-abbreviation] Metab Syndr Relat Disord
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K01 DK 64716-01; United States / NCRR NIH HHS / RR / M01 RR14288; United States / NIA NIH HHS / AG / R01 AG 19346-01
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin
  • [Other-IDs] NLM/ PMC3135883
  •  go-up   go-down


38. Lee JY, Janes BK, Passalacqua KD, Pfleger BF, Bergman NH, Liu H, Håkansson K, Somu RV, Aldrich CC, Cendrowski S, Hanna PC, Sherman DH: Biosynthetic analysis of the petrobactin siderophore pathway from Bacillus anthracis. J Bacteriol; 2007 Mar;189(5):1698-710
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biosynthetic analysis of the petrobactin siderophore pathway from Bacillus anthracis.
  • The asbABCDEF gene cluster from Bacillus anthracis is responsible for biosynthesis of petrobactin, a catecholate siderophore that functions in both iron acquisition and virulence in a murine model of anthrax.
  • We initiated studies to determine the biosynthetic details of petrobactin assembly based on mutational analysis of the asb operon, identification of accumulated intermediates, and addition of exogenous siderophores to asb mutant strains.
  • As a starting point, in-frame deletions of each of the genes in the asb locus (asbABCDEF) were constructed.
  • The individual mutations resulted in complete abrogation of petrobactin biosynthesis when strains were grown on iron-depleted medium.
  • However, in vitro analysis showed that each asb mutant grew to a very limited extent as vegetative cells in iron-depleted medium.
  • In contrast, none of the B. anthracis asb mutant strains were able to outgrow from spores under the same culture conditions.
  • Provision of exogenous petrobactin was able to rescue the growth defect in each asb mutant strain.
  • Taken together, these data provide compelling evidence that AsbA performs the penultimate step in the biosynthesis of petrobactin, involving condensation of 3,4-dihydroxybenzoyl spermidine with citrate to form 3,4-dihydroxybenzoyl spermidinyl citrate.
  • As a final step, the data reveal that AsbB catalyzes condensation of a second molecule of 3,4-dihydroxybenzoyl spermidine with 3,4-dihydroxybenzoyl spermidinyl citrate to form the mature siderophore.
  • This work sets the stage for detailed biochemical studies with this unique acyl carrier protein-dependent, nonribosomal peptide synthetase-independent biosynthetic system.
  • [MeSH-major] Bacillus anthracis / metabolism. Benzamides / metabolism
  • [MeSH-minor] Base Sequence. Chromatography, High Pressure Liquid. Genetic Complementation Test. Iron / metabolism. Mass Spectrometry. Molecular Sequence Data. Mutation. Operon

  • HSDB. structure - IRON.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Microbiol. 2000;54:881-941 [11018148.001]
  • [Cites] Biochemistry. 2007 Apr 3;46(13):4147-57 [17346033.001]
  • [Cites] Int J Med Microbiol. 2001 May;291(2):67-79 [11437341.001]
  • [Cites] J Am Chem Soc. 2002 Jan 23;124(3):378-9 [11792199.001]
  • [Cites] JAMA. 2002 May 1;287(17):2236-52 [11980524.001]
  • [Cites] Microbiol Mol Biol Rev. 2002 Jun;66(2):223-49 [12040125.001]
  • [Cites] Infect Immun. 2002 Oct;70(10):5870-2 [12228320.001]
  • [Cites] Nat Biotechnol. 2003 Jul;21(7):796-802 [12778056.001]
  • [Cites] Mol Microbiol. 2004 Jan;51(2):407-17 [14756782.001]
  • [Cites] J Org Chem. 2004 May 14;69(10):3530-7 [15132566.001]
  • [Cites] Curr Microbiol. 2004 Aug;49(2):89-94 [15297912.001]
  • [Cites] Microbiol Rev. 1978 Mar;42(1):45-66 [379572.001]
  • [Cites] J Bacteriol. 1986 Feb;165(2):570-8 [2935523.001]
  • [Cites] J Bacteriol. 1986 Jul;167(1):350-5 [3087960.001]
  • [Cites] Mol Gen Genet. 1987 Sep;209(2):335-42 [2823077.001]
  • [Cites] Gene. 1999 Jan 21;226(2):297-305 [9931504.001]
  • [Cites] N Engl J Med. 1999 Sep 9;341(11):815-26 [10477781.001]
  • [Cites] J Nat Prod. 2004 Nov;67(11):1897-9 [15568785.001]
  • [Cites] Chembiochem. 2005 Apr;6(4):601-11 [15719346.001]
  • [Cites] Biometals. 2005 Dec;18(6):577-85 [16388397.001]
  • [Cites] J Med Chem. 2006 Jan 12;49(1):31-4 [16392788.001]
  • [Cites] FEBS J. 2006 Jan;273(2):409-19 [16403027.001]
  • [Cites] Nat Chem Biol. 2005 Jun;1(1):29-32 [16407990.001]
  • [Cites] J Med Microbiol. 2006 Mar;55(Pt 3):251-8 [16476787.001]
  • [Cites] Infect Immun. 2006 Mar;74(3):1949-53 [16495572.001]
  • [Cites] J Bacteriol. 2006 Jun;188(11):3837-48 [16707676.001]
  • [Cites] Curr Microbiol. 2006 Aug;53(2):141-7 [16845564.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 15;348(1):320-5 [16875672.001]
  • [Cites] Res Microbiol. 2001 Apr-May;152(3-4):291-301 [11421276.001]
  • (PMID = 17189355.001).
  • [ISSN] 0021-9193
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / petrobactin; E1UOL152H7 / Iron
  • [Other-IDs] NLM/ PMC1855748
  •  go-up   go-down


39. Stein GE, Schooley SL, Peloquin CA, Kak V, Havlichek DH, Citron DM, Tyrrell KL, Goldstein EJ: Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother; 2005 Mar;39(3):427-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.
  • BACKGROUND: Linezolid is an oxazolidinone antimicrobial with excellent oral bioavailability and tissue penetration and is active against multidrug-resistant skin/soft tissue pathogens.
  • OBJECTIVE: To study the pharmacokinetics and antibacterial activity of linezolid against selective skin/soft tissue pathogens in obese patients.
  • METHODS: We obtained multiple serum samples from 7 obese patients (>50% over their calculated ideal body weight) receiving oral linezolid 600 mg every 12 hours for treatment of cellulitis.
  • Following a minimum of 3 doses, serum concentrations of linezolid were measured in each subject prior to (trough) and 1 and 6 hours after a dose.
  • These samples were then tested against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) (linezolid minimum inhibitory concentrations [MICs] 1.0, 2.0, 4.0 microg/mL) and one strain each of vancomycin-resistant Enterococcus faecium (VRE) (MIC 2.0 microg/mL), Bacteroides fragilis (MIC 2.0 microg/mL), and Peptostreptococcus magnus (MIC 1.0 microg/mL).
  • Serum inhibitory titers (SITs) and bactericidal titers (SBTs) were measured at each time point, and the median activity for these 7 patients was calculated.
  • RESULTS: Mean linezolid serum concentrations were 4.2, 12.3, and 7.2 microg/mL at these respective time points.
  • Median SITs for 12 hours (100% of the dosing interval) were observed against each organism with the exception of the least susceptible strain of MRSA (MIC 4.0 microg/mL); serum inhibitory activity was observed only at the one-hour time point against this isolate.
  • Furthermore, prolonged (> or =6 h) median SBTs were observed against one isolate of MRSA (MIC 1.0 microg/mL) as well as the strain of VRE and P. magnus.
  • CONCLUSIONS: Serum concentrations of oral linezolid in this patient population were diminished compared with those of healthy volunteers, but still provided prolonged serum inhibitory activity against common pathogens associated with skin/soft tissue infections.
  • One treatment concern would be an obese patient receiving oral linezolid who was infected with a less susceptible (MIC > or =4.0 microg/mL) strain of S. aureus.
  • Bactericidal activity was also observed against selective pathogens.
  • [MeSH-major] Acetamides / pharmacology. Anti-Bacterial Agents / pharmacology. Cellulitis / drug therapy. Obesity / complications. Oxazolidinones / pharmacology. Skin Diseases, Bacterial / drug therapy. Soft Tissue Infections / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Drug Resistance, Multiple, Bacterial. Female. Half-Life. Humans. Male. Microbial Sensitivity Tests. Middle Aged. Serum Bactericidal Test

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Cellulitis.
  • MedlinePlus Health Information. consumer health - Obesity.
  • HSDB. structure - LINEZOLID.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701775.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetamides; 0 / Anti-Bacterial Agents; 0 / Oxazolidinones; 165800-03-3 / linezolid
  •  go-up   go-down


40. Larsen DH, Poinsignon C, Gudjonsson T, Dinant C, Payne MR, Hari FJ, Rendtlew Danielsen JM, Menard P, Sand JC, Stucki M, Lukas C, Bartek J, Andersen JS, Lukas J: The chromatin-remodeling factor CHD4 coordinates signaling and repair after DNA damage. J Cell Biol; 2010 Sep 6;190(5):731-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Autoantigens / genetics. Autoantigens / metabolism. Cell Cycle / genetics. Cell Line, Tumor. Chromosomes / metabolism. DNA / genetics. DNA / metabolism. DNA Breaks, Double-Stranded. Genes, cdc. Humans. Mi-2 Nucleosome Remodeling and Deacetylase Complex / genetics. Mi-2 Nucleosome Remodeling and Deacetylase Complex / metabolism. RNA Interference. RNA, Small Interfering / metabolism. RNA, Small Interfering / pharmacology. Radiation, Ionizing. Ubiquitin / genetics. Ubiquitin / metabolism. Ubiquitination. cdc25 Phosphatases / genetics. cdc25 Phosphatases / metabolism

  • ResearchGate. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 1990 Apr 1;267(1):125-32 [2327978.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):792-804 [15459660.001]
  • [Cites] Cell. 1998 Oct 16;95(2):279-89 [9790534.001]
  • [Cites] Nature. 1998 Oct 29;395(6705):917-21 [9804427.001]
  • [Cites] Mol Cell. 1998 Dec;2(6):851-61 [9885572.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):316-23 [15549093.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9035-40 [15604269.001]
  • [Cites] Cell. 2005 Dec 29;123(7):1213-26 [16377563.001]
  • [Cites] J Cell Biol. 2006 Apr 24;173(2):195-206 [16618811.001]
  • [Cites] DNA Repair (Amst). 2006 May 10;5(5):534-43 [16531125.001]
  • [Cites] Curr Biol. 2006 Jul 11;16(13):1344-50 [16824923.001]
  • [Cites] Mol Cell. 2006 Aug 4;23(3):307-18 [16885021.001]
  • [Cites] Science. 2007 May 25;316(5828):1160-6 [17525332.001]
  • [Cites] Curr Opin Cell Biol. 2007 Apr;19(2):238-45 [17303408.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10253-7 [17079442.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):861-9 [17943134.001]
  • [Cites] Nat Struct Mol Biol. 2007 Nov;14(11):1096-104 [17934473.001]
  • [Cites] Cell. 2007 Nov 30;131(5):887-900 [18001824.001]
  • [Cites] Cell. 2007 Nov 30;131(5):901-14 [18001825.001]
  • [Cites] Science. 2007 Dec 7;318(5856):1637-40 [18006705.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20759-63 [18077395.001]
  • [Cites] Mol Cell Biol. 2008 Oct;28(19):5912-23 [18644863.001]
  • [Cites] Cell. 2009 Feb 6;136(3):420-34 [19203578.001]
  • [Cites] Cell. 2009 Feb 6;136(3):435-46 [19203579.001]
  • [Cites] PLoS Genet. 2009 Mar;5(3):e1000435 [19325889.001]
  • [Cites] Trends Cell Biol. 2009 May;19(5):207-17 [19342239.001]
  • [Cites] Nat Cell Biol. 2009 Oct;11(10):1261-7 [19734887.001]
  • [Cites] Nature. 2009 Oct 22;461(7267):1071-8 [19847258.001]
  • [Cites] J Cell Biol. 2010 Sep 6;190(5):741-9 [20805320.001]
  • [Cites] Biochemistry. 1999 Nov 2;38(44):14711-7 [10545197.001]
  • [Cites] Science. 2000 May 26;288(5470):1425-9 [10827953.001]
  • [Cites] Nat Genet. 2002 Mar;30(3):290-4 [11850621.001]
  • [Cites] Mol Cell Proteomics. 2002 May;1(5):376-86 [12118079.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):198-207 [12634793.001]
  • [Cites] Nat Cell Biol. 2003 Mar;5(3):255-60 [12598907.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8063-71 [14603247.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 15;1677(1-3):52-7 [15020045.001]
  • [Cites] Genes Dev. 2004 Jun 15;18(12):1423-38 [15175241.001]
  • [Cites] EMBO J. 2004 Jul 7;23(13):2674-83 [15201865.001]
  • [Cites] DNA Repair (Amst). 2004 Aug-Sep;3(8-9):959-67 [15279782.001]
  • [Cites] Curr Biol. 1998 Jul 2;8(14):843-6 [9663395.001]
  • (PMID = 20805324.001).
  • [ISSN] 1540-8140
  • [Journal-full-title] The Journal of cell biology
  • [ISO-abbreviation] J. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantigens; 0 / CHD4 protein, human; 0 / Chromatin; 0 / RNA, Small Interfering; 0 / Ubiquitin; 9007-49-2 / DNA; EC 3.1.3.48 / cdc25 Phosphatases; EC 3.5.1.98 / Mi-2 Nucleosome Remodeling and Deacetylase Complex
  • [Other-IDs] NLM/ PMC2935572
  •  go-up   go-down


41. Lee JH, Yang DH, Park HS, Cho Y, Jeong MH, Kim YJ, Kim KS, Hur SH, Seong IW, Hong TJ, Cho MC, Kim CJ, Jun JE, Park WH, Chae SC, Korea Acute Myocardial Infarction Registry Investigators: Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea Acute Myocardial Infarction Registry: prescription rate, predictors, and prognostic value. Am Heart J; 2010 Jun;159(6):1012-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between November 2005 and January 2008, we evaluated the discharge medications among 9,294 post-MI survivors who did not have any documented contraindications to antiplatelet drugs, beta-blockers, angiotensin-converting enzyme inhibitors (ACE-Is)/angiotensin II receptor blockers (ARBs), or statins in the Korea Acute Myocardial Infarction Registry.

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Statins.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20569714.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Prescription Drugs
  •  go-up   go-down


42. Kittendorf JD, Beck BJ, Buchholz TJ, Seufert W, Sherman DH: Interrogating the molecular basis for multiple macrolactone ring formation by the pikromycin polyketide synthase. Chem Biol; 2007 Aug;14(8):944-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrogating the molecular basis for multiple macrolactone ring formation by the pikromycin polyketide synthase.
  • The pikromycin polyketide synthase (PKS) is unique in its ability to generate both 12 and 14 membered ring macrolactones.
  • As such, dissection of the molecular basis for controlling metabolic diversity in this system remains an important objective for understanding modular PKS function and expanding chemical diversity.
  • Here, we describe a series of experiments designed to probe the importance of the protein-protein interaction that occurs between the final two monomodules, PikAIII (module 5) and PikAIV (module 6), for the production of the 12 membered ring macrolactone 10-deoxymethynolide.
  • The results obtained from these in vitro studies demonstrate that PikAIII and PikAIV generate the 12 membered ring macrocycle most efficiently when engaged in their native protein-protein interaction.
  • Accordingly, the data are consistent with PikAIV adopting an alternative conformation that enables the terminal thioesterase domain to directly off-load the PikAIII-bound hexaketide intermediate for macrocyclization.
  • [MeSH-major] Lactones / chemistry. Macrolides / metabolism. Polyketide Synthases / metabolism
  • [MeSH-minor] Base Sequence. Catalytic Domain. Cyclization. DNA Primers. Esterases / metabolism. Mutagenesis, Site-Directed

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol. 2003 Aug;10(8):723-31 [12954331.001]
  • [Cites] J Am Chem Soc. 2003 Apr 23;125(16):4682-3 [12696866.001]
  • [Cites] Chem Commun (Camb). 2003 Nov 21;(22):2780-2 [14651102.001]
  • [Cites] Chem Biol. 2003 Dec;10(12):1225-32 [14700630.001]
  • [Cites] Chem Biol. 2004 Jan;11(1):87-97 [15112998.001]
  • [Cites] Nature. 1990 Nov 8;348(6297):176-8 [2234082.001]
  • [Cites] Science. 1991 May 3;252(5006):675-9 [2024119.001]
  • [Cites] Chem Biol. 1996 Nov;3(11):923-36 [8939709.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12111-6 [9770448.001]
  • [Cites] Chem Biol. 1999 Feb;6(2):117-25 [10021418.001]
  • [Cites] Chem Biol. 2005 Feb;12(2):249-56 [15734652.001]
  • [Cites] J Am Chem Soc. 2005 Jun 15;127(23):8441-52 [15941278.001]
  • [Cites] J Am Chem Soc. 2005 Jun 29;127(25):8910-1 [15969542.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Nov 25;44(46):7557-60 [16247819.001]
  • [Cites] Nat Rev Microbiol. 2005 Dec;3(12):925-36 [16322741.001]
  • [Cites] Science. 2006 Mar 3;311(5765):1258-62 [16513975.001]
  • [Cites] Chembiochem. 2006 Mar;7(3):485-94 [16470766.001]
  • [Cites] Structure. 2006 Apr;14(4):737-48 [16564177.001]
  • [Cites] J Nat Prod. 2006 May;69(5):847-9 [16724858.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11124-9 [16844787.001]
  • [Cites] Curr Opin Biotechnol. 2006 Dec;17(6):597-605 [17046237.001]
  • [Cites] ACS Chem Biol. 2006 Sep 19;1(8):505-9 [17168537.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):571-5 [10676969.001]
  • [Cites] Curr Opin Chem Biol. 2000 Feb;4(1):22-7 [10679375.001]
  • [Cites] Gene. 2000 Mar 7;245(1):203-11 [10713461.001]
  • [Cites] Biochemistry. 2001 Feb 27;40(8):2326-31 [11327852.001]
  • [Cites] Chem Biol. 2001 May;8(5):475-85 [11358694.001]
  • [Cites] J Am Chem Soc. 2001 Jul 11;123(27):6465-74 [11439032.001]
  • [Cites] J Nat Prod. 2001 Nov;64(11):1447-50 [11720530.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):13082-90 [11809757.001]
  • [Cites] Chem Biol. 2002 May;9(5):575-83 [12031664.001]
  • [Cites] Protein Expr Purif. 2002 Jun;25(1):1-7 [12071692.001]
  • [Cites] Protein Expr Purif. 2002 Jun;25(1):8-15 [12071693.001]
  • [Cites] Biochemistry. 2002 Oct 22;41(42):12590-7 [12379101.001]
  • [Cites] J Am Chem Soc. 2003 Oct 15;125(41):12551-7 [14531700.001]
  • (PMID = 17719493.001).
  • [ISSN] 1074-5521
  • [Journal-full-title] Chemistry & biology
  • [ISO-abbreviation] Chem. Biol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM075641; United States / NIGMS NIH HHS / GM / R01 GM076477; United States / NIGMS NIH HHS / GM / R01 GM076477; United States / NIGMS NIH HHS / GM / R01 GM076477-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Lactones; 0 / Macrolides; 19721-56-3 / picromycin; 79956-01-7 / Polyketide Synthases; EC 3.1.- / Esterases
  • [Other-IDs] NLM/ NIHMS29672; NLM/ PMC2707933
  •  go-up   go-down


43. Wang Y, Novotny M, Quaiserová-Mocko V, Swain GM, Wang DH: TRPV1-mediated protection against endotoxin-induced hypotension and mortality in rats. Am J Physiol Regul Integr Comp Physiol; 2008 May;294(5):R1517-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRPV1-mediated protection against endotoxin-induced hypotension and mortality in rats.
  • This study was designed to test the hypothesis that the transient receptor potential vanilloid type 1 (TRPV1) channel, expressed primarily in sensory nerves, and substance P (SP), released by sensory nerves, play a protective role against lipopolysaccharide (LPS)-induced hypotension.
  • LPS (10 mg/kg iv) elicited tachycardia and hypotension in anesthetized male Wistar rats, which peaked at 10 min and gradually recovered 1 h after the injection.
  • Blockade of TRPV1 with its selective antagonist capsazepine (CAPZ, 3 mg/kg iv) impaired recovery given that the fall in mean arterial pressure (MAP) was greater 1 h after CAPZ plus LPS injections compared with LPS injection alone (45 +/- 5 vs. 25 +/- 4 mmHg, P < 0.05).
  • Blockade of the neurokinin 1 (NK1) receptor with its selective antagonists RP-67580 (5 mg/kg iv) or L-733,060 (4 mg/kg iv) prevented recovery, considering that falls in MAP were not different 1 h after injections of NK1 antagonists plus LPS from their peak decreases (66 +/- 9 vs. 74 +/- 5 mmHg or 60 +/- 7 vs. 69 +/- 3 mmHg, respectively, P > 0.05).
  • LPS increased plasma SP, norepinephrine (NE), and epinephrine (Epi) levels compared with vehicles, and the increases in plasma SP, NE, and Epi were significantly inhibited by CAPZ or RP-67580.
  • The survival rate at 24 or 48 h after LPS injection (20 mg/kg ip) was lower in conscious rats pretreated with CAPZ or RP-67580 compared with rats treated with LPS alone (P < 0.05).
  • Thus our results show that the TRPV1, possibly via triggering release of SP which activates the NK1 and stimulates the sympathetic axis, plays a protective role against endotoxin-induced hypotension and mortality, suggesting that TRPV1 receptors are essential in protecting vital organ perfusion and survival during the endotoxic condition.
  • [MeSH-major] Endotoxins / toxicity. Hypotension / chemically induced. Hypotension / prevention & control. TRPV Cation Channels / physiology
  • [MeSH-minor] Animals. Blood Pressure / drug effects. Capsaicin / analogs & derivatives. Capsaicin / pharmacology. Catecholamines / blood. Heart Rate / drug effects. Isoindoles / pharmacology. Lipopolysaccharides / toxicity. Male. Neurons, Afferent / drug effects. Rats. Rats, Wistar. Receptors, Neurokinin-1 / physiology. Substance P / metabolism

  • MedlinePlus Health Information. consumer health - Low Blood Pressure.
  • HSDB. structure - CAPSAICIN.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Pharmacol. 1995 Jun;115(3):486-90 [7582461.001]
  • [Cites] Am J Physiol. 1993 Aug;265(2 Pt 1):E284-8 [8368298.001]
  • [Cites] New Horiz. 1996 May;4(2):168-78 [8774793.001]
  • [Cites] Hypertension. 1996 Oct;28(4):682-6 [8843898.001]
  • [Cites] Pain. 1996 Sep;67(1):189-95 [8895247.001]
  • [Cites] Eur J Pharmacol. 1996 Dec 12;317(1):129-35 [8982729.001]
  • [Cites] Br J Pharmacol. 1997 Jan;120(1):25-30 [9117094.001]
  • [Cites] Hypertension. 1997 May;29(5):1204-10 [9149688.001]
  • [Cites] Am J Physiol. 1997 Aug;273(2 Pt 2):R609-14 [9277545.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):816-24 [9349813.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 1997 Nov 7;701(1):115-9 [9389345.001]
  • [Cites] FASEB J. 1998 Aug;12(11):1035-44 [9707176.001]
  • [Cites] N Engl J Med. 1999 Jan 21;340(3):207-14 [9895401.001]
  • [Cites] Eur J Pharmacol. 1999 Feb 19;367(2-3):239-45 [10078998.001]
  • [Cites] Pharmacol Rev. 1999 Jun;51(2):159-212 [10353985.001]
  • [Cites] Nature. 1999 Jul 29;400(6743):452-7 [10440374.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Mar;288(3):H1016-21 [15706038.001]
  • [Cites] Hypertension. 2005 Oct;46(4):986-91 [16144988.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):177-88 [16816371.001]
  • [Cites] J Pharmacol Exp Ther. 2007 May;321(2):763-9 [17308041.001]
  • [Cites] FASEB J. 2007 Nov;21(13):3747-55 [17601984.001]
  • [Cites] Peptides. 2000 Apr;21(4):535-41 [10822109.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Nov;279(5):R1685-94 [11049850.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 May;280(5):R1564-72 [11294782.001]
  • [Cites] Nature. 2001 Sep 13;413(6852):203-10 [11557989.001]
  • [Cites] Circ Res. 2001 Nov 23;89(11):983-90 [11717154.001]
  • [Cites] J Pharmacol Exp Ther. 2002 May;301(2):536-42 [11961054.001]
  • [Cites] N Engl J Med. 2003 Jan 9;348(2):138-50 [12519925.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H891-8 [12738616.001]
  • [Cites] J Physiol. 2003 Sep 1;551(Pt 2):515-23 [12829722.001]
  • [Cites] Peptides. 2004 Mar;25(3):413-23 [15134864.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 Aug;287(2):H595-600 [15059774.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 Oct;287(4):H1868-74 [15205172.001]
  • [Cites] Ann Surg. 1973 Jul;178(1):102-7 [4717703.001]
  • [Cites] Am J Pathol. 1978 Nov;93(2):526-618 [362943.001]
  • [Cites] Neuroscience. 1982 Mar;7(3):647-54 [6175922.001]
  • [Cites] Circ Shock. 1986;18(2):141-55 [3004777.001]
  • [Cites] Clin Chem. 1986 Nov;32(11):2030-3 [3096593.001]
  • [Cites] Annu Rev Neurosci. 1988;11:13-28 [3284438.001]
  • [Cites] Brain Res. 1988 Aug 23;458(2):205-11 [2463045.001]
  • [Cites] J Neurosci. 1989 Jan;9(1):258-79 [2536418.001]
  • [Cites] Brain Res. 1989 May 22;487(2):392-6 [2471579.001]
  • [Cites] Brain Res. 1989 Sep 18;497(2):280-90 [2479449.001]
  • [Cites] FASEB J. 1990 Apr 1;4(6):1606-15 [1969374.001]
  • [Cites] Lancet. 1991 Sep 21;338(8769):732-6 [1679876.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10208-12 [1719549.001]
  • [Cites] Neuroscience. 1992;46(3):739-54 [1312231.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1471-7 [8479467.001]
  • [Cites] Peptides. 1995;16(8):1439-45 [8745056.001]
  • (PMID = 18337316.001).
  • [ISSN] 0363-6119
  • [Journal-full-title] American journal of physiology. Regulatory, integrative and comparative physiology
  • [ISO-abbreviation] Am. J. Physiol. Regul. Integr. Comp. Physiol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 67620; United States / NHLBI NIH HHS / HL / HL 57853; United States / NHLBI NIH HHS / HL / HL 73287; United States / NIDDK NIH HHS / DK / R01 DK067620; United States / NIDDK NIH HHS / DK / R01 DK067620-04; United States / NHLBI NIH HHS / HL / R01 HL057853; United States / NHLBI NIH HHS / HL / R01 HL057853-07; United States / NHLBI NIH HHS / HL / R01 HL073287; United States / NHLBI NIH HHS / HL / R01 HL073287-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Catecholamines; 0 / Endotoxins; 0 / Isoindoles; 0 / Lipopolysaccharides; 0 / Receptors, Neurokinin-1; 0 / TRPV Cation Channels; 0 / Trpv1 protein, rat; 135911-02-3 / 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one; 33507-63-0 / Substance P; LFW48MY844 / capsazepine; S07O44R1ZM / Capsaicin
  • [Other-IDs] NLM/ NIHMS96819; NLM/ PMC2668825
  •  go-up   go-down


44. Hamer DH, Singh MP, Wylie BJ, Yeboah-Antwi K, Tuchman J, Desai M, Udhayakumar V, Gupta P, Brooks MI, Shukla MM, Awasthy K, Sabin L, MacLeod WB, Dash AP, Singh N: Burden of malaria in pregnancy in Jharkhand State, India. Malar J; 2009;8:210
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burden of malaria in pregnancy in Jharkhand State, India.
  • BACKGROUND: Past studies in India included only symptomatic pregnant women and thus may have overestimated the proportion of women with malaria.
  • Given the large population at risk, a cross sectional study was conducted in order to better define the burden of malaria in pregnancy in Jharkhand, a malaria-endemic state in central-east India.
  • METHODS: Cross-sectional surveys at antenatal clinics and delivery units were performed over a 12-month period at two district hospitals in urban and semi-urban areas, and a rural mission hospital.
  • Malaria was diagnosed by Giemsa-stained blood smear and/or rapid diagnostic test using peripheral or placental blood.
  • RESULTS: 2,386 pregnant women were enrolled at the antenatal clinics and 718 at the delivery units.
  • 1.8% (43/2382) of the antenatal clinic cohort had a positive diagnostic test for malaria (53.5% Plasmodium falciparum, 37.2% Plasmodium vivax, and 9.3% mixed infections).
  • Peripheral parasitaemia was more common in pregnant women attending antenatal clinics in rural sites (adjusted relative risk [aRR] 4.31, 95%CI 1.84-10.11) and in those who were younger than 20 years (aRR 2.68, 95%CI 1.03-6.98).
  • Among delivery unit participants, 1.7% (12/717) had peripheral parasitaemia and 2.4% (17/712) had placental parasitaemia.
  • Women attending delivery units were more likely to be parasitaemic if they were in their first or second pregnancy (aRR 3.17, 95%CI 1.32-7.61), had fever in the last week (aRR 5.34, 95%CI 2.89-9.90), or had rural residence (aRR 3.10, 95%CI 1.66-5.79).
  • Malaria control measures including indoor residual spraying (IRS) and untreated bed nets were common, whereas insecticide-treated bed nets (ITN) and malaria chemoprophylaxis were rarely used.
  • CONCLUSION: The prevalence of malaria among pregnant women was relatively low.
  • However, given the large at-risk population in this malaria-endemic region of India, there is a need to enhance ITN availability and use for prevention of malaria in pregnancy, and to improve case management of symptomatic pregnant women.
  • [MeSH-major] Malaria, Falciparum / epidemiology. Malaria, Vivax / epidemiology. Pregnancy Complications, Infectious / epidemiology
  • [MeSH-minor] Adult. Animals. Blood / parasitology. Cross-Sectional Studies. Female. Humans. India / epidemiology. Plasmodium falciparum / isolation & purification. Plasmodium vivax / isolation & purification. Pregnancy. Prevalence. Young Adult

  • Genetic Alliance. consumer health - Malaria.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Infections and Pregnancy.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trans R Soc Trop Med Hyg. 2000 Apr;94 Suppl 1:S1-90 [11103309.001]
  • [Cites] Malar J. 2009;8:93 [19419588.001]
  • [Cites] Clin Microbiol Rev. 2004 Oct;17(4):760-9, table of contents [15489346.001]
  • [Cites] N Engl J Med. 1985 Jan 10;312(2):82-90 [3880598.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1985;79(2):181-4 [3890280.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1988;82(3):376-9 [3068848.001]
  • [Cites] J Pediatr. 1991 Sep;119(3):417-23 [1880657.001]
  • [Cites] Indian J Malariol. 1995 Mar;32(1):6-13 [8549840.001]
  • [Cites] Am J Trop Med Hyg. 1996;55(1 Suppl):33-41 [8702035.001]
  • [Cites] Am J Trop Med Hyg. 1996;55(1 Suppl):95-100 [8702046.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1996 Sep-Oct;90(5):535-9 [8944266.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1997 May-Jun;91(3):256-62 [9231189.001]
  • [Cites] J Commun Dis. 1997 Sep;29(3):201-8 [9465524.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1998 Mar;29(1):10-7 [9740260.001]
  • [Cites] Bull World Health Organ. 1999;77(7):567-72 [10444880.001]
  • [Cites] Nature. 2005 Mar 10;434(7030):214-7 [15759000.001]
  • [Cites] Am J Trop Med Hyg. 2005 Nov;73(5):855-8 [16282293.001]
  • [Cites] Lancet Infect Dis. 2007 Feb;7(2):93-104 [17251080.001]
  • [Cites] Lancet Infect Dis. 2007 Feb;7(2):126-35 [17251083.001]
  • [Cites] Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):69-78 [18165477.001]
  • [Cites] Malar J. 2008;7:126 [18620560.001]
  • [Cites] Indian J Med Res. 2008 Sep;128(3):246-53 [19052334.001]
  • [Cites] Am J Trop Med Hyg. 2004 May;70(5):481-5 [15155979.001]
  • (PMID = 19728882.001).
  • [ISSN] 1475-2875
  • [Journal-full-title] Malaria journal
  • [ISO-abbreviation] Malar. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2744702
  •  go-up   go-down


45. Min SH, Kim MH, Seo JB, Lee JY, Lee DH: The quantitative analysis of back muscle degeneration after posterior lumbar fusion: comparison of minimally invasive and conventional open surgery. Asian Spine J; 2009 Dec;3(2):89-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The results of conventional open surgery was compared with those from minimally invasive transforaminal lumbar interbody fusion (MI-TLIF) for lumbar fusion to determine which approach resulted in less postoperative paraspinal muscle degeneration.
  • OVERVIEW OF LITERATURE: MI TLIF is new surgical technique that appears to minimize iatrogenic injury.
  • There were 17 cases of conventional open surgery and 31 cases of MI-TLIF (31 cases of single segment fusion and 17 cases of multi-segment fusion).
  • RESULTS: A comparison of the traditional posterior fusion method with MI-TLIF revealed single segment fusion to result in an average increase in fat infiltration in the paraspinal muscle of 4.30% and 1.37% and a decrease in cross-sectional area of 0.10 and 0.07 before and after surgery, respectively.
  • CONCLUSIONS: A comparison of conventional open surgery with MI-TLIF upon degeneration of the paraspinal muscle with a 1 year follow-up evaluation revealed that both single and multi segment fusion showed less change in fat infiltration percentage and cross-sectional area in the MI-TLIF but there was no significant difference between the two groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Spine (Phila Pa 1976). 1998 Feb 1;23(3):354-8 [9507625.001]
  • [Cites] J Appl Physiol (1985). 1998 Jul;85(1):115-22 [9655763.001]
  • [Cites] Muscle Nerve. 1996 Mar;19(3):302-10 [8606693.001]
  • [Cites] Spine (Phila Pa 1976). 1994 Nov 15;19(22):2598-602 [7855687.001]
  • [Cites] Spine (Phila Pa 1976). 1994 Nov 15;19(22):2590-7 [7855686.001]
  • [Cites] Radiol Clin North Am. 1991 Jul;29(4):675-90 [2063000.001]
  • [Cites] Neurosurgery. 2004 Jun;54(6):1413-20; discussion 1420 [15157298.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Aug 1;28(15 Suppl):S26-35 [12897471.001]
  • [Cites] Spine (Phila Pa 1976). 2002 Dec 15;27(24):2758-62 [12486343.001]
  • [Cites] Spine (Phila Pa 1976). 2002 Jun 1;27(11):1131-41 [12045508.001]
  • [Cites] J Bone Joint Surg Am. 2001 Nov;83-A(11):1650-5 [11701786.001]
  • [Cites] Neurol Med Chir (Tokyo). 2000 Mar;40(3):151-4; discussion 154-5 [10842484.001]
  • [Cites] Psychol Bull. 1979 Mar;86(2):420-8 [18839484.001]
  • [Cites] J Neurosci Nurs. 2008 Feb;40(1):32-9 [18330408.001]
  • [Cites] Spine (Phila Pa 1976). 2008 Feb 1;33(3):318-25 [18303466.001]
  • [Cites] Surg Neurol. 2008 Feb;69(2):109-13; discussion 113 [18261638.001]
  • [Cites] J Korean Med Sci. 2007 Aug;22(4):646-51 [17728503.001]
  • [Cites] Spine (Phila Pa 1976). 2007 Jul 1;32(15):1687-92 [17621220.001]
  • [Cites] BMC Med. 2007;5:2 [17254322.001]
  • [Cites] J Spinal Disord Tech. 2006 Jul;19(5):318-22 [16826001.001]
  • [Cites] J Spinal Disord Tech. 2006 Apr;19(2):77-86 [16760779.001]
  • [Cites] Eur Spine J. 2006 Jun;15(6):764-73 [15895259.001]
  • [Cites] Spine (Phila Pa 1976). 2006 Mar 15;31(6):712-6 [16540878.001]
  • [Cites] J Spinal Disord Tech. 2005 Feb;18 Suppl:S1-6 [15699793.001]
  • [Cites] Spine (Phila Pa 1976). 1999 May 15;24(10):1023-8 [10332796.001]
  • [Cites] Acta Radiol. 1999 May;40(3):314-21 [10335971.001]
  • [Cites] Spine (Phila Pa 1976). 1996 Nov 15;21(22):2683-8 [8961456.001]
  • (PMID = 20404953.001).
  • [ISSN] 1976-7846
  • [Journal-full-title] Asian spine journal
  • [ISO-abbreviation] Asian Spine J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2852079
  • [Keywords] NOTNLM ; Fat degeneration / MRI / Paraspainal muscle / Posterior fusion
  •  go-up   go-down


46. Liu Y, Peng Y, Mi M, Guevara-Patino J, Munn DH, Fu N, He Y: Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice. J Immunol; 2009 May 15;182(10):5960-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.
  • Recombinant lentivector immunization has been demonstrated to induce potent CD8 T cell responses in vivo.
  • In this study, we investigated whether lentivector delivering a self/tumor Ag, tyrosinase related protein 1 (TRP1), could stimulate effective antitumor T cell responses.
  • We found that immunization with lentivector expressing mutated TRP1 Ag elicited potent CD8 T cell responses against multiple TRP1 epitopes.
  • Importantly, the activated CD8 T cells effectively recognize wild-type TRP1 epitopes.
  • At peak times, as many as 10% of CD8 T cells were effector cells against TRP1 Ag.
  • These cells killed wild-type TRP1 peptide-pulsed target cells in vivo and produced IFN-gamma after ex vivo stimulation.
  • The CD8 T cell responses were long-lasting (3-4 wk).
  • Immunized mice were protected from B16 tumor cell challenge.
  • In a therapeutic setting, lentivector immunization induced potent CD8 T cell responses in tumor bearing mice.
  • The number of infiltrating T cells and the ratio of CD8/CD4 were dramatically increased in the tumors of immunized mice.
  • The tumor-infiltrating CD8 T cells were functional and produced IFN-gamma.
  • The potent CD8 T cell responses stimulated by lentivector immunization eliminated small 3-day s.c.
  • B16 tumors and strongly inhibited the growth of more established 5-day tumors.
  • These studies demonstrate that genetic immunization with lentivector expressing mutated self/tumor Ag can generate potent CD8 T cell immune responses and antitumor immunity that prevent and inhibit B16 tumor growth, suggesting that lentivector immunization has the potential for tumor immunotherapy and immune prevention.
  • [MeSH-major] Antigens, Neoplasm / immunology. CD8-Positive T-Lymphocytes / immunology. Cancer Vaccines / immunology. Genetic Vectors / immunology. Melanoma, Experimental / immunology. Membrane Glycoproteins / immunology. Oxidoreductases / immunology
  • [MeSH-minor] Animals. Autoantigens / genetics. Autoantigens / immunology. Epitopes, T-Lymphocyte / immunology. Flow Cytometry. Fluorescent Antibody Technique. Lentivirus / genetics. Lentivirus / immunology. Lymphocytes, Tumor-Infiltrating / immunology. Mice. Mutation

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 2000 May;30(5):1356-63 [10820382.001]
  • [Cites] J Immunol. 2002 Jan 1;168(1):338-47 [11751979.001]
  • [Cites] Hum Gene Ther. 2001 Dec 10;12(18):2203-13 [11779404.001]
  • [Cites] J Gene Med. 2002 Jan-Feb;4(1):38-45 [11828386.001]
  • [Cites] Methods Enzymol. 2002;346:454-65 [11883085.001]
  • [Cites] Nat Rev Immunol. 2002 Apr;2(4):251-62 [12001996.001]
  • [Cites] J Virol. 2003 Apr;77(8):4911-27 [12663797.001]
  • [Cites] J Clin Invest. 2003 Jun;111(11):1673-81 [12782670.001]
  • [Cites] J Gene Med. 2003 Aug;5(8):654-67 [12898635.001]
  • [Cites] J Exp Med. 2003 Aug 18;198(4):569-80 [12925674.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1582-7 [14734738.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1140-5 [14871849.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] Crit Rev Oncog. 1996;7(5-6):433-56 [9467666.001]
  • [Cites] J Exp Med. 1998 May 4;187(9):1383-93 [9565631.001]
  • [Cites] J Immunol. 1998 Jul 15;161(2):897-908 [9670968.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):277-86 [9670040.001]
  • [Cites] J Exp Med. 1998 Dec 21;188(12):2205-13 [9858507.001]
  • [Cites] Immunity. 1999 Mar;10(3):281-7 [10204484.001]
  • [Cites] Nat Med. 2005 Mar;11(3):312-9 [15711557.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3808-17 [15749922.001]
  • [Cites] Mol Ther. 2006 Feb;13(2):310-9 [16275163.001]
  • [Cites] Nat Med. 2006 Feb;12(2):198-206 [16444264.001]
  • [Cites] Gene Ther. 2006 Apr;13(7):630-40 [16355115.001]
  • [Cites] Annu Rev Immunol. 2006;24:175-208 [16551247.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1382-90 [16614758.001]
  • [Cites] Immunity. 2006 May;24(5):643-56 [16713981.001]
  • [Cites] Adv Immunol. 2006;90:243-95 [16730266.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1935-45 [16778987.001]
  • [Cites] Adv Drug Deliv Rev. 2006 Oct 1;58(8):931-47 [17030074.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):792-801 [17234791.001]
  • [Cites] Nat Protoc. 2006;1(2):672-82 [17406295.001]
  • [Cites] Curr Opin Immunol. 2007 Aug;19(4):408-15 [17656078.001]
  • [Cites] J Clin Invest. 2007 Sep;117(9):2570-82 [17710230.001]
  • [Cites] Curr Opin Mol Ther. 2007 Oct;9(5):439-46 [17932808.001]
  • [Cites] J Exp Med. 2007 Oct 29;204(11):2733-46 [17954572.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):299-308 [18354418.001]
  • [Cites] Expert Rev Vaccines. 2007 Dec;6(6):913-24 [18377355.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2993-3000 [18413769.001]
  • [Cites] J Immunol. 2008 Jul 1;181(1):104-8 [18566374.001]
  • [Cites] Eur J Immunol. 2008 Jul;38(7):1867-76 [18546142.001]
  • [Cites] J Exp Med. 2008 Sep 1;205(9):2125-38 [18725522.001]
  • [Cites] Nature. 2009 Mar 12;458(7235):206-10 [19078956.001]
  • [ErratumIn] J Immunol. 2009 Jul 15;183(2):1496
  • (PMID = 19414747.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116444; United States / NCI NIH HHS / CA / R01 CA116444-03; United States / NCI NIH HHS / CA / R01CA16444
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantigens; 0 / Cancer Vaccines; 0 / Epitopes, T-Lymphocyte; 0 / Membrane Glycoproteins; EC 1.- / Oxidoreductases; EC 1.14.18.- / Tyrp1 protein, mouse
  • [Other-IDs] NLM/ NIHMS255664; NLM/ PMC3077746
  •  go-up   go-down


47. Tsai S, Strouse PJ, Drongowski RA, Islam S, Teitelbaum DH: Failure of cholecystokinin-octapeptide to prevent TPN-associated gallstone disease. J Pediatr Surg; 2005 Jan;40(1):263-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure of cholecystokinin-octapeptide to prevent TPN-associated gallstone disease.
  • PURPOSE: Gallstone formation is a common problem in neonates on prolonged courses of total parenteral nutrition (TPN).
  • The authors hypothesized that the use of cholecystokinin-octapeptide (CCK), given at the time of TPN administration, would prevent gallstone formation in a high-risk group of patients with TPN.
  • METHODS: A prospective, randomized, blinded, controlled trial of neonates who were on a prolonged course of TPN for prematurity (25 infants), necrotizing enterocolitis (NEC, 8 infants), or abdominal surgery (5 infants) were selected randomly to receive CCK vs placebo.
  • Patients remained on the study until taking more than 50% of energy enterally.
  • Children were recalled between 2 and 4 years after completing TPN for ultrasonographic examination of their hepatobiliary tree.
  • RESULTS: Neonates (38 studied) required a mean (+/-SD) of 33 +/- 16 days of TPN.
  • Cholelithiasis was detected in 4 (10%) infants.
  • Cholecystokinin-octapeptide was not effective in preventing the formation of gallstones (3 stones in infants receiving CCK, P = .51).
  • Diagnosis (P = .56), birth weight (P = .54), gestational age (P = .18), and duration of TPN (P = .53) did not correlate with gallstone formation.
  • To address the management of these stones, all 4 were placed on a prolonged course of ursodeoxycholic acid (mean duration, 11.6 +/- 5.4 months).
  • Two additional infants (not in the original study) with TPN-associated gallstone disease were also given a trial of ursodeoxycholic acid.
  • Serial ultrasounds were performed every 6 months.
  • No patient achieved any degree of stone dissolution.
  • One patient underwent cholecystectomy for symptomatology.
  • CONCLUSIONS: Total parenteral nutrition-associated gallstones were detected in 10% of children, and most are nonsymptomatic.
  • Cholecystokinin-octapeptide prophylaxis was not effective in preventing TPN-associated gallstones.
  • In addition, the use of ursodeoxycholic acid did not dissolve gallstones, once identified.
  • Future methods will be needed to address the prevention and treatment of these stones.
  • [MeSH-major] Cholagogues and Choleretics / therapeutic use. Gallstones / prevention & control. Parenteral Nutrition, Total / adverse effects. Sincalide / therapeutic use
  • [MeSH-minor] Double-Blind Method. Gastrointestinal Agents / therapeutic use. Humans. Infant. Infant, Newborn. Prospective Studies. Treatment Failure. Ursodeoxycholic Acid / therapeutic use

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868595.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholagogues and Choleretics; 0 / Gastrointestinal Agents; 724L30Y2QR / Ursodeoxycholic Acid; M03GIQ7Z6P / Sincalide
  •  go-up   go-down


48. Craig DH, Haimovich B, Basson MD: Alpha-actinin-1 phosphorylation modulates pressure-induced colon cancer cell adhesion through regulation of focal adhesion kinase-Src interaction. Am J Physiol Cell Physiol; 2007 Dec;293(6):C1862-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-actinin-1 phosphorylation modulates pressure-induced colon cancer cell adhesion through regulation of focal adhesion kinase-Src interaction.
  • Physical forces including pressure, strain, and shear can be converted into intracellular signals that regulate diverse aspects of cell biology.
  • Exposure to increased extracellular pressure stimulates colon cancer cell adhesion by a beta(1)-integrin-dependent mechanism that requires an intact cytoskeleton and activation of focal adhesion kinase (FAK) and Src. alpha-Actinin facilitates focal adhesion formation and physically links integrin-associated focal adhesion complexes with the cytoskeleton.
  • We therefore hypothesized that alpha-actinin may be necessary for the mechanical response pathway that mediates pressure-stimulated cell adhesion.
  • We reduced alpha-actinin-1 and alpha-actinin-4 expression with isoform-specific small interfering (si)RNA.
  • Silencing of alpha-actinin-1, but not alpha-actinin-4, blocked pressure-stimulated cell adhesion in human SW620, HT-29, and Caco-2 colon cancer cell lines.
  • Cell exposure to increased extracellular pressure stimulated alpha-actinin-1 tyrosine phosphorylation and alpha-actinin-1 interaction with FAK and/or Src, and enhanced FAK phosphorylation at residues Y397 and Y576.
  • The requirement for alpha-actinin-1 phosphorylation in the pressure response was investigated by expressing the alpha-actinin-1 tyrosine phosphorylation mutant Y12F in the colon cancer cells.
  • Expression of Y12F blocked pressure-mediated adhesion and inhibited the pressure-induced association of alpha-actinin-1 with FAK and Src, as well as FAK activation.
  • Furthermore, siRNA-mediated reduction of alpha-actinin-1 eliminated the pressure-induced association of alpha-actinin-1 and Src with beta(1)-integrin receptor, as well as FAK-Src complex formation.
  • These results suggest that alpha-actinin-1 phosphorylation at Y12 plays a crucial role in pressure-activated cell adhesion and mechanotransduction by facilitating Src recruitment to beta(1)-integrin, and consequently the association of FAK with Src, to enhance FAK phosphorylation.
  • [MeSH-major] Actinin / metabolism. Carcinoma / metabolism. Colonic Neoplasms / metabolism. Focal Adhesion Protein-Tyrosine Kinases / metabolism. Mechanotransduction, Cellular / physiology. src-Family Kinases / metabolism
  • [MeSH-minor] Antigens, CD29 / metabolism. Blotting, Western. Caco-2 Cells. Cell Adhesion / physiology. Gene Silencing. HT29 Cells. Humans. Immunoprecipitation. Mutation. Phosphorylation. Pressure. RNA, Small Interfering. Transfection

  • Genetics Home Reference. consumer health - SI Gene.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17898132.001).
  • [ISSN] 0363-6143
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK06771
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ACTN1 protein, human; 0 / Antigens, CD29; 0 / RNA, Small Interfering; 11003-00-2 / Actinin; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.10.2 / src-Family Kinases
  •  go-up   go-down


49. Lobo JD, Kim AC, Davis RP, Segura BJ, Alpert H, Teitelbaum DH, Geiger JD, Mychaliska GB: No free ride? The hidden costs of delayed operative management using a spring-loaded silo for gastroschisis. J Pediatr Surg; 2010 Jul;45(7):1426-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No free ride? The hidden costs of delayed operative management using a spring-loaded silo for gastroschisis.
  • PURPOSE: The ideal management of gastroschisis (primary vs staged closure) has not yet been established.
  • Despite the ease of silo placement, anecdotal experience shows that silos do not always offer benefit.
  • The aim of this study was to highlight concerns regarding use of spring loaded silos and compare outcomes to primary closure.
  • METHODS: Thirty-seven neonates with gastroschisis treated with either primary (n = 10) or staged closure with a spring-loaded silo (n = 27) were reviewed (1998-2007).
  • Variables included ventilator days, daily intravenous fluid, hospital days, and complication rates.
  • SPSS (SPSS Inc, Chicago, Ill) was used to perform t test and chi(2) analyses (significance P < .05).
  • RESULTS: Survival for primary closure was 100% (10/10) compared to 89% (24/27) for staged closure (P = .548).
  • Patients managed with silos required prolonged ventilation (16.1 +/- 4 days vs 3.6 +/- 1 days; P < or = .05) and greater intravenous fluids on days 3, 4, and 5 of life (132 +/- 25 mL/kg per day vs 104 +/- 18 mL/kg per day; P < or = .01).
  • Although there was no difference in the complication rates between the groups, several problems were evident in the silo group: 15% (4/27) required silo replacement, 44% (12/27) required fascial defect enlargement for silo placement, and 19% (5/27) required mesh at closure.
  • No significant differences in recovery of intestinal function were observed.
  • Three silo patients developed ischemic complications because of vascular insufficiency at the level of the abdominal wall, leading to significant intestinal loss, ventilator and total parenteral nutrition dependence, and increased hospital stay.
  • CONCLUSIONS: Patients managed with a silo had longer ventilator requirements and greater fluid needs.
  • This Specific technical complications leading to bowel ischemia were notable in the silo group.
  • The silo should be carefully placed to avoid bowel twisting and the funnel effect.
  • Larger prospective studies should be performed to provide decision-making criteria for the use of a silo vs primary closure.
  • [MeSH-major] Digestive System Surgical Procedures / methods. Gastroschisis / surgery. Prostheses and Implants / adverse effects
  • [MeSH-minor] Female. Humans. Infant, Newborn. Intestinal Obstruction / etiology. Intestinal Obstruction / prevention & control. Intestines / blood supply. Male. Prosthesis Design. Retrospective Studies. Sepsis / etiology. Sepsis / prevention & control. Short Bowel Syndrome / etiology. Short Bowel Syndrome / prevention & control. Treatment Outcome

  • Genetic Alliance. consumer health - Gastroschisis.
  • Genetics Home Reference. consumer health - abdominal wall defect.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20638519.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Lemesle G, Bonello L, de Labriolle A, Steinberg DH, Roy P, Pinto Slottow TL, Torguson R, Kaneshige K, Xue Z, Suddath WO, Satler LF, Kent KM, Lindsay J, Pichard AD, Waksman R: Prognostic value of the Syntax score in patients undergoing coronary artery bypass grafting for three-vessel coronary artery disease. Catheter Cardiovasc Interv; 2009 Apr 1;73(5):612-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the 1-year follow-up, cardiovascular events including death, myocardial infarction (MI), and stroke were systematically indexed.
  • The primary end point was the composite criteria death/MI/stroke.
  • No statistical difference was found for the composite criteria death/MI/stroke: 9.4% versus 7.5% versus 10.4% in the groups with a Syntax score <24.5, 24.5-34, and >34, respectively (P = 0.754).

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • ResearchGate. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • [CommentIn] Catheter Cardiovasc Interv. 2009 Apr 1;73(5):618-9 [19309708.001]
  • (PMID = 19309700.001).
  • [ISSN] 1522-726X
  • [Journal-full-title] Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  • [ISO-abbreviation] Catheter Cardiovasc Interv
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Hashish MS, Dawoud HH, Hirschl RB, Bruch SW, El Batarny AM, Mychaliska GB, Drongowski RA, Ehrlich PF, Hassaballa SZ, El-Dosuky NI, Teitelbaum DH: Long-term functional outcome and quality of life in patients with high imperforate anus. J Pediatr Surg; 2010 Jan;45(1):224-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term functional outcome and quality of life in patients with high imperforate anus.
  • PURPOSE: Anorectal malformations (ARMs) are associated with a large number of functional sequale that may affect a child's long-term quality of life (QOL).
  • The purposes of this study were to better quantify patient functional stooling outcome and to identify how these outcomes related to the QOL in patients with high imperforate anus.
  • METHODS: Forty-eight patients from 2 children's hospitals underwent scoring of stooling after 4 years of life.
  • Scoring consisted of a 13-item questionnaire to assess long-term stooling habits (score range: 0-30, worst to best).
  • These results were then correlated with a QOL survey as judged by a parent or guardian.
  • RESULT: Mean (SD) age at survey was 6.5 (1.6) years.
  • Comparison of QOL and clinical scoring showed no signficant difference between the 2 institutions (P > .05).
  • There was a direct correlation between the QOL and stooling score (Pearson r(2) = 0.827; beta coefficient = 24.7, P < .001).
  • Interestingly, functional stooling scores worsened with increasing age (Pearson r(2) = 0.318, P = .02).
  • Patients with associated congenital anomalies had a high rate of poor QOL (44% in poor range; P = .001).
  • Stooling scores decreased significantly with increasing severity/complexity of the ARM (P = .001).
  • CONCLUSION: A large number of children experience functional stooling problems, and these were directly associated with poor QOL.
  • In contrast to previous perceptions, our study showed that stooling patterns are perceived to worsen with age.
  • This suggests that children with ARMs need long-term follow-up and counseling.
  • [MeSH-major] Anus, Imperforate / psychology. Anus, Imperforate / surgery. Defecation / physiology. Quality of Life
  • [MeSH-minor] Abnormalities, Multiple / epidemiology. Age Factors. Anal Canal / surgery. Child. Constipation / epidemiology. Constipation / psychology. Constipation / surgery. Cross-Cultural Comparison. Digestive System Surgical Procedures / methods. Egypt / epidemiology. Enema / methods. Humans. Laparoscopy / methods. Longitudinal Studies. Outcome Assessment (Health Care). Patient Satisfaction. Questionnaires. Reoperation. Severity of Illness Index. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Imperforate anus.
  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20105608.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Aittaleb M, Gao G, Evelyn CR, Neubig RR, Tesmer JJ: A conserved hydrophobic surface of the LARG pleckstrin homology domain is critical for RhoA activation in cells. Cell Signal; 2009 Nov;21(11):1569-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The catalytic core of LARG is a Dbl homology (DH) domain whose activity is modulated by an adjacent pleckstrin homology (PH) domain.
  • In this study, we used a transcriptional assay and confocal microscopy to examine the roles of several novel structural features of the LARG DH/PH domains, including a conserved and exposed hydrophobic patch on the PH domain that mediates protein-protein interactions in crystal structures of LARG and its close homolog PDZ-RhoGEF.

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • Faculty of 1000. See the articles recommended by F1000Prime's Faculty of more than 5,000 expert scientists and clinical researchers. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2145-50 [10681437.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):47352-62 [15331592.001]
  • [Cites] FEBS Lett. 2000 Nov 24;485(2-3):183-8 [11094164.001]
  • [Cites] Oncogene. 2001 Mar 26;20(13):1661-8 [11313914.001]
  • [Cites] J Biol Chem. 2001 Jan 26;276(4):2474-9 [11036069.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27145-51 [11373293.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):28897-905 [11384980.001]
  • [Cites] Biochem Soc Trans. 2001 Aug;29(Pt 4):377-84 [11497993.001]
  • [Cites] J Biol Chem. 2001 Nov 23;276(47):44247-57 [11546812.001]
  • [Cites] J Cell Biol. 2001 Nov 26;155(5):809-20 [11724822.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):1174-81 [11698392.001]
  • [Cites] EMBO J. 2002 Mar 15;21(6):1315-26 [11889037.001]
  • [Cites] Neuron. 2002 Jul 3;35(1):51-63 [12123608.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12085-90 [12196628.001]
  • [Cites] Nature. 2002 Dec 12;420(6916):629-35 [12478284.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):733-8 [12515866.001]
  • [Cites] Biochem J. 2003 May 1;371(Pt 3):709-20 [12534370.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2003 Oct;59(Pt 10):1859-62 [14501138.001]
  • [Cites] Circ Res. 2003 Oct 31;93(9):848-56 [14512443.001]
  • [Cites] Cell Signal. 2004 Feb;16(2):201-9 [14636890.001]
  • [Cites] Oncogene. 2004 May 20;23(23):4098-106 [15064738.001]
  • [Cites] Structure. 2004 Nov;12(11):1955-65 [15530360.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Feb;6(2):167-80 [15688002.001]
  • [Cites] Nat Struct Mol Biol. 2005 Feb;12(2):191-7 [15665872.001]
  • [Cites] Biochemistry. 2006 Jan 10;45(1):167-74 [16388592.001]
  • [Cites] Methods Enzymol. 2006;406:425-37 [16472675.001]
  • [Cites] Biochem J. 2006 Dec 15;400(3):563-72 [17007612.001]
  • [Cites] Mol Cancer Ther. 2007 Aug;6(8):2249-60 [17699722.001]
  • [Cites] Mol Pharmacol. 2007 Oct;72(4):993-1002 [17609419.001]
  • [Cites] J Biol Chem. 2007 Nov 9;282(45):33064-75 [17848575.001]
  • [Cites] Science. 2007 Dec 21;318(5858):1923-7 [18096806.001]
  • [Cites] J Cell Biochem. 2008 Aug 1;104(5):1660-70 [18320579.001]
  • [Cites] Mol Cell. 2008 Oct 24;32(2):169-79 [18951085.001]
  • [Cites] J Biol Chem. 2009 Feb 20;284(8):5000-9 [19074425.001]
  • [Cites] J Biomol Screen. 2009 Feb;14(2):161-72 [19196702.001]
  • [Cites] Cell Signal. 2009 Jun;21(6):996-1006 [19249348.001]
  • [Cites] Mol Biol Cell. 2008 Jan;19(1):30-40 [17959834.001]
  • [Cites] EMBO J. 1994 Jun 1;13(11):2600-10 [7516876.001]
  • [Cites] J Biol Chem. 1995 Jul 14;270(28):17000-5 [7622521.001]
  • [Cites] J Biol Chem. 1996 Aug 9;271(32):19017-20 [8702569.001]
  • [Cites] Oncogene. 1997 Dec 4;15(23):2827-31 [9419973.001]
  • [Cites] Science. 1998 Jan 23;279(5350):560-3 [9438849.001]
  • [Cites] Science. 1998 Jun 26;280(5372):2109-11 [9641915.001]
  • [Cites] Science. 1998 Jun 26;280(5372):2112-4 [9641916.001]
  • [Cites] Cell. 1998 Oct 16;95(2):259-68 [9790532.001]
  • [Cites] Cell. 1998 Oct 16;95(2):269-77 [9790533.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12973-6 [9789025.001]
  • [Cites] J Biol Chem. 1998 Dec 25;273(52):34954-60 [9857026.001]
  • [Cites] J Biol Chem. 1999 Jan 22;274(4):2279-85 [9890991.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5868-79 [10026210.001]
  • [Cites] J Biol Chem. 1999 Sep 17;274(38):26815-21 [10480888.001]
  • [Cites] FEBS Lett. 1999 Oct 15;459(3):313-8 [10526156.001]
  • [Cites] J Biol Chem. 2000 May 19;275(20):14992-9 [10747909.001]
  • (PMID = 19560536.001).
  • [ISSN] 1873-3913
  • [Journal-full-title] Cellular signalling
  • [ISO-abbreviation] Cell. Signal.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / 5R01GM039561; United States / NHLBI NIH HHS / HL / HL071818; United States / NHLBI NIH HHS / HL / HL086865; United States / NIGMS NIH HHS / GM / R01 GM039561; United States / NIGMS NIH HHS / GM / R01 GM039561-19; United States / NIGMS NIH HHS / GM / R01 GM039561-20; United States / NHLBI NIH HHS / HL / R01 HL071818; United States / NHLBI NIH HHS / HL / R01 HL071818-01A1; United States / NHLBI NIH HHS / HL / R01 HL071818-06; United States / NHLBI NIH HHS / HL / R01 HL086865; United States / NHLBI NIH HHS / HL / R01 HL086865-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARHGEF12 protein, human; 0 / Guanine Nucleotide Exchange Factors; 0 / Rho Guanine Nucleotide Exchange Factors; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, G12-G13; EC 3.6.5.2 / rhoA GTP-Binding Protein
  • [Other-IDs] NLM/ NIHMS128265; NLM/ PMC2735620
  •  go-up   go-down


53. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med; 2008 Apr 10;358(15):1547-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telmisartan, ramipril, or both in patients at high risk for vascular events.
  • BACKGROUND: In patients who have vascular disease or high-risk diabetes without heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and morbidity from cardiovascular causes, but the role of angiotensin-receptor blockers (ARBs) in such patients is unknown.
  • We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes.
  • METHODS: After a 3-week, single-blind run-in period, patients underwent double-blind randomization, with 8576 assigned to receive 10 mg of ramipril per day, 8542 assigned to receive 80 mg of telmisartan per day, and 8502 assigned to receive both drugs (combination therapy).
  • The primary composite outcome was death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure.
  • RESULTS: Mean blood pressure was lower in both the telmisartan group (a 0.9/0.6 mm Hg greater reduction) and the combination-therapy group (a 2.4/1.4 mm Hg greater reduction) than in the ramipril group.
  • At a median follow-up of 56 months, the primary outcome had occurred in 1412 patients in the ramipril group (16.5%), as compared with 1423 patients in the telmisartan group (16.7%; relative risk, 1.01; 95% confidence interval [CI], 0.94 to 1.09).
  • As compared with the ramipril group, the telmisartan group had lower rates of cough (1.1% vs. 4.2%, P<0.001) and angioedema (0.1% vs. 0.3%, P=0.01) and a higher rate of hypotensive symptoms (2.6% vs. 1.7%, P<0.001); the rate of syncope was the same in the two groups (0.2%).
  • In the combination-therapy group, the primary outcome occurred in 1386 patients (16.3%; relative risk, 0.99; 95% CI, 0.92 to 1.07); as compared with the ramipril group, there was an increased risk of hypotensive symptoms (4.8% vs. 1.7%, P<0.001), syncope (0.3% vs. 0.2%, P=0.03), and renal dysfunction (13.5% vs. 10.2%, P<0.001).
  • CONCLUSIONS: Telmisartan was equivalent to ramipril in patients with vascular disease or high-risk diabetes and was associated with less angioedema.
  • The combination of the two drugs was associated with more adverse events without an increase in benefit. (ClinicalTrials.gov number, NCT00153101 [ClinicalTrials.gov].).
  • [MeSH-major] Angiotensin II Type 1 Receptor Blockers / therapeutic use. Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Benzimidazoles / therapeutic use. Benzoates / therapeutic use. Cardiovascular Diseases / drug therapy. Diabetes Mellitus / drug therapy. Ramipril / therapeutic use
  • [MeSH-minor] Aged. Angioedema / chemically induced. Blood Pressure / drug effects. Creatinine / blood. Double-Blind Method. Drug Therapy, Combination. Female. Follow-Up Studies. Hospitalization. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Risk

  • MedlinePlus Health Information. consumer health - Diabetes.
  • HSDB. structure - TELMISARTAN.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Foro APS(Comentarios en Espanol). commentaries/discussion - Foro APS(Comentarios en Espanol) (registration required).
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827853577 for PMID:18378520 [PharmGKB] .
  • Faculty of 1000. See the articles recommended by F1000Prime's Faculty of more than 5,000 expert scientists and clinical researchers. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Massachusetts Medical Society.
  • [CommentIn] N Engl J Med. 2008 Apr 10;358(15):1615-6 [18378521.001]
  • [CommentIn] Am J Kidney Dis. 2009 Feb;53(2):192-6 [19166798.001]
  • [CommentIn] N Engl J Med. 2008 Jul 24;359(4):426 [18650521.001]
  • [CommentIn] Curr Hypertens Rep. 2008 Oct;10(5):345-8 [18775109.001]
  • [CommentIn] Curr Hypertens Rep. 2008 Oct;10(5):343-4 [18775108.001]
  • [CommentIn] Curr Hypertens Rep. 2008 Oct;10(5):385-6 [18775115.001]
  • [CommentIn] Kardiol Pol. 2008 Jun;66(6):705-6; discussion 707 [18700309.001]
  • [CommentIn] J Clin Hypertens (Greenwich). 2008 Jul;10(7):582-4 [18607144.001]
  • [CommentIn] J Fam Pract. 2009 Jan;58(1):24-7 [19141267.001]
  • [CommentIn] Prev Cardiol. 2008 Summer;11(3):179-82 [18612263.001]
  • [CommentIn] Curr Hypertens Rep. 2008 Aug;10(4):303-4 [18625160.001]
  • [CommentIn] Postgrad Med. 2009 Mar;121(2):202-4 [19332981.001]
  • [CommentIn] Curr Diab Rep. 2009 Jun;9(3):185-7 [19490818.001]
  • [CommentIn] Curr Hypertens Rep. 2009 Apr;11(2):85-7 [19278596.001]
  • [CommentIn] Evid Based Med. 2008 Oct;13(5):147 [18836115.001]
  • (PMID = 18378520.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00153101
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Benzimidazoles; 0 / Benzoates; AYI8EX34EU / Creatinine; L35JN3I7SJ / Ramipril; U5SYW473RQ / telmisartan
  • [Investigator] Yusuf S; Sleight P; Anderson C; Teo K; Copland I; Ramos B; Richardson L; Murphy J; Haehl M; Hilbrich L; Svaerd R; Martin K; Murwin D; Meinicke T; Schlosser A; Schmidt G; Creek R; Schumacher H; Distel M; Aubert B; Pogue J; Dyal L; Schmieder R; Unger T; Asmar R; Mancia G; Diaz R; Paolasso E; Piegas L; Avezum A; Dagenais G; Cardona Munoz E; Probstfield J; Weber M; Young J; Fagard R; Jansky P; Mallion J; Mann J; Böhm M; Eber B; Karatzas NB; Keltai M; Trimarco B; Verdecchia P; Maggioni A; Verheugt FW; Holwerda NJ; Ceremuzynski L; Budaj A; Ferreira R; Chazova I; Rydén L; Svendsen TL; Metsärinne K; Dickstein K; Fodor G; Commerford P; Redon J; Luescher TR; Oto A; Binbrek A; Parkhomenko A; Jennings G; Liu LS; Yu CM; Dans AL; Shah R; Kim JH; Chen JH; Chaithiraphan S; Cairns J; Wilhelmsen L; Chalmers J; Wittes J; Gent M; Hennekens CH; Dagenais G; Anderson N; Avezum A; Budaj A; Fodor G; Keltai M; Maggioni A; Mann J; Parkhomenko A; Yusoff K; Auger P; Bernstein V; Lonn E; Panju A; Anand I; Bigger JT; Linz P; Healey J; Held C; McGorrian C; Rokoss M; Villar J; Sleight P; Anderson C; Creek R; Dans A; Diaz R; Fagard R; Probstfield J; Svaerd R; Teo K; Unger T; Yusuf S; Teo K; Copland I; Ramos B; McDonald A; Pogue J; Dyal L; Afzal R; Zhao F; Yusuf S; Sleight P; Richardson L; Anderson C; Murphy J; Diaz R; Paolasso E; Ahuad Guerrero RA; Amuchastegui M; Baglivo HP; Bendersky M; Bono J; Bustos B; Caccavo A; Cartasegna LR; Castellanos CR; Cipullo MA; Crunger P; Cuneo CA; Focaccia M; Fuselli JJ; Hasbani E; Hominal MA; Humphreys J; Inserra F; Killinger CR; Kuschnir E; Majul CR; Manuale OD; Martinez G; Marzetti EM; Nordaby R; Orlandini AD; Pomposiello JC; Rodríguez GM; Salas J; Salomone OA; Sanchez RA; Serra C; Vico ML; Jennings GL; Amerena JV; Arnolda LF; Aroney GM; Aylward PE; Bladin CF; Bridgeman JC; Chambers BR; Corbett AJ; Crimmins DS; Cross DB; Davies L; Davis SM; Donnan GA; Eccleston DS; Frayne JH; Hendriks R; Herkes GK; Hill AT; Jeffery IM; Karrasch JA; Koshy G; Marwick TH; Owensby DA; Parsons MW; Rees DM; Russell A; Schwartz R; Singh B; Thompson PL; Waites JH; Walsh WF; Walters DL; Watts RW; Whelan AP; Böhm M; Eber BE; Bonelli JB; Dolliner P; Hohenecker JH; Steurer GS; Weihs WW; Fagard R; Bekaert I; Brohet C; Chaumont P; Cheron P; Crasset V; Degaute JP; Dendale P; Dujardin K; Elshot S; Hellemans S; Herssens M; Heyndrickx G; Laloux P; Lesseliers H; Noyens P; Quinonez M; Stammen F; Striekwold H; Thoeng J; Van Mieghem W; Vanhooren G; Vervoort G; Vrolix M; Wollaert B; Piegas L; Avezum A; Abrantes JA; Armaganijan D; Ayoub JC; Bodanese LC; Carvalho AC; Coutinho M; Esteves JP; Franco RJ; Jardim PC; Saraiva JF; Leães PE; Maia LN; Marin-Neto JA; Mion D Jr; Moreira JR Jr; Oigman W; Pedrosa RC; Pelloso EA; Plavnik FL; Polanczyk CA; Rabelo A Jr; Rassi S; Reis G; Ribeiro AB; Ribeiro JM; Rocha JC; Rossi PR; Santos RD; Tarastchuk JC; Villalón MN; Teo K; Dagenais G; Abramson B; Arnold M; Ashton T; Auger P; Bata I; Bayly K; Beauchef J; Bélanger A; Bernstein V; Bhargava R; Booth AW; Bose S; Boulianne M; Cameron M; Chan YK; Constance C; Costi P; Dion D; Douketis J; Fell D; Giannoccaro JP; Glanz A; Gosselin G; Gould D; Goulet S; Grondin F; Gupta M; Gyenes G; Heath JW; Heath VA; Hess A; Hiscock JG; Hoag G; Honos G; Imrie J; Kuritzky R; Lai C; Lalani A; Lamy A; LeBouthillier P; Lochnan H; Lonn E; Lubelsky B; Mackey A; Meunier M; Milot A; Mitchell LB; Nawaz S; Omichinski M; Panju A; Pilon C; Pilon D; Polasek P; Proulx G; Rebane T; Ricci AJ; Rupka DW; Sabbah E; Savard D; Sharma NK; Shu D; St Hilaire R; St Maurice F; Starra R; Sussex B; Szaky T; Talbot P; Tan KW; To TB; Tobe S; Tytus R; Vexler R; Whitsitt P; Woo V; Liu L; Bai X; Chen X; Feng J; Fu S; Ge Y; Gong L; He Z; Huang J; Jiang Y; Li L; Li QH; Liao Y; Lu Z; Lu F; Ma S; Niu F; Pan C; Qian F; Shi X; Sun N; Sun M; Sun G; Wang J; Wang S; Wang Y; Wu Z; Yan X; Yang X; Yang H; Ye X; Yuan S; Zhang T; Zhang C; Zhang F; Zhang S; Zhao D; Zheng B; Zhou HY; Zhou S; Zhu J; Janský P; Dedek V; Dvorák J; Holaj R; Kotous J; Pederzoliová E; Polák M; Povolný J; Smetana K; Spác J; Svendsen TL; Götzsche L; Juhl HF; Koelendorf K; Lund P; Pedersen F; Perdersen OL; Pindborg T; Rasmussen LH; Rasmussen SL; Thygesen K; Tuxen C; Metsärinne K; Antikainen R; Jääskivi M; Kantola I; Kastarinen M; Kohonen-Jalonen P; Koistinen A; Lehmus E; Nuuttila R; Tuominen ML; Ylihärsilä H; Mallion J; Abenhaim N; Allix J; Boucher L; Bourgoin M; Boye A; Breton N; Cadinot D; Campagne A; Churet J; Constantin C; De Sainte Lorette E; El Sawy A; Etchegarray G; Farhat S; Lacoin F; Latte T; Magnani C; Pineau-Valenciennes D; Pithon M; Quéguiner A; Sicard J; Sorbe G; Taminau D; Vilarem H; Vogel JY; HEbert HH; Genth-Zotz S; Hermanns N; Holzer C; Minnich J; Schimkus D; Boehm M; Mann J; Brado B; Claus G; Dietz U; Griebenow R; Haak T; Hahn K; Hampel R; Heitzer H; Holle G; Horacek T; Jordan J; Klein C; Kolloch R; Ludewig S; Motz W; Muenzel T; Nast HP; Nauck M; Nebelsieck H; Rybak K; Samer H; Schaefer T; Scholze J; Schulze B; Schleppinghoff; Schmieder R; Schwaab B; Sechtem U; Sehnert W; Steinhagen-Thiessen E; Stenzel G; Trenkwalder P; Wedler B; Zippel J; Karatzas N; Achimastos A; Diamantopoulos E; Efstratopoulos A; Elisaf M; Karvounis H; Mentzikof D; Mytas D; Papadogiannis D; Pyrgakis V; Stefanadis C; Symeonidis D; Tsoukas A; Vogiatzis I; Voyaki S; Zamboulis C; Yu CM; Chan CK; Lam L; Lau YK; Sanderson J; Wong J; Wu EB; Yue CS; Keltai M; Czuriga I; Edes I; Farsang CS; Kalina A; Karlócai K; Keltai K; Kozma M; László Z; Nagy V; Nagy A; Polák GY; Préda I; Rónaszéki A; Sereg M; Simon K; Sonkodi S; Szegedi J; Timár S; Tóth K; Vándorfi GY; Vértes A; Feely J; Maher VM; Stanton AV; Sullivan P; Trimarco B; Verdecchia P; Maggioni A; Rosei EA; Ambrosio GB; Bentivoglio M; Branzi A; Perin PC; Chiariello M; Cirrincione V; Ferrari R; Gattobigio R; Giovannini E; Giugliano D; Lacchè A; Lauro R; Lembo G; Marchetti G; Moretti L; Pancaldi L; Partemi L; Pede S; Pettinati G; Reboldi G; Ricci R; Rosiello G; Rozza F; Sardone MG; Scabbia EV; Selvetella G; Tavazzi L; Terrosu P; Venco A; Vetrano A; Volpe M; Zilio G; Ismail T; Shah RP; Singaraveloo M; Ahmad WA; Yusof Z; Yusoff K; Abidin IZ; Zambahari R; Cardona Munoz E; Alcocer Diaz L; Pascoe-Gonzalez S; Arriaga Nava R; De la Peña Topete G; Elizondo Sifuentes LA; Hernández García HR; Illescas-Diaz J; Macías Islas MA; Noriega Arellano JA; Olvera Ruiz R; Parra Carrillo JZ; Velasco Sánchez G; Vidrio Velásquez M; Verheugt FW; Holwerda NJ; Basart DC; Boermans AJ; Bosker HA; Bouter KP; Buiks CP; de Backer WA; de Graaf JJ; Deppenbroek JH; Eefting FD; Gunneweg FC; Michels HR; Poldermans D; Schrijver G; Sedney MI; Slagboom T; Smilde JG; Storms GE; Tjon RM; van Bergen PF; van Doesburg GJ; van Kempen LH; van Mierlo HF; Veerman A; Vermetten FA; Wester A; Bagg W; Benatar J; Coxon R; Doughty RN; Friedlander DH; Luke RA; Nairn PL; Ratnasabapathy Y; Richards AM; Singh GP; Stewart RA; Troughton RW; White HD; Williams M; Wong SP; Dickstein K; Bogale N; Lier JO; Otterstad JE; Rønnevik PK; Skeie S; Walle PO; Dans AL; Abola MT; Añonuevo JC; Jaro JM; Marañon DR; Mendoza VL; Morales DR; Pacheco EP; Reyes EB; Roxas AA; Sedurante MB; Ceremuzynski L; Budaj A; Binio Z; Bronisz M; Buszman P; Czerski T; Dalkowski M; Gessek J; Gieroba A; Janik K; Janion M; Kawka-Urbanek T; Klabisz R; Krauze-Wielicka M; Malinowski S; Miekus P; Mormul J; Ogorek M; Opolski G; Skura M; Szpajer M; Tendera M; Waszyrowski T; Wierzchowiecki M; Zalska B; Ferreira R; Capucho R; Correia C; Cunha L; Ferro JM; Gama Ribeiro V; Gil V; Marques da Silva P; Oliveira Carrageta M; Sebra Gomes R; Veloso Gomes M; Chazova I; Ageev F; Belenkov Y; Ivleva A; Karpov Y; Shestakova M; Shlyakhto E; Shustov A; Sidorenko B; Chang HM; Kwok B; Fodor G; Dukát A; Gonsorcík J; Hranai M; Lietava J; Pella D; Rybar R; Ruffini L; Commerford P; Bonnici F; Brown B; Dalby AJ; Gibson GJ; Herbst L; King J; Klug E; Middle M; Naidoo DP; Pretorius M; Podgorski G; Ranjith N; Silwa-Hahnle K; Theron H; Kim JH; Chae SC; Chung NS; Hong KP; Jeong MH; Kang HJ; Kim JJ; Kim MH; Seo HS; Shin EK; Redón J; Abellán J; Aranda P; Barrios V; Calvo C; De La Figuera M; De Teresa E; Durá R; Escobar F; Fernandez-Cruz F; Galve E; Garcia-Puig J; Gil-Extremera B; Gomis R; Gonzalez-Albarran O; González-Juanatey JR; Llacer A; López-Bescós L; Oliván J; Picó A; Pose A; Roca-Cusachs A; Ruilope LM; Rydén L; Alvång A; Boström PA; Dellborg M; Ericsson UB; Herlitz J; Juhlin T; Pedersen K; Sträng B; Sundqvist B; Tengmark BO; Ulvenstam G; Westerdahl B; Winberg L; Luescher TR; Baumgartner I; Dubach P; Gallino A; Moccetti T; Noll G; Nordmann A; Rickli H; Schläpfer H; Weber K; Chen JH; Chao TH; Chen CY; Cheng JJ; Chiou HC; Fu CC; Fu M; Lai WT; Li YH; Lien LM; Tsai CD; Wang JH; Yeh PS; Chaithiraphan S; Chantadansuwan T; Jirasirirojanakorn K; Krittayaphong R; Laothavorn P; Mahanonda N; Sitthisook S; Tanomsup S; Tansuphaswadikul S; Tatsanavivat P; Yamwong S; Oto A; Akin M; Caglar NT; Ergin A; Müderrisoglu H; Oguz A; Ongen Z; Sansoy V; Tetiker T; Uysal A; Parkhomenko A; Amosova E; Cherkasova O; Dykun Y; Dzyak G; Galystska A; Grishyna O; Jaremenko O; Kononenko L; Koval E; Kovalenko V; Netyazhenko V; Pertseva T; Prokhorov A; Radchenko G; Rudyk YU; Sirenko Y; Skarzhevsky A; Binbrek AS; Al Hajiri AA; Al Hatou E; Al-Sousi AA; Alomairi M; Wajib IM; Sleight P; Adgey AA; Andrews R; Ball SG; Barer DH; Barnett AH; Bridges AB; Bryson V; Cowie AS; De Belder AJ; Donnelly R; Francis CM; Furnace J; Glen SK; Gough N; Heagerty AM; Jackson PR; Jackson SH; Joyce E; McEneaney DJ; Moriarty AJ; Murdoch DL; O'Hare JP; Penny WJ; Reid CJ; Tilley J; Vora JP; Webster J; Williams B; Probstfield J; Weber M; Young J; Ahmed I; Anand IS; Anderson JL; Aponte Pagán JS; Barzilay J; Basile JN; Bass PF 3rd; Blumenthal SS; Bommer WJ; Brautigam DF; Brown CD; Brown N; Byrum JD; Carr AA; Chinn J; Chiu D; Cho NR; Ciocon JO; Colón-Ortíz PJ; Cruz JB; Dachman WD; Dolson GM; Dorfman SG; Drummond W; East C; Eelani F; Ellison HS; Felicetta JV; Fishbach MH; Force RW; Giddings SJ; Goldberg MC; Goldman S; Gomez Adrover R; Goss SL; Graham SP; Granger CB; Greenspan MM; Grimm RH; Habib GB; Hagen MR; Hart PD; Hartney TJ; Henriquez MA; Holland JJ; Hoogwerf BJ; Hossfeld M; Jacobson AK; Jelley MJ; Jones TV; Kaplan RA; Karalis DG; Katz LA; Kereiakes DJ; Khan M; Kipperman RM; Kozinn MJ; Kozlowski JG; Lader EW; Landau C; Landzberg JS; Laughrun D; Lewis SJ; Liang CS; Limacher MC; Linz PE; Lo TS; Lopez-Arostegui F; Maddox RR; Mahrer PR; Maurer MS; McGuire DK; Mercando AD; Mersey JH; Meyer M; Mooss AN; Narayan P; Oparil S; Padhiar DN; Phillips AL; Prisant M; Qureshi N; Raghuwanshi MP; Randall RR; Retta TM; Ringrose RE; Rizvi AA; Rizvi MD; Saklayen MG; Sastrasinh S; Savani IK; Schlau A; Schultz HS; Schweiger MJ; Smith RD; Sosa-Padilla M; Streja D; Stuver TP; Subich DC; Sulak FC; Swagler WA 3rd; Taitano M; Tavarez-Valle JA; Taylor EM; White WB; Wickemeyer WJ; Wiegmann TB; Zee PA; Zhao XQ
  •  go-up   go-down


54. Wylie BJ, Hashmi AH, Singh N, Singh MP, Tuchman J, Hussain M, Sabin L, Yeboah-Antwi K, Banerjee C, Brooks MI, Desai M, Udhayakumar V, Macleod WB, Dash AP, Hamer DH: Availability and utilization of malaria prevention strategies in pregnancy in eastern India. BMC Public Health; 2010;10:557
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Availability and utilization of malaria prevention strategies in pregnancy in eastern India.
  • BACKGROUND: Malaria in pregnancy in India, as elsewhere, is responsible for maternal anemia and adverse pregnancy outcomes such as low birth weight and preterm birth.It is not known whether prevention and treatment strategies for malaria in pregnancy (case management, insecticide-treated bednets, intermittent preventive therapy) are widely utilized in India.
  • METHODS: This cross-sectional study was conducted during 2006-2008 in two states of India, Jharkhand and Chhattisgarh, at 7 facilities representing a range of rural and urban populations and areas of more versus less stable malaria transmission.
  • 280 antenatal visits (40/site) were observed by study personnel coupled with exit interviews of pregnant women to assess emphasis upon, availability and utilization of malaria prevention practices by health workers and pregnant women.
  • The facilities were assessed for the availability of antimalarials, lab supplies and bednets.
  • RESULTS: All participating facilities were equipped to perform malaria blood smears; none used rapid diagnostic tests.
  • Chloroquine, endorsed for chemoprophylaxis during pregnancy by the government at the time of the study, was stocked regularly at all facilities although the quantity stocked varied.
  • Availability of alternative antimalarials for use in pregnancy was less consistent.
  • In Jharkhand, no health worker recommended bednet use during the antenatal visit yet over 90% of pregnant women had bednets in their household.
  • In Chhattisgarh, bednets were available at all facilities but only 14.4% of health workers recommended their use.
  • 40% of the pregnant women interviewed had bednets in their household.
  • Only 1.4% of all households owned an insecticide-treated bednet; yet 40% of all women reported their households had been sprayed with insecticide.
  • Antimalarial chemoprophylaxis with chloroquine was prescribed in only 2 (0.7%) and intermittent preventive therapy prescribed in only one (0.4%) of the 280 observed visits.
  • CONCLUSIONS: A disconnect remains between routine antenatal practices in India and known strategies to prevent and treat malaria in pregnancy.
  • Prevention strategies, in particular the use of insecticide-treated bednets, are underutilized.
  • Gaps highlighted by this study combined with recent estimates of the prevalence of malaria during pregnancy in these areas should be used to revise governmental policy and target increased educational efforts among health care workers and pregnant women.
  • [MeSH-major] Health Services Accessibility. Malaria / prevention & control. Preventive Health Services / utilization
  • [MeSH-minor] Adolescent. Adult. Case Management. Cross-Sectional Studies. Female. Humans. India. Pregnancy. Young Adult

  • Genetic Alliance. consumer health - Malaria.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Malaria.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trans R Soc Trop Med Hyg. 1988;82(3):376-9 [3068848.001]
  • [Cites] Bull World Health Organ. 2003;81(5):316-23 [12856049.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1990 Jul-Aug;84(4):496-8 [2091336.001]
  • [Cites] Indian J Malariol. 1995 Mar;32(1):6-13 [8549840.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1996 Sep-Oct;90(5):535-9 [8944266.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1997 May-Jun;91(3):256-62 [9231189.001]
  • [Cites] J Commun Dis. 1997 Sep;29(3):201-8 [9465524.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1998 Mar;29(1):10-7 [9740260.001]
  • [Cites] Bull World Health Organ. 1999;77(7):567-72 [10444880.001]
  • [Cites] Am J Trop Med Hyg. 2005 Nov;73(5):855-8 [16282293.001]
  • [Cites] Lancet Infect Dis. 2007 Feb;7(2):93-104 [17251080.001]
  • [Cites] Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):69-78 [18165477.001]
  • [Cites] J Biosci. 2008 Nov;33(4):583-92 [19208983.001]
  • [Cites] Malar J. 2009;8:210 [19728882.001]
  • [Cites] Ann Trop Med Parasitol. 2001 Jan;95(1):19-29 [11235550.001]
  • [Cites] Am J Trop Med Hyg. 2001 Jan-Feb;64(1-2 Suppl):28-35 [11425175.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1374-82 [12766831.001]
  • [Cites] Trop Med Int Health. 2003 Jun;8(6):488-506 [12791054.001]
  • [Cites] Ann Trop Med Parasitol. 1990 Feb;84(1):1-9 [2184784.001]
  • (PMID = 20849590.001).
  • [ISSN] 1471-2458
  • [Journal-full-title] BMC public health
  • [ISO-abbreviation] BMC Public Health
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R03 HD52167-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2949771
  •  go-up   go-down


55. Jackson KJ, McIntosh JM, Brunzell DH, Sanjakdar SS, Damaj MI: The role of alpha6-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal. J Pharmacol Exp Ther; 2009 Nov;331(2):547-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of alpha6-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal.
  • The alpha6 nicotinic acetylcholine receptor (nAChR) subunit is involved in nicotine-stimulated dopamine release in the striatum.
  • It is expressed in brain regions and coexpressed with nAChR subtypes implicated in nicotine dependence behaviors; hence, this subunit may play a role in nicotine dependence.
  • Using the alpha6-selective antagonist alpha-conotoxin H9A;L15A (MII[H9A;L15A]), we determined the role of alpha6* nAChRs in the pharmacological and behavioral effects of nicotine.
  • We measured effects of pretreatment with MII[H9A;L15A] on analgesia, locomotion, and body temperature after a single injection of nicotine.
  • Effects of MII[H9A;L15A] on nicotine reward were measured using the conditioned place preference (CPP) paradigm.
  • We further measured physical (somatic signs and hyperalgesia) and affective [anxiety-related behavior and conditioned place aversion (CPA)] nicotine withdrawal behaviors after extended nicotine exposure.
  • Results showed that MII[H9A;L15A] did not block acute nicotine effects on the behaviors measured.
  • Conversely, MII[H9A:l15A] blocked the expression of nicotine CPP, as well as withdrawal-associated CPA and anxiety-related behavior in the elevated plus maze, but not withdrawal-induced somatic signs or hyperalgesia.
  • These results suggest a role for the alpha6 nAChR subunit in nicotine reward and affective nicotine withdrawal but not acute nicotine-induced or physical withdrawal behaviors.
  • [MeSH-major] Nicotine / pharmacology. Nicotinic Agonists / pharmacology. Receptors, Nicotinic / drug effects. Reward. Substance Withdrawal Syndrome / physiopathology
  • [MeSH-minor] Animals. Anxiety / psychology. Avoidance Learning / drug effects. Body Temperature / drug effects. Calcium Channel Blockers / pharmacology. Conditioning, Operant / drug effects. Conotoxins / pharmacology. Dose-Response Relationship, Drug. Injections, Intraventricular. Male. Mice. Mice, Inbred C57BL. Motor Activity / drug effects. Nicotinic Antagonists / pharmacology. Pain Measurement / drug effects. Reaction Time / drug effects

  • HSDB. structure - NICOTINE.
  • HSDB. structure - NICOTINE TARTRATE.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharmacol. 2005 May;67(5):1639-47 [15681595.001]
  • [Cites] Science. 2004 Nov 5;306(5698):1029-32 [15528443.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Dec;82(4):758-65 [16413603.001]
  • [Cites] Psychopharmacology (Berl). 2006 Mar;184(3-4):339-44 [16416156.001]
  • [Cites] Psychopharmacology (Berl). 2006 Aug;187(2):189-99 [16752141.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Jul;322(1):399-407 [17446302.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Apr;325(1):302-12 [18184829.001]
  • [Cites] Neuron. 2008 Oct 9;60(1):123-36 [18940593.001]
  • [Cites] J Neurosci. 2008 Nov 19;28(47):12318-27 [19020025.001]
  • [Cites] Neuroreport. 1999 Aug 20;10(12):2497-501 [10574359.001]
  • [Cites] J Neurosci. 2001 Mar 1;21(5):1452-63 [11222635.001]
  • [Cites] Psychopharmacology (Berl). 2001 Aug;157(1):105-10 [11512050.001]
  • [Cites] J Neurosci. 2002 Feb 15;22(4):1208-17 [11850448.001]
  • [Cites] J Neurosci. 2002 Oct 15;22(20):8785-9 [12388584.001]
  • [Cites] Mol Psychiatry. 2003 Jan;8(1):50-9, 9 [12556908.001]
  • [Cites] J Neurosci. 2003 Aug 27;23(21):7820-9 [12944511.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Nov;307(2):526-34 [12970387.001]
  • [Cites] Nicotine Tob Res. 2004 Feb;6(1):145-58 [14982698.001]
  • [Cites] Mol Pharmacol. 2004 Apr;65(4):944-52 [15044624.001]
  • [Cites] Mol Pharmacol. 2004 Jun;65(6):1526-35 [15155845.001]
  • [Cites] Neuroreport. 2004 Jun 28;15(9):1479-81 [15194878.001]
  • [Cites] Eur J Pharmacol. 2004 Jun 28;494(2-3):167-77 [15212971.001]
  • [Cites] Neuropharmacology. 2004 Sep;47(4):572-9 [15380374.001]
  • [Cites] Acta Physiol Scand. 1986 Nov;128(3):351-8 [3788613.001]
  • [Cites] Brain Res. 1990 Aug 27;526(1):45-53 [2078817.001]
  • [Cites] Psychopharmacology (Berl). 1992;107(2-3):285-9 [1615127.001]
  • [Cites] Br J Pharmacol. 1992 Apr;105(4):849-56 [1504716.001]
  • [Cites] Brain Res. 1994 Aug 8;653(1-2):278-84 [7982062.001]
  • [Cites] Neuroendocrinology. 1995 Apr;61(4):383-92 [7783852.001]
  • [Cites] Neuron. 1996 May;16(5):905-8 [8630247.001]
  • [Cites] Nature. 1996 Jul 18;382(6588):255-7 [8717040.001]
  • [Cites] Eur J Neurosci. 1996 Nov;8(11):2428-39 [8950106.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):173-7 [9428762.001]
  • [Cites] Brain Res. 1998 Jan 1;779(1-2):214-25 [9473676.001]
  • [Cites] Nature. 1999 Apr 29;398(6730):805-10 [10235262.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12126-31 [10518587.001]
  • [Cites] Neuroreport. 2005 Oct 17;16(15):1683-6 [16189477.001]
  • (PMID = 19644040.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA023114; United States / NIDA NIH HHS / DA / DA05274; United States / NIDA NIH HHS / DA / DA12610; United States / NIGMS NIH HHS / GM / GM48677; United States / NIMH NIH HHS / MH / MH53631; United States / NIDA NIH HHS / DA / R03 DA023114
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Conotoxins; 0 / Nicotinic Agonists; 0 / Nicotinic Antagonists; 0 / Receptors, Nicotinic; 0 / nicotinic receptor alpha6; 54-11-5 / Nicotine
  • [Other-IDs] NLM/ PMC2775251
  •  go-up   go-down


56. Ciche TA, Kim KS, Kaufmann-Daszczuk B, Nguyen KC, Hall DH: Cell Invasion and Matricide during Photorhabdus luminescens Transmission by Heterorhabditis bacteriophora Nematodes. Appl Environ Microbiol; 2008 Apr;74(8):2275-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell Invasion and Matricide during Photorhabdus luminescens Transmission by Heterorhabditis bacteriophora Nematodes.
  • Many animals and plants have symbiotic relationships with beneficial bacteria.
  • Experimentally tractable models are necessary to understand the processes involved in the selective transmission of symbiotic bacteria.
  • One such model is the transmission of the insect-pathogenic bacterial symbionts Photorhabdus spp. by Heterorhabditis bacteriophora infective juvenile (IJ)-stage nematodes.
  • By observing egg-laying behavior and IJ development, it was determined that IJs develop exclusively via intrauterine hatching and matricide (i.e., endotokia matricida).
  • By transiently exposing nematodes to fluorescently labeled symbionts, it was determined that symbionts infect the maternal intestine as a biofilm and then invade and breach the rectal gland epithelium, becoming available to the IJ offspring developing in the pseudocoelom.
  • Cell- and stage-specific infection occurs again in the pre-IJ pharyngeal intestinal valve cells, which helps symbionts to persist as IJs develop and move to a new host.
  • Synchronous with nematode development are changes in symbiont and host behavior (e.g., adherence versus invasion).
  • Thus, Photorhabdus symbionts are maternally transmitted by an elaborate infectious process involving multiple selective steps in order to achieve symbiont-specific transmission.
  • [MeSH-major] Photorhabdus / growth & development. Rhabditoidea / microbiology
  • [MeSH-minor] Animals. Biofilms / growth & development. Genes, Reporter. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Intestinal Mucosa / microbiology. Intestines / microbiology. Microscopy, Electron, Transmission. Pharynx / microbiology. Symbiosis

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invertebr Pathol. 2000 Jan;75(1):55-8 [10631058.001]
  • [Cites] BMC Genomics. 2008;9:40 [18221513.001]
  • [Cites] Appl Environ Microbiol. 2003 Apr;69(4):1890-7 [12676661.001]
  • [Cites] Science. 2004 Feb 27;303(5662):1305-7 [14988540.001]
  • [Cites] Environ Microbiol. 2004 Jul;6(7):726-32 [15186351.001]
  • [Cites] Microbiol Mol Biol Rev. 2004 Jun;68(2):280-300 [15187185.001]
  • [Cites] Nature. 2004 Jul 8;430(6996):250-6 [15241423.001]
  • [Cites] Nat Rev Microbiol. 2004 Aug;2(8):632-42 [15263898.001]
  • [Cites] Genetics. 1980 Oct;96(2):435-54 [7262539.001]
  • [Cites] J Comp Neurol. 1983 Oct 1;219(4):461-81 [6643716.001]
  • [Cites] Appl Environ Microbiol. 1988 Jun;54(6):1602-5 [3415225.001]
  • [Cites] Gene. 1991 Dec 20;109(1):167-8 [1661697.001]
  • [Cites] Methods Cell Biol. 1995;48:395-436 [8531736.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2873-8 [8610134.001]
  • [Cites] J Bacteriol. 1951 Sep;62(3):293-300 [14888646.001]
  • [Cites] Science. 2004 Nov 12;306(5699):1186-8 [15539604.001]
  • [Cites] Trends Microbiol. 2005 Mar;13(3):119-27 [15737730.001]
  • [Cites] Cell Microbiol. 2005 Jun;7(6):741-51 [15888078.001]
  • [Cites] Appl Environ Microbiol. 2005 Nov;71(11):6934-46 [16269728.001]
  • [Cites] Emerg Infect Dis. 2006 Oct;12(10):1562-4 [17176572.001]
  • [Cites] Curr Opin Microbiol. 2007 Feb;10(1):17-23 [17208514.001]
  • [Cites] Annu Rev Immunol. 2007;25:697-743 [17201680.001]
  • [Cites] Curr Biol. 2007 May 15;17(10):898-904 [17475494.001]
  • [Cites] Curr Opin Microbiol. 2007 Jun;10(3):225-30 [17553732.001]
  • [Cites] Annu Rev Microbiol. 2007;61:131-48 [17480182.001]
  • [Cites] BMC Dev Biol. 2007;7:101 [17803822.001]
  • [Cites] J Bacteriol. 2001 May;183(10):3117-26 [11325940.001]
  • (PMID = 18281425.001).
  • [ISSN] 1098-5336
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR 12596
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ PMC2293164
  •  go-up   go-down


57. Spencer AU, Neaga A, West B, Safran J, Brown P, Btaiche I, Kuzma-O'Reilly B, Teitelbaum DH: Pediatric short bowel syndrome: redefining predictors of success. Ann Surg; 2005 Sep;242(3):403-9; discussion 409-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric short bowel syndrome: redefining predictors of success.
  • OBJECTIVE: To determine predictors of survival and of weaning off parenteral nutrition (PN) in pediatric short bowel syndrome (SBS) patients.
  • SUMMARY BACKGROUND DATA: Pediatric SBS carries extensive morbidity and high mortality, but factors believed to predict survival or weaning from PN have been based on limited studies.
  • This study reviews outcomes of a large number of SBS infants and identifies predictors of success.
  • METHODS: Multivariate Cox proportional hazards analysis was conducted on 80 pediatric SBS patients.
  • Primary outcome was survival; secondary outcome was ability to wean off PN.
  • Nonsignificant covariates were eliminated.
  • P < 0.05 was considered significant.
  • RESULTS: Over a mean of 5.1 years of follow-up, survival was 58 of 80 (72.5%) and 51 weaned off PN (63.8%).
  • Cholestasis (conjugated bilirubin > or =2.5 mg/dL) was the strongest predictor of mortality (relative risk [RR] 22.7, P = 0.005).
  • Although absolute small bowel length was only slightly predictive, percentage of normal bowel length (for a given infant's gestational age) was strongly predictive of mortality (if <10% of normal length, RR of death was 5.7, P = 0.003) and of weaning PN (if > or =10% of normal, RR of weaning PN was 11.8, P = 0.001).
  • Presence of the ileocecal valve (ICV) also strongly predicted weaning PN (RR 3.9, P < 0.0005); however, ICV was not predictive of survival.
  • CONCLUSIONS: Cholestasis and age-adjusted small bowel length are the major predictors of mortality in pediatric SBS.
  • Age-adjusted small bowel length and ICV are the major predictors of weaning from PN.
  • These data permit better prediction of outcomes of pediatric SBS, which may help to direct future management of these challenging patients.
  • [MeSH-major] Child Nutritional Physiological Phenomena. Parenteral Nutrition. Short Bowel Syndrome / therapy
  • [MeSH-minor] Child, Preschool. Cholestasis / etiology. Cholestasis / mortality. Female. Humans. Infant. Male. Organ Size / drug effects. Prognosis. Retrospective Studies. Survival Analysis


58. Xie C, Sachs JR, Wang DH: Interdependent regulation of afferent renal nerve activity and renal function: role of transient receptor potential vanilloid type 1, neurokinin 1, and calcitonin gene-related peptide receptors. J Pharmacol Exp Ther; 2008 Jun;325(3):751-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interdependent regulation of afferent renal nerve activity and renal function: role of transient receptor potential vanilloid type 1, neurokinin 1, and calcitonin gene-related peptide receptors.
  • Our previous studies have shown that the activation of the transient receptor potential vanilloid type 1 (TRPV1) expressed in the renal pelvis leads to an increase in ipsilateral afferent renal nerve activity (ARNA) and contralateral renal excretory function, but the molecular mechanisms of TRPV1 action are largely unknown.
  • This study tests the hypothesis that activation of receptors of neurokinin 1 (NK1) or calcitonin gene-related peptide (CGRP) by endogenously released substance P (SP) or CGRP following TRPV1 activation, respectively, governs TRPV1-induced increases in ARNA and renal excretory function.
  • Capsaicin (CAP; 0.04, 0.4, and 4 nM), a selective TRPV1 agonist, administered into the renal pelvis dose-dependently increased ARNA.
  • CAP (4 nM)-induced increases in ipsilateral ARNA or contralateral urine flow rate (Uflow) and urinary sodium excretion (UNa) were abolished by capsazepine (CAPZ), a selective TRPV1 antagonist, or 2-[1-imino-2-(2-methoxyphenyl)ethyl]-7,7-diphenyl-4-perhydroisoindolone (3aR,7aR) (RP67580) or cis-2-(diphenylmethyl)-N-[(2-iodophenyl)-methyl]-1 azabicyclo[2.2.2]octan-3-amine (L703,606), selective NK1 antagonists, but not by CGRP8-37, a selective CGRP receptor antagonist.
  • Both SP (7.4 nM) and CGRP (0.13 muM) increased ARNA, Uflow, or UNa, and increases in these parameters induced by CGRP but not SP were abolished by CAPZ.
  • CAP at 4 nM perfused into the renal pelvis caused the release of SP and CGRP, which was blocked by CAPZ but not by RP67580, L703,606, or CGRP8-37.
  • Immunofluorescence results showed that NK1 receptors were expressed in sensory neurons in dorsal root ganglion and sensory nerve fibers innervating the renal pelvis.
  • Taken together, our data indicate that NK1 activation induced by SP release upon TRPV1 activation governs TRPV1 function and that a TRPV1-dependent mechanism is operant in CGRP action.
  • [MeSH-major] Ganglia, Spinal / physiology. Kidney Pelvis / physiology. Neurons, Afferent / physiology. Receptors, Calcitonin Gene-Related Peptide / physiology. Receptors, Neurokinin-1 / physiology. Substance P / physiology. TRPV Cation Channels / physiology
  • [MeSH-minor] Animals. Blood Pressure. Calcitonin Gene-Related Peptide / pharmacology. Calcitonin Gene-Related Peptide / urine. Capsaicin / analogs & derivatives. Capsaicin / pharmacology. Isoindoles / pharmacology. Male. Neurokinin-1 Receptor Antagonists. Peptide Fragments / pharmacology. Quinuclidines / pharmacology. Rats. Rats, Wistar

  • HSDB. structure - CAPSAICIN.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Apr;278(4):R937-46 [10749782.001]
  • [Cites] Am J Nephrol. 2007;27(5):530-7 [17717412.001]
  • [Cites] J Am Soc Nephrol. 2002 Apr;13(4):1008-16 [11912260.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Jul;283(1):F164-72 [12060598.001]
  • [Cites] J Am Soc Nephrol. 2002 Jul;13(7):1872-83 [12089383.001]
  • [Cites] J Neurosci. 2004 Aug 25;24(34):7549-56 [15329402.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 Oct;287(4):H1868-74 [15205172.001]
  • [Cites] Neuroscience. 1987 Nov;23(2):693-703 [3501848.001]
  • [Cites] Am J Physiol. 1991 Jan;260(1 Pt 2):R232-9 [1704197.001]
  • [Cites] Eur J Pharmacol. 1993 Feb 16;231(3):375-80 [8383600.001]
  • [Cites] Am J Physiol. 1993 Mar;264(3 Pt 2):R647-53 [8384427.001]
  • [Cites] Br J Pharmacol. 1993 Aug;109(4):918-24 [8401945.001]
  • [Cites] Am J Physiol. 1994 Oct;267(4 Pt 2):R1109-17 [7943422.001]
  • [Cites] Peptides. 1995;16(4):673-81 [7479302.001]
  • [Cites] Am J Physiol. 1996 Apr;270(4 Pt 2):R720-7 [8967399.001]
  • [Cites] J Biol Chem. 1998 Aug 7;273(32):20168-74 [9685362.001]
  • [Cites] Am J Physiol. 1998 Dec;275(6 Pt 2):R1780-92 [9843867.001]
  • [Cites] Hypertension. 1999 Jan;33(1 Pt 2):493-8 [9931154.001]
  • [Cites] Eur J Neurosci. 1999 Mar;11(3):946-58 [10103088.001]
  • [Cites] Acta Physiol Scand. 1999 Jun;166(2):159-65 [10383496.001]
  • [Cites] Brain Res Mol Brain Res. 2005 Jul 29;138(1):35-44 [15869822.001]
  • [Cites] Hypertension. 2005 Oct;46(4):992-7 [16087784.001]
  • [Cites] Hypertension. 2006 Mar;47(3):609-14 [16365187.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Oct;319(1):192-8 [16844842.001]
  • [Cites] J Neurosci. 2007 Jun 27;27(26):7070-80 [17596456.001]
  • [Cites] Nature. 2001 Sep 13;413(6852):203-10 [11557989.001]
  • (PMID = 18364471.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK067620; United States / NIDDK NIH HHS / DK / R01 DK067620-03; United States / NIDDK NIH HHS / DK / R01 DK067620-04; United States / NHLBI NIH HHS / HL / R01 HL057853; United States / NHLBI NIH HHS / HL / R01 HL057853-06; United States / NHLBI NIH HHS / HL / R01 HL057853-07; United States / NHLBI NIH HHS / HL / R01 HL073287; United States / NHLBI NIH HHS / HL / R01 HL073287-04; United States / NHLBI NIH HHS / HL / R01 HL073287-05
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoindoles; 0 / Neurokinin-1 Receptor Antagonists; 0 / Peptide Fragments; 0 / Quinuclidines; 0 / Receptors, Calcitonin Gene-Related Peptide; 0 / Receptors, Neurokinin-1; 0 / TRPV Cation Channels; 0 / Trpv1 protein, rat; 119911-68-1 / calcitonin gene-related peptide (8-37); 135911-02-3 / 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one; 144425-84-3 / L 703606; 33507-63-0 / Substance P; 83652-28-2 / Calcitonin Gene-Related Peptide; LFW48MY844 / capsazepine; S07O44R1ZM / Capsaicin
  • [Other-IDs] NLM/ NIHMS96838; NLM/ PMC2689370
  •  go-up   go-down


59. Craig DH, Zhang J, Basson MD: Cytoskeletal signaling by way of alpha-actinin-1 mediates ERK1/2 activation by repetitive deformation in human Caco2 intestinal epithelial cells. Am J Surg; 2007 Nov;194(5):618-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoskeletal signaling by way of alpha-actinin-1 mediates ERK1/2 activation by repetitive deformation in human Caco2 intestinal epithelial cells.
  • BACKGROUND: Repetitive deformation stimulates proliferation in human Caco2 intestinal epithelial cells by way of an ERK1/2-dependent pathway.
  • We examined the effects of cytoskeletal perturbation on deformation-induced signaling in Caco2 cells.
  • METHODS: The Caco2 cell cytoskeleton was disrupted with either cytochalasin D, phalloidin, colchicine, or paclitaxel.
  • Levels of alpha-actinin-1 and -4 and paxillin were reduced by specific small interfering RNA.
  • Cells on collagen I-precoated membranes were subjected to 10% repetitive deformation at 10 cycles/min.
  • After 1 hour, cells were lysed for Western blot analysis.
  • RESULTS: Strain-activated ERK1/2, focal adhesion kinase, and Src phosphorylation in dimethyl sulfoxide- and/or nontargeting small interfering RNA-treated control cell populations.
  • Cytochalasin D and paclitaxel, but not phalloidin and colchicine, blocked ERK1/2 phosphorylation.
  • A decrease in alpha-actinin-1, but not in alpha-actinin-4 or paxillin, inhibited ERK1/2 and focal adhesion kinase phosphorylation, whereas Src activation appears to be independent of these effects.
  • CONCLUSIONS: The intestinal epithelial cell cytoskeleton may transduce mechanical signals by way of alpha-actinin-1 into the focal adhesion complex, culminating in ERK1/2 activation and proliferation.
  • [MeSH-major] Actinin / metabolism. Cytoskeleton / drug effects. Cytoskeleton / physiology. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism
  • [MeSH-minor] Caco-2 Cells. Cell Proliferation / drug effects. Humans. Phosphorylation. Signal Transduction

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1687-97 [15917311.001]
  • [Cites] Surgery. 1999 Aug;126(2):127-34 [10455874.001]
  • [Cites] Surgery. 2006 Aug;140(2):212-20 [16904972.001]
  • [Cites] J Cell Biochem. 2006 Aug 15;98(6):1507-16 [16552730.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1179-89 [17030187.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1169-78 [16855384.001]
  • [Cites] J Biol Chem. 2007 Jan 5;282(1):14-28 [17088251.001]
  • [Cites] Biochem J. 1999 Nov 15;344 Pt 1:117-23 [10548541.001]
  • [Cites] Int J Biochem Cell Biol. 2000 Feb;32(2):171-88 [10687952.001]
  • [Cites] APMIS. 2001 Apr;109(4):241-62 [11469496.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jan;280(1):G75-87 [11123200.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):26436-40 [10840040.001]
  • [Cites] Nat Cell Biol. 2002 Apr;4(4):286-93 [11912490.001]
  • [Cites] J Gastrointest Surg. 2001 Sep-Oct;5(5):503-13 [11986001.001]
  • [Cites] Ann Biomed Eng. 2002 Mar;30(3):297-304 [12051615.001]
  • [Cites] Space Med Med Eng (Beijing). 2002 Aug;15(4):309-12 [12425342.001]
  • [Cites] Metabolism. 2002 Dec;51(12):1525-7 [12489062.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9327-31 [12519770.001]
  • [Cites] J Cell Sci. 2003 Apr 15;116(Pt 8):1397-408 [12640025.001]
  • [Cites] FASEB J. 2003 May;17(8):926-8 [12626437.001]
  • [Cites] Digestion. 2003;68(4):217-25 [14739529.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12001-4 [14960578.001]
  • [Cites] J Cell Physiol. 2004 Sep;200(3):377-86 [15254965.001]
  • [Cites] Biochem Soc Trans. 1991 Nov;19(4):1065-9 [1794463.001]
  • [Cites] J Clin Invest. 1992 Jul;90(1):15-23 [1634605.001]
  • [Cites] Exp Cell Res. 1996 Jun 15;225(2):301-5 [8660918.001]
  • [Cites] J Cell Physiol. 1996 Aug;168(2):476-88 [8707883.001]
  • [Cites] Annu Rev Physiol. 1997;59:575-99 [9074778.001]
  • [Cites] J Cell Biol. 1998 Mar 23;140(6):1383-93 [9508771.001]
  • [Cites] Biochimie. 1998 May-Jun;80(5-6):357-62 [9782376.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5968-74 [16740738.001]
  • (PMID = 17936423.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK060771; United States / NIDDK NIH HHS / DK / R01 DK060771-06; United States / NIDDK NIH HHS / DK / R01 DK060771-07; United States / NIDDK NIH HHS / DK / R01 DK60771
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 11003-00-2 / Actinin; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  • [Other-IDs] NLM/ NIHMS32861; NLM/ PMC2084063
  •  go-up   go-down


60. Koga H, Yang H, Haxhija EQ, Teitelbaum DH: The role of angiotensin II type 1a receptor on intestinal epithelial cells following small bowel resection in a mouse model. Pediatr Surg Int; 2008 Dec;24(12):1279-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of angiotensin II type 1a receptor on intestinal epithelial cells following small bowel resection in a mouse model.
  • AIM: We have previously shown that inhibition of angiotensin converting enzyme (ACE) significantly reduced intestinal epithelial cell (EC) apoptosis and improved morphometric intestinal adaptation in a mouse model of massive small-bowel resection (SBR).
  • This study attempted to further examine the downstream signaling factors in this system by blocking the action of angiotensin II (ATII), hypothesizing that this would lead to similar improvement of intestinal adaptation after SBR.
  • METHOD: Two groups of mice (C57BL/6J) underwent either a 60% mid-intestinal resection (SBR group) or a transection/re-anastomosis (Sham group).
  • Because real-time PCR studies showed that only ATII receptor type 1a (ATII-1a) expression was significantly increased after SBR, compared to SHAM mice, we decided to use the specific ATII-1a receptor antagonist Losartan to block this signaling pathway.
  • An additional two groups of mice received daily i.p. injections of Losartan (SBR + Losartan and Sham + Losartan group).
  • At 7 days, the adaptive response was assessed in the remnant gut including villus height, crypt depth, EC apoptosis (TUNEL staining) and proliferation (BrdU incorporation).
  • The apoptotic and proliferation signaling pathways were addressed by analysis of EC mRNA expression.
  • RESULT: SBR (with and without Losartan) led to a significant increase in villus height and crypt depth.
  • Losartan treatment did not significantly change EC proliferation, but did significantly reduce EC apoptosis rates as compared to the non-treated SBR group.
  • Losartan treatment was associated with a significant reduction of the bax-to-bcl-2 ratio and TNF-alpha expression after SBR compared to non-treated groups.
  • Interestingly, Losartan-treated groups showed a tremendous increase in proliferation of signaling factors EGFR, KGFR and IL7R, which may indicate an expanded potential for further intestinal adaptation also beyond 7 days after SBR.
  • CONCLUSION: This study showed that the ATII-1a receptor may be of crucial importance for the modulation of intestinal EC apoptosis, and for regulating the post-resectional EC adaptive response.
  • [MeSH-major] Epithelial Cells / physiology. Intestine, Small / drug effects. Intestine, Small / physiology. Receptor, Angiotensin, Type 1 / physiology
  • [MeSH-minor] Adaptation, Physiological / drug effects. Angiotensin II Type 1 Receptor Blockers / pharmacology. Animals. Apoptosis / drug effects. Cell Proliferation / drug effects. Intestinal Mucosa / drug effects. Intestinal Mucosa / physiology. Losartan / pharmacology. Male. Mice. Mice, Inbred C57BL. Models, Animal. Signal Transduction

  • HSDB. structure - LOSARTAN POTASSIUM.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1998 Feb 2;187(3):389-402 [9449719.001]
  • [Cites] Science. 1994 Nov 18;266(5188):1253-5 [7973709.001]
  • [Cites] J Surg Res. 1998 Jun;77(1):17-22 [9698526.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1291-4 [9797389.001]
  • [Cites] J Gastrointest Surg. 1998 Jan-Feb;2(1):44-9 [9841967.001]
  • [Cites] Kidney Int. 1998 Nov;54(5):1570-80 [9844133.001]
  • [Cites] J Hypertens. 1998 Nov;16(11):1603-9 [9856360.001]
  • [Cites] J Pediatr Surg. 1999 May;34(5):800-4 [10359184.001]
  • [Cites] Circulation. 2005 May 17;111(19):2509-17 [15883213.001]
  • [Cites] Toxicology. 2005 Dec 15;216(2-3):181-7 [16182431.001]
  • [Cites] Pediatr Surg Int. 2006 Jan;22(1):37-42 [16307277.001]
  • [Cites] Apoptosis. 2005 Dec;10(6):1305-15 [16215678.001]
  • [Cites] Gastroenterology. 2006 Feb;130(2):412-23 [16472596.001]
  • [Cites] Gastroenterology. 2006 Feb;130(2 Suppl 1):S93-9 [16473079.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):719-24; discussion 719-24 [16567183.001]
  • [Cites] Physiol Rev. 2006 Jul;86(3):747-803 [16816138.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Aug;21(8):1250-6 [16872305.001]
  • [Cites] Dig Dis Sci. 2007 Apr;52(4):1060-70 [17342403.001]
  • [Cites] Pediatr Surg Int. 2007 May;23(5):379-90 [17205293.001]
  • [Cites] BJU Int. 2007 Nov;100(5):1161-5 [17784886.001]
  • [Cites] Cell Biol Int. 2008 Feb;32(2):264-70 [17959395.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 2008 May-Jun;32(3):254-65 [18443137.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2814-21 [18441208.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G88-G98 [18483182.001]
  • [Cites] Am J Physiol. 1999 Dec;277(6 Pt 1):L1245-50 [10600897.001]
  • [Cites] J Surg Res. 2000 Jun 1;91(1):38-42 [10816347.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Jul;279(1):L143-51 [10893213.001]
  • [Cites] Surgery. 2000 Aug;128(2):165-70 [10922987.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Dec;281(6):G1487-93 [11705754.001]
  • [Cites] J Histochem Cytochem. 2002 Feb;50(2):275-82 [11799146.001]
  • [Cites] Am J Surg. 2002 Apr;183(4):361-71 [11975923.001]
  • [Cites] Circulation. 2002 Aug 13;106(7):847-53 [12176959.001]
  • [Cites] Am J Med. 2002 Oct 1;113(5):409-18 [12401536.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 2002 Nov-Dec;26(6):333-40; discussion 340-1 [12405644.001]
  • [Cites] J Surg Res. 2002 Dec;108(2):235-42 [12505047.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Mar;284(3):L501-7 [12573988.001]
  • [Cites] J Pediatr Surg. 2003 Jun;38(6):875-80 [12778384.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Aug;285(2):G404-13 [12724132.001]
  • [Cites] Circulation. 2003 Aug 5;108(5):598-604 [12874189.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):220-30 [14699502.001]
  • [Cites] J Immunol. 2004 Apr 1;172(7):4151-8 [15034027.001]
  • [Cites] Surgery. 2004 Aug;136(2):121-6 [15300170.001]
  • [Cites] Am J Physiol. 1993 Jul;265(1 Pt 1):G21-7 [8338170.001]
  • [Cites] Semin Cancer Biol. 1993 Dec;4(6):327-32 [8142617.001]
  • [Cites] Int J Exp Pathol. 1997 Aug;78(4):219-43 [9505935.001]
  • (PMID = 18989682.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / 2R01-AI044076-10; United States / NIAID NIH HHS / AI / R01 AI044076; United States / NIAID NIH HHS / AI / R01 AI044076-08; United States / NIAID NIH HHS / AI / R01 AI044076-09; United States / NIAID NIH HHS / AI / R01 AI044076-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Receptor, Angiotensin, Type 1; JMS50MPO89 / Losartan
  • [Other-IDs] NLM/ NIHMS169214; NLM/ PMC2814528
  •  go-up   go-down


61. Houlihan LM, Christoforou A, Arbuckle MI, Torrance HS, Anderson SM, Muir WJ, Porteous DJ, Blackwood DH, Evans KL: A case-control association study and family-based expression analysis of the bipolar disorder candidate gene PI4K2B. J Psychiatr Res; 2009 Dec;43(16):1272-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case-control association study and family-based expression analysis of the bipolar disorder candidate gene PI4K2B.
  • Bipolar disorder, schizophrenia and recurrent major depression are complex psychiatric illnesses with a substantial, yet unknown genetic component.
  • Linkage of bipolar disorder and recurrent major depression with markers on chromosome 4p15-p16 has been identified in a large Scottish family and three smaller families.
  • Analysis of haplotypes in the four chromosome 4p-linked families, identified two regions, each shared by three of the four families, which are also supported by a case-control association study.
  • The candidate gene phosphatidylinositol 4-kinase type-II beta (PI4K2B) lies within one of these regions.
  • PI4K2B is a strong functional candidate as it is a member of the phosphatidylinositol pathway, which is targeted by lithium for therapeutic effect in bipolar disorder.
  • Two approaches were undertaken to test the PI4K2B candidate gene as a susceptibility factor for psychiatric illness.
  • First, a case-control association study, using tagging SNPs from the PI4K2B genomic region, in bipolar disorder (n=368), schizophrenia (n=386) and controls (n=458) showed association with a two-marker haplotype in schizophrenia but not bipolar disorder (rs10939038 and rs17408391, global P=0.005, permuted global P=0.039).
  • Second, expression studies at the allele-specific mRNA and protein level using lymphoblastoid cell lines from members of the large Scottish family, which showed linkage to 4p15-p16 in bipolar disorder and recurrent major depression, showed no difference in expression differences between affected and non-affected family members.
  • There is no evidence to suggest that PI4K2B is contributing to bipolar disorder in this family but a role for this gene in schizophrenia has not been excluded.
  • [MeSH-major] Bipolar Disorder / genetics. Family Health. Genetic Predisposition to Disease. Phosphotransferases (Alcohol Group Acceptor) / genetics. Polymorphism, Single Nucleotide / genetics
  • [MeSH-minor] Case-Control Studies. Female. Gene Frequency. Genome-Wide Association Study / methods. Genotype. Humans. Male. Schizophrenia / genetics

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • (NIF). NIF Registry Automated Crawl Data: Resource: Registry .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 May 18;276(20):16635-40 [11279162.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):20041-50 [11923287.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46586-93 [12324459.001]
  • [Cites] Bioinformatics. 2003 Jan;19(1):149-50 [12499305.001]
  • [Cites] Genome Res. 2003 Aug;13(8):1855-62 [12902379.001]
  • [Cites] Genet Epidemiol. 2003 Sep;25(2):115-21 [12916020.001]
  • [Cites] Physiol Genomics. 2004 Jan 15;16(2):184-93 [14583597.001]
  • [Cites] Schizophr Res. 2004 Mar 1;67(1):41-52 [14741323.001]
  • [Cites] Mol Psychiatry. 2004 Apr;9(4):406-16 [14743183.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2004 May;28(3):559-76 [15093964.001]
  • [Cites] Cell. 1989 Nov 3;59(3):411-9 [2553271.001]
  • [Cites] Nat Genet. 1996 Apr;12(4):427-30 [8630499.001]
  • [Cites] Mol Psychiatry. 1998 Jul;3(4):310-20 [9702739.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5604-9 [10318931.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2005 Feb 5;133B(1):1-5 [15645418.001]
  • [Cites] Bioinformatics. 2005 Aug 15;21(16):3445-7 [15947021.001]
  • [Cites] Pharmacopsychiatry. 2006 Jan;39(1):35-8 [16453253.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2006 Apr 5;141B(3):261-8 [16526044.001]
  • [Cites] Curr Opin Psychiatry. 2007 Jan;20(1):8-12 [17143075.001]
  • [Cites] Psychiatry Clin Neurosci. 2007 Feb;61(1):3-19 [17239033.001]
  • [Cites] Biol Psychiatry. 2007 Mar 15;61(6):797-805 [16996484.001]
  • [Cites] Genes Brain Behav. 2007 Mar;6(2):113-9 [17410640.001]
  • [Cites] Mol Psychiatry. 2007 Nov;12(11):1011-25 [17457313.001]
  • (PMID = 19539307.001).
  • [ISSN] 1879-1379
  • [Journal-full-title] Journal of psychiatric research
  • [ISO-abbreviation] J Psychiatr Res
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0700704B; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.67 / phosphatidylinositol phosphate 4-kinase
  • [Other-IDs] NLM/ PMC2789249
  •  go-up   go-down


62. Kotsis DH, Masko EM, Sigoillot FD, Di Gregorio R, Guy-Evans HI, Evans DR: Protein kinase A phosphorylation of the multifunctional protein CAD antagonizes activation by the MAP kinase cascade. Mol Cell Biochem; 2007 Jul;301(1-2):69-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein kinase A phosphorylation of the multifunctional protein CAD antagonizes activation by the MAP kinase cascade.
  • The flux through the de novo pyrimidine biosynthetic pathway is controlled by the multifunctional protein CAD, which catalyzes the first three steps.
  • The cell cycle dependent regulation of pyrimidine biosynthesis is a consequence of sequential phosphorylation of CAD Thr456 and Ser1406 by the MAP kinase and PKA cascades, respectively.
  • Coordinated regulation of the pathway requires precise timing of the two phosphorylation events.
  • These studies show that phosphorylation of purified CAD by PKA antagonizes MAP kinase phosphorylation, and vice versa.
  • Similar results were observed in vivo.
  • Forskolin activation of PKA in BHK-21 cells resulted in a 8.5 fold increase in Ser1406 phosphorylation and severely curtailed the MAP kinase mediated phosphorylation of CAD Thr456.
  • Moreover, the relative activity of MAP kinase and PKA was found to determine the extent of Thr456 phosphorylation.
  • Transfectants expressing elevated levels of MAP kinase resulted in a 11-fold increase in Thr456 phosphorylation, whereas transfectants that overexpress PKA reduced Thr456 phosphorylation 5-fold.
  • While phosphorylation of one site by one kinase may induce conformational changes that interfere with phosphorylation by the other, the observation that both MAP kinase and PKA form stable complexes with CAD suggest that the mutual antagonism is the result of steric interference by the bound kinases.
  • The reciprocal antagonism of CAD phosphorylation by MAP kinase and PKA provides an elegant mechanism to coordinate the cell cycle-dependent regulation of pyrimidine biosynthesis ensuring that signals for up- and down-regulation of the pathway do not conflict.
  • [MeSH-major] Aspartate Carbamoyltransferase / metabolism. Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing) / metabolism. Cyclic AMP-Dependent Protein Kinases / metabolism. Dihydroorotase / metabolism. MAP Kinase Signaling System / physiology
  • [MeSH-minor] Animals. Carbamoyl-Phosphate Synthase (Ammonia) / metabolism. Cell Line. Colforsin / metabolism. Cricetinae. Cricetulus. Enzyme Activation. Enzyme Inhibitors / metabolism. Epidermal Growth Factor / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Phosphorylation. Protein Subunits / metabolism

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206380.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / GM/CA 60371; United States / NIGMS NIH HHS / GM / GM47399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CAD trifunctional enzyme; 0 / Enzyme Inhibitors; 0 / Protein Subunits; 1F7A44V6OU / Colforsin; 62229-50-9 / Epidermal Growth Factor; EC 2.1.3.2 / Aspartate Carbamoyltransferase; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.5.2.3 / Dihydroorotase; EC 6.3.4.16 / Carbamoyl-Phosphate Synthase (Ammonia); EC 6.3.5.5 / Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing)
  •  go-up   go-down


63. Segvich SJ, Smith HC, Kohn DH: The adsorption of preferential binding peptides to apatite-based materials. Biomaterials; 2009 Mar;30(7):1287-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The adsorption of preferential binding peptides to apatite-based materials.
  • The objective of this work was to identify peptide sequences with high affinity to bone-like mineral (BLM) to provide alternative design methods for functional bone regeneration peptides.
  • Adsorption of preferential binding peptide sequences on four apatite-based substrates [BLM and three sintered apatite disks pressed from powders containing 0% CO(3)(2-) (HA), 5.6% CO(3)(2-) (CA5), 10.5% CO(3)(2-) (CA10)] with varied compositions and morphologies was investigated.
  • A combination of phage display, ELISA, and computational modeling was used to elucidate three 12-mer peptide sequences APWHLSSQYSRT (A), STLPIPHEFSRE (S), and VTKHLNQISQSY (V), from 243 candidates with preferential adsorption on BLM and HA.
  • Overall, peptides S and V have a significantly higher adsorption to the apatite-based materials in comparison to peptide A (for S vs. A, BLM p=0.001, CA5 p<0.001, CA10 p<0.001, HA p=0.038; for V vs. A, BLM p=0.006, CA5 p=0.033, CA10 p=0.029).
  • FT-IR analysis displayed carbonate levels in CA5 and CA10 dropped to approximately 1.1-2.2% after sintering, whereas SEM imaging displayed CA5 and CA10 possess distinct morphologies.
  • Adsorption results normalized to surface area indicate that small changes in carbonate percentage at a similar morphological scale did not provide enough carbonate incorporation to show statistical differences in peptide adsorption.
  • Because the identified peptides (S and V) have preferential binding to apatite, their use can now be investigated in bone and dentin tissue engineering, tendon and ligament repair, and enamel formation.
  • [MeSH-major] Apatites / chemistry. Bone Substitutes / chemistry. Peptides / chemistry. Peptides / metabolism
  • [MeSH-minor] Adsorption. Amino Acid Sequence. Animals. Biocompatible Materials / chemistry. Materials Testing. Molecular Sequence Data. Peptide Library. Protein Binding. Spectroscopy, Fourier Transform Infrared. Surface Properties

  • ResearchGate. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 1990 Jun;187(2):292-301 [2382830.001]
  • [Cites] Curr Opin Biotechnol. 2005 Aug;16(4):470-5 [16019201.001]
  • [Cites] J Cell Biol. 1995 Sep;130(5):1189-96 [7657703.001]
  • [Cites] Biochim Biophys Acta. 1996 Jan 4;1292(1):53-60 [8547349.001]
  • [Cites] Biomaterials. 1996 Jan;17(2):175-85 [8624394.001]
  • [Cites] J Biomed Mater Res. 1996 Aug;31(4):555-67 [8836853.001]
  • [Cites] Matrix Biol. 1997 Apr;16(1):21-8 [9181551.001]
  • [Cites] J Biomed Mater Res. 1998 Apr;40(1):48-56 [9511098.001]
  • [Cites] J Biomed Mater Res. 1998 Jun 5;40(3):371-7 [9570067.001]
  • [Cites] Proc Inst Mech Eng H. 1998;212(2):137-47 [9612005.001]
  • [Cites] Biotechnol Prog. 1999 Jan-Feb;15(1):19-32 [9933510.001]
  • [Cites] Biomaterials. 1999 Feb;20(4):377-84 [10048411.001]
  • [Cites] Curr Opin Biotechnol. 1999 Feb;10(1):87-93 [10047512.001]
  • [Cites] Curr Opin Biotechnol. 1999 Apr;10(2):123-9 [10209141.001]
  • [Cites] J Biomed Mater Res. 1999 May;45(2):140-7 [10397968.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Oct;63(10):1418-25 [16182908.001]
  • [Cites] Biomaterials. 2006 Mar;27(7):1175-86 [16137760.001]
  • [Cites] Acta Biomater. 2007 May;3(3):289-99 [17257913.001]
  • [Cites] J Biomed Mater Res. 2000 Feb;49(2):200-10 [10571906.001]
  • [Cites] Biomaterials. 1999 Dec;20(23-24):2323-31 [10614938.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):16213-8 [10748043.001]
  • [Cites] Nature. 2000 Jun 8;405(6787):665-8 [10864319.001]
  • [Cites] Biomaterials. 2000 Aug;21(15):1567-77 [10885729.001]
  • [Cites] Biomed Sci Instrum. 1999;35:99-104 [11143400.001]
  • [Cites] J Biomed Mater Res. 2001 Nov;57(2):258-67 [11484189.001]
  • [Cites] Biomaterials. 2002 Feb;23(4):1237-47 [11791928.001]
  • [Cites] Clin Orthop Relat Res. 2002 Feb;(395):53-65 [11937866.001]
  • [Cites] J Neuroimmunol. 2002 Jun;127(1-2):13-21 [12044970.001]
  • [Cites] J Biomed Mater Res. 2002 Nov;62(2):292-8 [12209950.001]
  • [Cites] J Biomed Mater Res A. 2003 Feb 1;64(2):378-87 [12522826.001]
  • [Cites] Bioinformatics. 2003 Mar 1;19(4):483-9 [12611803.001]
  • [Cites] Biomaterials. 2003 Nov;24(24):4353-64 [12922148.001]
  • [Cites] Biomaterials. 2003 Nov;24(24):4385-415 [12922151.001]
  • [Cites] Biomaterials. 2004 Feb;25(5):895-906 [14609678.001]
  • [Cites] Peptides. 2003 Sep;24(9):1349-57 [14706549.001]
  • [Cites] Drug Discov Today. 2004 Jun 15;9(12):525-9 [15183160.001]
  • [Cites] Proteomics. 2004 May;4(5):1439-60 [15188413.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Sep;33(6):523-30 [15308249.001]
  • [Cites] Caries Res. 1984;18(1):63-6 [6580956.001]
  • [Cites] Cell. 1987 Oct 9;51(1):51-7 [3115595.001]
  • [Cites] J Biomed Mater Res A. 2007 Dec 15;83(4):970-9 [17580326.001]
  • [Cites] J Biomed Mater Res A. 2007 Dec 15;83(4):1076-86 [17584901.001]
  • [Cites] J Biomed Mater Res B Appl Biomater. 2008 Feb;84(2):340-9 [17618505.001]
  • [Cites] Cells Tissues Organs. 2009;189(1-4):245-51 [18701808.001]
  • [Cites] Bone. 1999 Jul;25(1):95-6 [10423030.001]
  • [Cites] Biol Bull. 1998 Jun;194(3):348-9; discussion 349-50 [11536880.001]
  • [Cites] Biomaterials. 2005 Aug;26(22):4507-15 [15722119.001]
  • [Cites] Biomaterials. 2005 Sep;26(25):5209-20 [15792548.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 26;334(2):524-32 [16005428.001]
  • [Cites] Biomaterials. 2005 Dec;26(34):7046-56 [15964067.001]
  • [Cites] Monogr Oral Sci. 1991;15:1-201 [1870604.001]
  • (PMID = 19095299.001).
  • [ISSN] 1878-5905
  • [Journal-full-title] Biomaterials
  • [ISO-abbreviation] Biomaterials
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / DE015411; United States / NIDCR NIH HHS / DE / R01 DE013380; United States / NIDCR NIH HHS / DE / R01 DE013380-06A2; United States / NIDCR NIH HHS / DE / R01 DE015411; United States / NIDCR NIH HHS / DE / R01 DE015411-04; United States / NIDCR NIH HHS / DE / R56 DE013380; United States / NIDCR NIH HHS / DE / R56 DE013380-06A1; United States / NIDCR NIH HHS / DE / T32 DE007057; United States / NIDCR NIH HHS / DE / T32 DE007057-29; United States / NIDCR NIH HHS / DE / T32-DE07057
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apatites; 0 / Biocompatible Materials; 0 / Bone Substitutes; 0 / Peptide Library; 0 / Peptides
  • [Other-IDs] NLM/ NIHMS124051; NLM/ PMC2744811
  •  go-up   go-down


64. Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Aoki K, Aramaki Y, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Barish KN, Bassalleck B, Basye AT, Bathe S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bickley AA, Bok JS, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Chen CH, Chi CY, Chiu M, Choi IJ, Choudhury RK, Christiansen P, Chujo T, Chung P, Chvala O, Cianciolo V, Citron Z, Cole BA, Connors M, Constantin P, Csanád M, Csörgo T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, David G, Denisov A, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Durham JM, Durum A, Dutta D, Edwards S, Efremenko YV, Ellinghaus F, Engelmore T, Enokizono A, En'yo H, Esumi S, Fadem B, Fields DE, Finger M Jr, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong H, Gonin M, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HA, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Hanks J, Han R, Hartouni EP, Haslum E, Hayano R, Heffner M, Hegyi S, Hemmick TK, Hester T, He X, Hill JC, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Ide J, Ikeda Y, Imai K, Inaba M, Isenhower D, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Jacak BV, Jia J, Jin J, Johnson BM, Joo KS, Jouan D, Jumper DS, Kajihara F, Kametani S, Kamihara N, Kamin J, Kang JH, Kapustinsky J, Karatsu K, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kim BI, Kim DH, Kim DJ, Kim EJ, Kim E, Kim SH, Kim YJ, Kinney E, Kiriluk K, Kiss A, Kistenev E, Kochenda L, Komkov B, Konno M, Koster J, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kunde GJ, Kurita K, Kurosawa M, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Lee DM, Lee J, Lee KB, Lee K, Lee KS, Leitch MJ, Leite MA, Leitner E, Lenzi B, Liebing P, Linden Levy LA, Liska T, Litvinenko A, Liu H, Liu MX, Li X, Love B, Luechtenborg R, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mannel E, Mao Y, Masui H, Matathias F, McCumber M, McGaughey PL, Means N, Meredith B, Miake Y, Mignerey AC, Mikes P, Miki K, Milov A, Mishra M, Mitchell JT, Mohanty AK, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Murata J, Nagamiya S, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Nouicer R, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Okada K, Oka M, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park IH, Park J, Park SK, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Reygers K, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rosen CA, Rosendahl SS, Rosnet P, Rukoyatkin P, Ruzicka P, Sahlmueller B, Saito N, Sakaguchi T, Sakashita K, Samsonov V, Sano S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Slunecka M, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Sparks NA, Stankus PW, Stenlund E, Stoll SP, Sugitate T, Sukhanov A, Sziklai J, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarján P, Themann H, Thomas TL, Togawa M, Toia A, Tomásek L, Torii H, Towell RS, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Wei F, Wei R, Wessels J, White SN, Winter D, Wood JP, Woody CL, Wright RM, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Ying J, Yokkaichi S, Young GR, Younus I, You Z, Yushmanov IE, Zajc WA, Zhang C, Zhou S, Zolin L, PHENIX Collaboration: Elliptic and hexadecapole flow of charged hadrons in Au+Au collisions at sq.rt(s(NN))=200  GeV. Phys Rev Lett; 2010 Aug 6;105(6):062301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elliptic and hexadecapole flow of charged hadrons in Au+Au collisions at sq.rt(s(NN))=200  GeV.
  • Differential measurements of the elliptic (v(2)) and hexadecapole (v(4)) Fourier flow coefficients are reported for charged hadrons as a function of transverse momentum (p(T)) and collision centrality or number of participant nucleons (N(part)) for Au+Au collisions at sq.rt(s(NN))=200  GeV.
  • The v(2,4) measurements at pseudorapidity |η|≤0.35, obtained with four separate reaction-plane detectors positioned in the range 1.0<|η|<3.9, show good agreement, indicating the absence of significant Δη-dependent nonflow correlations.
  • Sizable values for v(4)(p(T)) are observed with a ratio v(4)(p(T),N(part))/v(2)(2)(p(T),N(part))≈0.8 for 50≲N(part)≲200, which is compatible with the combined effects of a finite viscosity and initial eccentricity fluctuations.
  • For N(part)≳200 this ratio increases up to 1.7 in the most central collisions.

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20867976.001).
  • [ISSN] 1079-7114
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Brown JK, Campbell BT, Drongowski RA, Alderman AK, Geiger JD, Teitelbaum DH, Quinn J, Coran AG, Hirschl RB: A prospective, randomized comparison of skin adhesive and subcuticular suture for closure of pediatric hernia incisions: cost and cosmetic considerations. J Pediatr Surg; 2009 Jul;44(7):1418-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective, randomized comparison of skin adhesive and subcuticular suture for closure of pediatric hernia incisions: cost and cosmetic considerations.
  • PURPOSE: In this study, we compared the skin adhesive 2-octylcyanoacrylate to subcuticular suture for closure of pediatric inguinal hernia incisions to determine if skin adhesive improves wound cosmesis, shortens skin closure time, and lowers operative costs.
  • METHODS: We prospectively randomized 134 children undergoing inguinal herniorrhaphy at our institution to have skin closure with either skin adhesive (n = 64) or subcuticular closure (n = 70).
  • Data collected included age, sex, weight, type of operation, total operative time, and skin closure time.
  • Digital photographs of healing incisions were taken at the 6-week postoperative visit.
  • The operating surgeon assessed cosmetic outcome of incisions using a previously validated visual analog scale, as well as an ordinate scale.
  • A blinded assessment of cosmetic outcome was then performed by an independent surgeon comparing these photographs to the visual analog scale.
  • Operating room time and resource use (ie, costs) relative to the skin closure were assessed.
  • Comparisons between groups were done using Student's t tests and chi(2) tests.
  • RESULTS: Children enrolled in the study had a mean +/- SE age of 3.7 +/- 0.3 years and weighed 16 +/- 0.8 kg.
  • Patients were predominantly male (82%).
  • Patients underwent 1 of 3 types of open hernia repair as follows: unilateral herniorrhaphy without peritoneoscopy (n = 41; 31%), unilateral herniorrhaphy with peritoneoscopy (n = 55; 41%), and bilateral herniorrhaphy (n = 38; 28%).
  • Skin closure time was significantly shorter in the skin adhesive group (adhesive = 1.4 +/- 0.8 minutes vs suture = 2.4 +/- 1.1 minutes; P = .001).
  • Mean wound cosmesis scores based on the visual analog scale were similar between groups (adhesive = 78 +/- 21; suture=78 +/- 18; P = .50).
  • Material costs related to herniorrhaphy were higher for skin adhesive (adhesive = $22.63 vs suture = $11.70; P < .001), whereas operating room time costs for adhesive skin closure were lower (adhesive = $9.33 +/- 5.33 vs suture = $16.00 +/- 7.33; P < .001).
  • Except for a 7% incidence of erythema in both groups, there were no complications encountered.
  • CONCLUSIONS: There is no difference in cosmetic outcome between skin adhesive and suture closure in pediatric inguinal herniorrhaphy.
  • Material costs are increased because of the high cost of adhesive relative to suture.
  • This is partially offset, however, by the cost savings from reduction in operating room time.
  • [MeSH-major] Hernia, Inguinal / surgery. Hospital Costs. Laparoscopy / methods. Patient Satisfaction. Suture Techniques / instrumentation. Sutures / ethics. Tissue Adhesives
  • [MeSH-minor] Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Prospective Studies. Treatment Outcome. Wound Healing

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19573672.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tissue Adhesives
  •  go-up   go-down


66. Creatore MI, Moineddin R, Booth G, Manuel DH, DesMeules M, McDermott S, Glazier RH: Age- and sex-related prevalence of diabetes mellitus among immigrants to Ontario, Canada. CMAJ; 2010 May 18;182(8):781-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age- and sex-related prevalence of diabetes mellitus among immigrants to Ontario, Canada.
  • BACKGROUND: The majority of immigrants to Canada originate from the developing world, where the most rapid increase in prevalence of diabetes mellitus is occurring.
  • We undertook a population-based study involving immigrants to Ontario, Canada, to evaluate the distribution of risk for diabetes in this population.
  • METHODS: We used linked administrative health and immigration records to calculate age-specific and age-adjusted prevalence rates among men and women aged 20 years or older in 2005.
  • We compared rates among 1,122,771 immigrants to Ontario by country and region of birth to rates among long-term residents of the province.
  • We used logistic regression to identify and quantify risk factors for diabetes in the immigrant population.
  • RESULTS: After controlling for age, immigration category, level of education, level of income and time since arrival, we found that, as compared with immigrants from western Europe and North America, risk for diabetes was elevated among immigrants from South Asia (odds ratio [OR] for men 4.01, 95% CI 3.82-4.21; OR for women 3.22, 95% CI 3.07-3.37), Latin America and the Caribbean (OR for men 2.18, 95% CI 2.08-2.30; OR for women 2.40, 95% CI: 2.29-2.52), and sub-Saharan Africa (OR for men 2.31, 95% CI 2.17-2.45; OR for women 1.83, 95% CI 1.72-1.95).
  • Increased risk became evident at an early age (35-49 years) and was equally high or higher among women as compared with men.
  • Lower socio-economic status and greater time living in Canada were also associated with increased risk for diabetes.
  • INTERPRETATION: Recent immigrants, particularly women and immigrants of South Asian and African origin, are at high risk for diabetes compared with long-term residents of Ontario.
  • This risk becomes evident at an early age, suggesting that effective programs for prevention of diabetes should be developed and targeted to immigrants in all age groups.
  • [MeSH-major] Diabetes Mellitus / epidemiology. Emigrants and Immigrants / statistics & numerical data
  • [MeSH-minor] Adult. Age Distribution. Aged. Educational Status. Female. Humans. Logistic Models. Male. Middle Aged. Ontario / epidemiology. Population Surveillance. Prevalence. Risk Assessment. Risk Factors. Sex Distribution. Social Class

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Soc Sci Med. 2000 Dec;51(11):1573-93 [11072880.001]
  • [Cites] Diabetes Care. 2002 Mar;25(3):512-6 [11874939.001]
  • [Cites] Diabetes Care. 2004 May;27(5):1047-53 [15111519.001]
  • [Cites] Diabetes Care. 2004 Oct;27(10):2317-24 [15451894.001]
  • [Cites] Br Med J (Clin Res Ed). 1985 Oct 19;291(6502):1081-4 [3931804.001]
  • [Cites] Diabetes. 1990 Mar;39(3):390-6 [2307296.001]
  • [Cites] Diabetes Res Clin Pract. 1994 Oct;24 Suppl:S37-42 [7859631.001]
  • [Cites] Diabetes Res Clin Pract. 1994 Oct;24 Suppl:S43-52 [7859632.001]
  • [Cites] Ann Epidemiol. 1996 Jan;6(1):67-73 [8680628.001]
  • [Cites] Diabetes Res Clin Pract. 1996 Oct;34 Suppl:S51-7 [9015670.001]
  • [Cites] Ethn Dis. 1999 Spring-Summer;9(2):190-200 [10421081.001]
  • [Cites] Soc Sci Med. 2005 Mar;60(6):1359-70 [15626530.001]
  • [Cites] Diabetologia. 2005 Apr;48(4):649-56 [15759110.001]
  • [Cites] Nutrition. 2007 Sep;23(9):696-708 [17679049.001]
  • [Cites] Soc Sci Med. 2008 Feb;66(3):675-90 [18036712.001]
  • [Cites] Diabetes Care. 2008 May;31(5):893-8 [18310309.001]
  • [Cites] Ambul Pediatr. 2008 May-Jun;8(3):205-9 [18501869.001]
  • [Cites] J Public Health (Oxf). 2008 Sep;30(3):327-31 [18522950.001]
  • [Cites] Am J Public Health. 2009 Feb;99(2):285-93 [19059866.001]
  • [Cites] Public Health Nutr. 2010 Mar;13(3):438-50 [19723366.001]
  • [Cites] Am J Public Health. 2001 Jan;91(1):76-83 [11189829.001]
  • [Cites] J Diabetes Complications. 2001 Nov-Dec;15(6):320-7 [11711326.001]
  • [Cites] Lancet. 2000 Jul 22;356(9226):279-84 [11071182.001]
  • [Cites] CMAJ. 2000 Sep 5;163(5):561-6 [11006768.001]
  • [Cites] Diabetes Care. 2000 Sep;23(9):1278-83 [10977060.001]
  • [Cites] Diabetes Metab Res Rev. 2000 Jul-Aug;16(4):230-6 [10934451.001]
  • (PMID = 20403889.001).
  • [ISSN] 1488-2329
  • [Journal-full-title] CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • [ISO-abbreviation] CMAJ
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2871200
  •  go-up   go-down


67. Akey DL, Razelun JR, Tehranisa J, Sherman DH, Gerwick WH, Smith JL: Crystal structures of dehydratase domains from the curacin polyketide biosynthetic pathway. Structure; 2010 Jan 13;18(1):94-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crystal structures of dehydratase domains from the curacin polyketide biosynthetic pathway.
  • Modular polyketide synthases (PKS) make novel natural products through a series of preprogrammed chemical steps catalyzed by an assembly line of multidomain modules.
  • Each assembly-line step involves unique extension and modification reactions, resulting in tremendous diversity of polyketide products.
  • Dehydratase domains catalyze formation of an alpha,beta-double bond in the nascent polyketide intermediate.
  • We present crystal structures of the four dehydratase domains from the curacin A PKS.
  • The catalytic residues and substrate binding site reside in a tunnel within a single monomer.
  • The positions of the catalytic residues and shape of the substrate tunnel explain how chirality of the substrate hydroxyl group may determine the configuration of the product double bond.
  • Access to the active site may require opening the substrate tunnel, forming an open trench.
  • The arrangement of monomers within the dimer is consistent among PKS dehydratases and differs from that seen in the related mammalian fatty acid synthases.
  • [MeSH-major] Cyclopropanes / metabolism. Hydro-Lyases / chemistry. Polyketide Synthases / chemistry. Thiazoles / metabolism
  • [MeSH-minor] Amino Acid Sequence. Biocatalysis. Crystallography, X-Ray. Models, Molecular. Molecular Sequence Data. Protein Multimerization. Protein Structure, Quaternary. Protein Structure, Tertiary. Sequence Alignment. Substrate Specificity

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Protein Expr Purif. 2006 Jun;47(2):446-54 [16497515.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11124-9 [16844787.001]
  • [Cites] Nat Chem Biol. 2006 Oct;2(10):537-42 [16969372.001]
  • [Cites] ACS Chem Biol. 2006 Sep 19;1(8):505-9 [17168537.001]
  • [Cites] Nucleic Acids Res. 2007 Jul;35(Web Server issue):W375-83 [17452350.001]
  • [Cites] Chem Biol. 2007 Aug;14(8):931-43 [17719492.001]
  • [Cites] Chembiochem. 2008 Apr 14;9(6):826-48 [18357594.001]
  • [Cites] J Am Chem Soc. 2008 Sep 3;130(35):11598-9 [18693734.001]
  • [Cites] Science. 2008 Sep 5;321(5894):1304-5 [18772425.001]
  • [Cites] Science. 2008 Sep 5;321(5894):1315-22 [18772430.001]
  • [Cites] J Mol Biol. 2008 Dec 26;384(4):941-53 [18952099.001]
  • [Cites] BMC Struct Biol. 2008;8:49 [19014592.001]
  • [Cites] ACS Chem Biol. 2009 Jan 16;4(1):41-52 [19146481.001]
  • [Cites] Nature. 2009 Jun 4;459(7247):731-5 [19494914.001]
  • [Cites] J Am Chem Soc. 2009 Nov 11;131(44):16033-5 [19835378.001]
  • [Cites] Appl Microbiol Biotechnol. 2001 Sep;56(5-6):718-23 [11601620.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14808-13 [11752428.001]
  • [Cites] Biochemistry. 2002 Oct 22;41(42):12598-606 [12379102.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2002 Nov;58(Pt 11):1948-54 [12393927.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2003 Jan;59(Pt 1):38-44 [12499537.001]
  • [Cites] Biochemistry. 2003 Jan 14;42(1):72-9 [12515540.001]
  • [Cites] Chembiochem. 2003 Jul 7;4(7):654-7 [12851937.001]
  • [Cites] Chem Biol. 2003 Aug;10(8):723-31 [12954331.001]
  • [Cites] Methods Enzymol. 2003;374:300-21 [14696379.001]
  • [Cites] J Nat Prod. 2004 Aug;67(8):1356-67 [15332855.001]
  • [Cites] J Biol Chem. 1969 Nov 10;244(21):6014-22 [4900506.001]
  • [Cites] Structure. 1996 Mar 15;4(3):253-64 [8805534.001]
  • [Cites] Mol Pharmacol. 1998 Jan;53(1):62-76 [9443933.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 1999 Apr;55(Pt 4):849-61 [10089316.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32 [15572765.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2256-68 [15572779.001]
  • [Cites] Protein Sci. 2005 Jun;14(6):1570-80 [15930004.001]
  • [Cites] Science. 2006 Mar 3;311(5765):1258-62 [16513975.001]
  • [Cites] Structure. 2006 Apr;14(4):737-48 [16564177.001]
  • [Cites] Mol Pharmacol. 1995 Sep;48(3):523-31 [7565634.001]
  • (PMID = 20152156.001).
  • [ISSN] 1878-4186
  • [Journal-full-title] Structure (London, England : 1993)
  • [ISO-abbreviation] Structure
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-108874; United States / NIDDK NIH HHS / DK / DK-42303; United States / NCI NIH HHS / CA / R01 CA108874; United States / NCI NIH HHS / CA / R01 CA108874-04; United States / NIDDK NIH HHS / DK / R01 DK042303; United States / NIDDK NIH HHS / DK / R01 DK042303-22; United States / NIGMS NIH HHS / GM / R01 GM076477; United States / NIGMS NIH HHS / GM / R01 GM076477-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclopropanes; 0 / Thiazoles; 155233-30-0 / curacin A; 79956-01-7 / Polyketide Synthases; EC 4.2.1.- / Hydro-Lyases
  • [Other-IDs] NLM/ NIHMS288082; NLM/ PMC3102235
  •  go-up   go-down


68. Weissman DH, Warner LM, Woldorff MG: Momentary reductions of attention permit greater processing of irrelevant stimuli. Neuroimage; 2009 Nov 15;48(3):609-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Momentary reductions of attention permit greater processing of irrelevant stimuli.
  • Momentary reductions of attention can have extremely adverse outcomes, but it remains unclear whether increased distraction from irrelevant stimuli contributes to such outcomes.
  • To investigate this hypothesis, we examined trial-by-trial relationships between brain activity and response time in twenty healthy adults while they performed a cross-modal selective attention task.
  • In each trial, participants identified a relevant visual letter while ignoring an irrelevant auditory letter, which was mapped either to the same response as the visual letter (congruent trials) or to a different response (incongruent trials).
  • As predicted, reductions of attention (i.e., increases of response time) were associated not only with decreased activity in sensory regions that processed the relevant visual stimuli, suggesting a failure to enhance the processing of those stimuli, but also with increased activity in sensory regions that processed the irrelevant auditory stimuli, suggesting a failure to suppress the processing of those stimuli.
  • Reductions of attention were also linked to larger increases of activity in incongruent than in congruent trials in anterior cingulate regions that detect response conflict, suggesting that failing to suppress the sensory processing of the irrelevant auditory stimuli during attentional reductions allowed those stimuli to more readily activate conflicting responses in incongruent trials.
  • These findings indicate that heightened levels of distraction during momentary reductions of attention likely stem, at least in part, from increased processing of irrelevant stimuli.
  • [MeSH-major] Attention / physiology. Auditory Perception / physiology. Brain / physiology. Visual Perception / physiology
  • [MeSH-minor] Acoustic Stimulation. Adult. Brain Mapping. Female. Gyrus Cinguli / physiology. Humans. Magnetic Resonance Imaging. Male. Neuropsychological Tests. Photic Stimulation. Reaction Time. Task Performance and Analysis. Young Adult

  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cogn Neurosci. 2000 Nov;12(6):988-1000 [11177419.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):676-82 [11209064.001]
  • [Cites] Annu Rev Neurosci. 2001;24:167-202 [11283309.001]
  • [Cites] Psychol Sci. 2001 May;12(3):213-8 [11437303.001]
  • [Cites] Neuropsychologia. 2001;39(9):937-49 [11516446.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1023-6 [14963333.001]
  • [Cites] J Neurosci. 1999 Nov 1;19(21):9480-96 [10531451.001]
  • [Cites] Nature. 1999 Nov 11;402(6758):179-81 [10647008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1944-8 [10677559.001]
  • [Cites] Nat Neurosci. 2000 Mar;3(3):284-91 [10700262.001]
  • [Cites] Science. 2000 Jun 9;288(5472):1835-8 [10846167.001]
  • [Cites] Neuroimage. 2000 Jun;11(6 Pt 1):735-59 [10860799.001]
  • [Cites] J Exp Psychol Gen. 2004 Sep;133(3):339-54 [15355143.001]
  • [Cites] Percept Psychophys. 1994 Aug;56(2):183-97 [7971119.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14878-83 [8962149.001]
  • [Cites] Neuron. 1998 Feb;20(2):285-96 [9491989.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1998 Aug 29;353(1373):1245-55 [9770219.001]
  • [Cites] J Neurosci. 2004 Dec 1;24(48):10941-9 [15574744.001]
  • [Cites] Biol Psychiatry. 2005 Jun 1;57(11):1416-23 [15950016.001]
  • [Cites] Dev Neuropsychol. 2005;28(1):507-37 [15992254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9673-8 [15976020.001]
  • [Cites] Accid Anal Prev. 2005 Nov;37(6):996-1004 [15955521.001]
  • [Cites] Accid Anal Prev. 2006 Mar;38(2):415-21 [16310750.001]
  • [Cites] Nat Neurosci. 2006 Jul;9(7):971-8 [16767087.001]
  • [Cites] Psychopharmacology (Berl). 2006 Aug;187(3):385-96 [16752139.001]
  • [Cites] Psychophysiology. 2006 Nov;43(6):541-9 [17076810.001]
  • [Cites] Science. 2007 Jan 19;315(5810):393-5 [17234951.001]
  • [Cites] Cereb Cortex. 2007 Sep;17 Suppl 1:i125-35 [17725995.001]
  • [Cites] Psychon Bull Rev. 2007 Jun;14(3):527-33 [17874601.001]
  • [Cites] Neuroimage. 2008 Jan 1;39(1):527-37 [17919929.001]
  • [Cites] J Neurosci. 2008 May 21;28(21):5519-28 [18495886.001]
  • (PMID = 19596451.001).
  • [ISSN] 1095-9572
  • [Journal-full-title] NeuroImage
  • [ISO-abbreviati